Synthesis of biologically active heterocyclic compounds by Wilson, Jennifer M.
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
Wilson, Jennifer M. (2007) Synthesis of biologically active heterocyclic 
compounds. PhD thesis. 
 
 
 
http://theses.gla.ac.uk/45/ 
 
 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
  
 
 
 
 
 
Synthesis of Biologically Active Heterocyclic 
Compounds 
 
 
 
 
 
 
 
Jennifer Margaret Wilson 
 
 
Thesis submitted in part fulfilment of the requirements for the Degree of Doctor of 
Philosophy 
 
 
 
 
 
Supervisors: Prof. D. J. Robins and Dr A. Sutherland 
 
Department of Chemistry 
 
Physical Sciences Faculty 
 
 
 
October 2007 
 Abstract 
 
 
More than 11 million people worldwide are diagnosed with cancer every year. New cancer 
drugs are required that are more effective and selective. Nitrogen mustard alkylating agents 
crosslink DNA inhibiting transcription and replication. Use of the mustard pharmacophore 
as  part  of  a  macrocycle  allows  metal  complexation  and  produces  a  prodrug.  Hypoxic 
tumour  cells  have  increased  concentrations  of  reductase  enzymes  which  could  lead  to 
reduction of the complex in situ and release of a cytotoxic drug. 
Human African Trypanosomiasis is commonly known as Sleeping Sickness and affects 
over 36 countries of sub-Saharan Africa. It is transmitted to humans by the tsetse fly which 
carries the parasitic subspecies Trypanosoma brucei rhodesiense and Trypanosoma brucei 
gambiense. Any compounds synthesised would also be tested to assess their potential as 
anti-parasitic agents. 
 
Parker synthesised a range of polyazamacrocycles. Testing of compound A in vitro gave 
highly  efficient  DNA  crosslinking  activity.  Copper  complexes  were  formed  of  the 
macrocycles and B was found to be 24 times more toxic against hypoxic cells than oxic 
cells thus exploiting tumour hypoxia and creating a selective drug. Jones synthesised a 
range of oxaazamacrocycles such as C which when tested in vitro exhibited comparable 
cross-linking activity to the azamacrocycles although it proved impossible to synthesise the 
corresponding copper complexes.
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It  was  decided  to  vary  the  leaving  group  on  the  alkylating  arms  to  see  if  the  DNA 
crosslinking results could be improved. Eight carbamates and the corresponding copper 
complexes were synthesised. The R-groups were alkyl and aromatic. Anti-cancer DNA 
crosslinking  and  hypoxia  selectivity  results  were  disappointing  however,  a  number  of 
compounds displayed significant activity when tested against T. brucei.  
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A  range  of  thiaazamacrocycles  would  complete  the  set  of  heteroatom-containing 
macrocycles (N, O, S) and might produce good DNA crosslinking results. It might also be 
possible  to  synthesise  the  corresponding  copper  complexes  producing  prodrugs.  Six 
thiaazamacrocycles were synthesised and 2-hydroxyethyl arms were attached. However it 
proved impossible to isolate the desired alkylating agents with the 2-chloroethyl arms. 
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In the body, the p53 protein activates the transcription of specific genes. In healthy cells, 
the levels of p53 have to be kept to a minimum to allow the normal running of the cell, e.g. 
growth and replication. This function is carried out by the HDM2 protein, which forms an 
auto-regulatory feedback loop with p53. In some tumours, the p53 function is disrupted 
due to genetic mutations of p53. However other tumours possess ‘wild type’ p53 – this 
type of p53 has lost the ability to respond to oncogenic stress due to over-expression of 
HDM2. Drugs that inhibit HDM2 should cause stabilisation of p53 and induce apoptosis in 
cancer cells.  A small library of 5-deazaflavins were synthesised and biologically tested 
producing some interesting biological results. 
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Abbreviations 
 
 
abs.      absolute 
AcOH     acetic acid 
ADEPT    antibody directed enzyme prodrug therapy 
ADP      adenosine diphosphate 
AIDS      autoimmune deficiency syndrome 
ALDH     aldehyde dehydrogenase 
ARF      auxin reponse factor 
aq.      aqueous 
BBB      blood brain barrier 
BC      before Christ 
BCEA     N,N-bis(2-chloroethyl)amine 
Boc      tert-butoxycarbonyl 
bs      broad singlet 
oC      degrees Celsius 
CDCl3     deuterated chloroform 
CI      chemical ionisation 
CML      chronic myeloid leukaemia 
CNS      central nervous system 
conc.      concentrated 
cyclen     1,4,7,10-tetraazacyclododecane 
d      days or doublet 
dd       doublet of doublets 
DMF      N,N-dimethylformamide 
DMSO     dimethylsulfoxide 
DNA      deoxyribose nucleic acid 
EC50      concentration of a drug to inhibit 50% of growth 
EI      electron impact ionisation 
EPO      erythropoietin 
Et      ethyl 
EtOH      ethanol 
eq.      equivalents 
FAB      fast atom bombardment 
g      gram 
GDEPT    gene directed enzyme prodrug therapy 6 
h      hours 
HAT      Human African Trypanosomiasis 
HBr      hydrobromic acid 
HCl      hydrochloric acid 
HDM2     human double minute gene 2 
HEK      human embryonic kidney 
HIV      human immunodeficiency virus 
HPDC     hypoxia activated prodrugs of diffusible cytotoxins 
HPLC     high performance liquid chromatography 
HSC      hypoxia selective cytotoxin 
Hz      hertz 
IC50      concentration of a drug to inhibit 50% of growth 
IR      infra-red 
J      NMR spectra coupling constant 
kDa      kiloDalton 
kg      kilogram 
L      litre or ligand 
µL      microlitre 
Leu      Leucine 
lit.      literature 
m      multiplet 
M      molar or metal centre of complex 
λmax      maximum UV absorbance 
MDM2    mouse double minute gene 2 
Me      methyl 
MeOH     methanol 
mg      milligram 
MHz      megaHertz 
mmol      millimole 
mM      millimolar 
µM      micromolar 
mL      millilitre 
mp      melting point 
Ms      methanesulfonyl 
MSF      Médecins Sans Frontières 
NMR      nuclear magnetic resonance 7 
ODC      ornithine decarboxylase 
P      partition coefficient 
Ph      phenyl 
Phe      phenylalanine 
q      quartet 
RPE      primary human pigment epithelial cells 
RT      room temperature 
s      seconds or singlet 
SDS-PAGE    sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SN1      nucleophilic primary substitution 
t      triplet 
T      temperature 
T.b.g.      Trypanosoma brucei gambiense 
T.b.r.      Trypanosoma brucei rhodesiense 
TEBA     triethylbenzyl ammonium chloride 
TETA     triethylene tetraamine 
THF      tetrahydrofuran 
TLC      thin layer chromatography 
Try      Tryptophan 
Ts or tosyl    para-toluenesulfonyl 
UV      ultraviolet 
WHO      World Health Organisation 
 8 
Table of Contents 
1  Cancer  .....................................................................................................................  11 
1.1  Cancer Treatments  ............................................................................................  11 
1.1.1  Surgery .....................................................................................................  11 
1.1.2  Radiotherapy ............................................................................................  12 
1.1.3  Biotherapy ................................................................................................  12 
1.1.4  Chemotherapy  ...........................................................................................  12 
1.2  Alkylating Agents  .............................................................................................  12 
1.2.1  Classifications of Alkylating Agents .........................................................  15 
1.2.1.1  Nitrogen Mustard Derivatives ...............................................................  15 
1.2.1.2  Alkyl Sulfonates ...................................................................................  17 
1.2.1.3  Nitrosoureas  ..........................................................................................  17 
1.2.1.4  Ethyleneimines .....................................................................................  17 
1.2.1.5  Triazenes ..............................................................................................  18 
2  Hypoxia and Cancer  ...............................................................................................  19 
2.1  The Problems Hypoxia Creates .........................................................................  20 
2.1.1  Metastasis
20 ..............................................................................................  20 
2.1.2  Angiogenesis
20,25.......................................................................................  20 
2.2  Strategies for the Treatment of Cancer by Exploiting Hypoxia  ..........................  21 
2.2.1  Anti-angiogenesis
27  ...................................................................................  21 
2.2.2  Vascular Targeting
29 .................................................................................  22 
2.2.3  Improving Oxygenation ............................................................................  22 
2.2.4  ARCON
32 .................................................................................................  23 
2.2.5  Exploitation of the Microenvironment  .......................................................  24 
2.2.5.1  Exploitation of Biological Responses
20 .................................................  24 
2.2.5.2  Bio-reductive Drugs
34 ...........................................................................  25 
2.3  Conclusion .......................................................................................................  35 
3  Human African Trypanosomiasis
65 .......................................................................  36 
3.1  Human African Trypanosomiasis  ......................................................................  36 
3.2  Trypanosomes Life Cycle
76 ..............................................................................  39 
3.3  Treatment of HAT
77..........................................................................................  39 
3.3.1  Pentamidine ..............................................................................................  40 
3.3.2  Suramin ....................................................................................................  40 
3.3.3  Melarsoprol ..............................................................................................  41 
3.3.4  Eflornithine  ...............................................................................................  42 
3.3.5  Nifurtimox ................................................................................................  42 
3.3.6  Megazol ....................................................................................................  42 
3.3.7  Treatment of Cattle ...................................................................................  43 
3.3.8  Vector Control ..........................................................................................  43 
3.4  Potential Drug Uptake Pathways
95 ....................................................................  44 
3.4.1  Glucose Metabolism .................................................................................  44 
3.4.2  Pentose Phosphate Pathway ......................................................................  45 
3.4.3  Thiol Metabolism  ......................................................................................  46 
3.4.4  Polyamine Metabolism .............................................................................  46 
3.4.5  Lipid and Sterol Metabolism .....................................................................  47 
3.5  Future of HAT Treatments  ................................................................................  47 
4  Previous Work within the Robins Group ..............................................................  48 
4.1  Piperidines  ........................................................................................................  48 
4.2  Bispiperidines  ...................................................................................................  48 
4.3  Bispyrrolidines .................................................................................................  48 
4.4  Azamacrocycles ...............................................................................................  49 9 
4.5  Aims of the Project ...........................................................................................  51 
5  Synthesis of Azamacrocyclic Mustard Derivatives ...............................................  52 
5.1  Synthesis of Cyclen ..........................................................................................  52 
5.1.1  Template Synthesis
121 ...............................................................................  52 
5.1.2  Richman Atkins Cyclisation  ......................................................................  53 
5.1.3  Phase Transfer Cyclisation ........................................................................  54 
5.1.4  Synthesis of Tosylated Cyclen ..................................................................  55 
5.1.4.1  Tosylation of Precursors  ........................................................................  55 
5.1.4.2  Cyclisation ............................................................................................  55 
5.1.5  Deprotection of Tosyl Groups ...................................................................  56 
5.2  Alkylation of Cyclen ........................................................................................  57 
5.3  Synthesis of Carbamates ...................................................................................  58 
5.3.1  Route I ......................................................................................................  58 
5.3.2  Route II.....................................................................................................  60 
5.4  Synthesis of Copper Complexes .......................................................................  61 
5.5  Unsuccessful Attempts at Formation of Other Leaving Groups .........................  63 
5.5.1  Sulfonamides ............................................................................................  63 
5.5.2  Chloroacetamides and Bromoacetamides ..................................................  64 
5.5.3  Finkelstein Reaction .................................................................................  64 
5.5.4  Carbonates ................................................................................................  65 
5.6  Biological Results  .............................................................................................  66 
5.6.1  Anti-Cancer Test Results ..........................................................................  66 
5.6.2  Anti-Parasite Test Results .........................................................................  67 
5.7  Synthesis of Carbamates to Investigate Structure- Activity Relationships .........  69 
5.7.1  Piperazine Based Bis-Carbamates .............................................................  69 
5.7.2  Linear Carbamates ....................................................................................  70 
5.8  Biological Results  .............................................................................................  70 
5.9  Conclusions and Future Work  ...........................................................................  71 
6  Synthesis of Thiaazamacrocycles ...........................................................................  72 
6.1  Amide Strategy  .................................................................................................  73 
6.1.1  Formation of Amide-Protected Macrocycles .............................................  74 
6.1.2  Reduction of Carbonyl Groups  ..................................................................  75 
6.2  Tosyl-protected Macrocycle Strategy  ................................................................  78 
6.2.1  Formation of Tosyl-protected Macrocycles ...............................................  78 
6.2.2  Tosyl Deprotection of Macrocycles  ...........................................................  81 
6.2.3  Addition of 2-Hydroxyethyl Arms ............................................................  82 
6.2.4  Chlorination of Macrocycles – Mustard Formation ...................................  83 
6.2.5  Carbamate Formation  ................................................................................  84 
6.3  Conclusions and Future Work  ...........................................................................  85 
7  Synthesis of Substituted Macrocycles ....................................................................  86 
7.1  Synthesis of an Alkyl Substituted Azamacrocycle.............................................  86 
7.1.1  Template Synthesis ...................................................................................  86 
7.1.2  High Dilution Amide Synthesis  .................................................................  87 
7.1.2.1  Formation of Macrocycle ......................................................................  87 
7.1.2.2  Formation of Free Base .........................................................................  89 
7.2  Synthesis of Aromatic-Substituted Thiaazamacrocycles  ....................................  90 
7.2.1  Synthesis of a Substituted Dithia-diazamacrocycle  ....................................  90 
7.2.1.1  Iron Templated Synthesis ......................................................................  90 
7.2.1.2  Future Work - High Dilution Amide Synthesis ......................................  91 
7.2.2  Synthesis of a Substituted Thia-triazamacrocycle ......................................  92 
7.3  Conclusions ......................................................................................................  93 
8  Synthesis of HDM2 Inhibitors ...............................................................................  94 
8.1  Introduction – p53: ‘Guardian of the Genome’  ..................................................  94 
8.1.1  Using HDM2 As A Therapeutic Target .....................................................  96 10 
8.1.2  Inhibitors Of The MDM2-p53 Complex  ....................................................  97 
8.2  Aims Of The Project .........................................................................................  98 
8.3  Synthesis of Deazaflavins ...............................................................................  100 
8.4  Biological Test Results ...................................................................................  105 
8.5  Conclusions ....................................................................................................  106 
9  Experimental ........................................................................................................  108 
9.1  General Experimental Details .........................................................................  108 
9.2  Experimental to Chapter .................................................................................  108 
9.2.1  General Procedures (A-C) .......................................................................  108 
9.2.2  Experimental Details  ...............................................................................  109 
9.3  Experimental to Chapter .................................................................................  125 
9.3.1  General Procedures (A-F) .......................................................................  125 
9.3.2  Experimental Details  ...............................................................................  126 
9.4  Experimental to Chapter .................................................................................  136 
9.5  Experimental to Chapter .................................................................................  139 
9.5.1  General Procedures (A & B) ...................................................................  139 
9.5.2  Experimental Details  ...............................................................................  139 
9.6  Biological Testing ..........................................................................................  149 
9.6.1  Biological Testing Chapter  ......................................................................  149 
9.6.1.1  DNA Cross-linking Activity of Macrocyclic Mustards ........................  149 
9.6.1.2  Cytotoxicity of Macrocyclic Mustards ................................................  149 
9.6.1.3  Trypanosome Cell Line .......................................................................  150 
9.6.1.4  Growth and Maintenance of Bloodstream-Form Trypanosome Stocks  .  150 
9.6.1.5  Trypanotoxicity  ...................................................................................  150 
9.6.1.6  Human Embryonic Kidney Cells .........................................................  151 
9.6.1.7  Fluorescence Assays ...........................................................................  151 
9.6.2  Biological Testing Chapter  ......................................................................  151 
9.7  Experimental Crystallography Details  .............................................................  153 
10  References  .............................................................................................................  155 
 11 
1  Cancer 
Cancer is defined in the Oxford English Dictionary as ‘a malignant growth or tumour in 
different parts of the body, that tends to spread indefinitely and to reproduce itself, as also 
to  return  after  removal;  it  eats  away  or  corrodes  the  part  in  which  it  is  situated,  and 
generally ends in death.’
1  
Mitosis is the name for the process by which a cell replicates, i.e. the division of a cell to 
produce  two  identical  daughter  cells.  Cancer  occurs  when  there  is  uncontrolled  cell 
division and the normal processes of mitosis such as initiation, control and termination 
cannot occur - generally this is due to genetic mutations.  This uncontrolled cell division 
results  in  the  growth  of  a  tumour.
2  There  are  two  categories  of  tumour:  benign  and 
malignant. A benign tumour will not spread to other parts of the body and rarely causes 
death. A malignant tumour can metastasise; this means that the cancer can invade other 
tissues.  
One in three people from the western world will contract cancer at some point in their lives 
and one in four will die as a result of the disease.
2 Although cancer is considered to be a 
disease of the modern world, the first reference to it appeared in an Egyptian papyrus 
dating from 3000-1500 BC that mentions breast tumours.
2 Cancer is not just confined to 
humans, since animals and plants have demonstrated tumorigenesis.
3 
1.1 Cancer Treatments 
Modern medicine has made huge advances towards the treatment of cancer. There are four 
main treatments used. Generally a combination of the treatments is given to ensure that the 
patient receives the best outcome. 
1.1.1 Surgery 
Surgery  was  once considered  to  be  the  only  option,  and  indeed  can  completely  ‘cure’ 
cancer by the removal of cancerous tissue. If the cancer has been diagnosed early then 
surgery can be the most effective treatment; however the problem is metastasis. Nowadays 
tissue  biopsies  are essential  for  diagnosis  and  surgery  is  carried  out in  90%  of cancer 
patients.
2 Jennifer M. Wilson, 2007     Chapter 1, 12 
1.1.2 Radiotherapy 
Radiation therapy can stop cell proliferation and disrupts atoms within tumour cells. The 
cell DNA is damaged beyond repair.
2 However the radiation can’t distinguish between 
healthy and cancer cells – especially rapidly dividing cells such as bone marrow and hair 
folicles so patients suffer from side-effects. Doses can be given internally or externally and 
advances  in  technology  mean  that  the  radiation  can  be  targeted  more  precisely  to  the 
desired area increasing dose efficiency and diminishing damage to healthy cells. 
1.1.3 Biotherapy 
The  cancer  is  controlled  by  the  body’s  natural  defence  system.  Immunotherapy  or 
biotherapy  uses  the  body’s  immune  system  to  fight  cancer.
2  It  is  designed  to  repair, 
stimulate or enhance the body’s immune response. The treatment should stop, control, or 
suppress processes that permit cancer growth by making cancer cells more recognizable, 
and therefore more susceptible, to destruction by the immune system. Biotherapy can also 
block  or reverse  the  process  that  changes  a  normal  cell or  a  pre-cancerous  cell  into  a 
cancerous cell.
  
1.1.4 Chemotherapy 
Chemicals are used to kill cancerous cells by damaging the cell proteins or the cell DNA. 
The  aim  is  to  cause  apoptosis  (cell  suicide).
2  Cytotoxic  drugs  such  as  antibiotics, 
antimitotics, hormones, antimetabolites, inorganic compounds and alkylating agents are 
currently  used  as  chemotherapeutic  agents.  Chemotherapy  cannot  distinguish  between 
healthy and cancerous cells so side effects are then experienced.
  
1.2 Alkylating Agents 
Alkylating agents are the best known anticancer cytotoxic therapeutic agents available for 
use in oncology departments today due to their effectiveness in cross-linking DNA, thus 
inhibiting cell  growth and ultimately leading to cell death. Covalent bonds are  formed 
between the DNA strand and the alkylating agent causing intermolecular cross-linking; cell 
death occurs because the DNA can no longer unwind and replicate. 
 Jennifer M. Wilson, 2007     Chapter 1, 13 
The anticancer properties of alkylating agents were discovered after the use of mustard gas 
in  World  War  I  –  casualties  developed  a  profound  fall  in  their  white  cell  count  with 
damage to marrow and lymphatic tissue.  
 
Sulfur gas 1 was first synthesised in 1860 by Frederick Guthrie using ethylene and sulfur 
dichloride
4 (Scheme 1), although the idea was first developed by M. Depretz in 1822.
5 In 
its pure form, mustard gas is a colourless, odourless, viscous liquid. However the warfare 
agent was used impure  as a yellow/brown substance  with an odour similar to mustard 
plants (it is not related to culinary mustard), garlic or horseradish.  
 
+   SCl2 S
Cl Cl
1  
Scheme 1 
Other names for 1 include HD, sengas, sulfur mustard, blister gas, s-lost, Kampstoff LOST, 
yellow cross liquid and yperite. The LOST part of the name comes from a reference to 
Lommel and Steinkopf who developed a process for mass producing the gas for war use by 
reacting thiodiglycol with HCl.
6 
 
Sulfur  gas  is  a  strong  vesiccant  (blister  causing  agent).  Upon  exposure  there  are  no 
immediate symptoms. Within 4-24 h of exposure any area of skin that comes into contact 
with the agent will develop deep itchy burning blisters and eyes will become sore and 
swollen leading to conjunctivitis or blindness. Inhalation of the agent leads to respiratory 
problems such as mucous membrane damage and pulmonary oedema. If more than 50% of 
the body surface area is exposed then the result is usually fatal.
7 Sulfur gas was first used 
effectively in 1917 by the Germans on Canadian soldiers during WW1. It has since been 
used in several conflicts including the Iraq-Iran war (1981-1988).
5 
 
The therapeutic effects of mustards were discovered in 1943 in the port of Bari, Italy when 
a  U.S.  stockpile of  mustard  gas  was  bombed  exposing  thousands  of  civilians  and  628 
Allied troops to the effects of the warfare agent. Medical workers discovered that white 
cell  counts  of  exposed  victims  were  decreased.  Dr  Cornelius  Packard  Rhoads  thus 
investigated the use of mustards as treatment for Hodgkin’s lymphoma.
8 Two American 
pharmacologists  (Goodman  and  Gilman  from  Yale)  were  also  investigating  nitrogen 
mustards  around  the  same  time.
9  This  was  essentially  the  birth  of  anti-cancer 
chemotherapy. Jennifer M. Wilson, 2007     Chapter 1, 14 
Alkylating agents are themselves carcinogenic as they damage the genetic material of the 
cell and the consequences of this genetic change can be the conversion of a normal cell 
into  a  cancerous  cell.  Fortunately  the  benefits  of  alkylating  agents  far  outweigh  the 
possibility that they will induce the development of a second cancer.  
 
Nowadays,  alkylating  agents  are  designed  to  form  reactive  intermediates  with  certain 
characteristics  such  as  electron  deficiency  because  these  reactive  electrophiles  will  be 
readily attacked by nucleophilic sites on biological molecules thus forming covalent bonds. 
Nucleophilic groups such as amino, carboxyl, sulfhydryl or imidazole moieties in proteins 
and  nucleic  acids can  be  alkylated.  The  intermolecular  cross-link  (Figure  1)  generally 
occurs  at  the  N-7  position  on  guanine.
10  Two  different  nucleophiles  on  separate  DNA 
strands attach to the alkylating agent preventing the unravelling of the DNA.  
 
N
R
 
Figure 1 
 
The spacing between the nucleophilic sites on each DNA strand and the number of carbon 
atoms between the two electrophilic sites on the alkylating agent are crucial. Ideally the 
two DNA strands will become locked in position to prevent replication. Cross-linking can 
occur on single strands on DNA – unfortunately this scenario is not serious and the DNA 
will repair itself. Bifunctional alkylating agents are responsible for forming rigid cross-
links between the two strands of DNA – these drugs are known as major groove-binders as 
a link is formed in the major groove of DNA. Jennifer M. Wilson, 2007     Chapter 1, 15 
 
1.2.1 Classifications of Alkylating Agents 
1.2.1.1  Nitrogen Mustard Derivatives 
There  are  four  main  nitrogen  mustard  derivatives  –  all  four  possess  the  same 
pharmacophore. The pharmacophore is an N-chloroethyl  group  that can attach itself to 
DNA. All the nitrogen mustards possess two chloroethyl groups, hence are bifunctional 
and able to crosslink DNA. This occurs by the release of a chloride ion as the molecule 
undergoes a first order reaction forming a positively charged reactive intermediate – an 
aziridinium ion. This intermediate covalently binds to the N-7 group on guanine, which is 
nucleophilic. The second ‘arm’ of the drug then undergoes similar reaction with the base 
on a separate strand of DNA forming the crosslink (Scheme 2).
11 Several of the nitrogen 
mustards are discussed below. 
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Mechlorethamine
12, commonly known as Mustargen 2, has a half-life of approximately one 
minute under physdiological conditions so it must be administered intravenously for the 
drug to have an effect. This drug is used to treat lymphomas. 
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Chlorambucil
13 3 has a half-life of twenty minutes which means that it can be taken orally 
in tablet form. Although 3 is insoluble in water, passive diffusion acts as the transport into 
cells. This drug exists mainly as a zwitterion – this means that the molecule is ionically 
doubly charged. This is not the reactive form of the drug because the nitrogen is protonated 
and unable to form the reactive intermediate. 
N
Cl
Cl HO
O
3  Jennifer M. Wilson, 2007     Chapter 1, 16 
To increase the stability of nitrogen mustards, ring structures were added to the molecule. 
This increases the stability by decreasing the number of unwanted side reactions as the 
nucleophilicity  of  the  nitrogen  is  reduced,  for  example  an  aromatic  ring  withdraws 
electrons  from  the  nitrogen  thus  reducing  the  nitrogen’s  ability  to  displace  one  of  the 
chloride  ions.  Chlorambucil  3  is  used  to  treat  chronic  lymphocytic  leukaemia,  ovarian 
cancers, trophoblastic neoplasms and Waldenström macroglobulinaemia as well as being 
used as an immunosuppressant.  
 
Melphalan
13 4 exists as a highly charged species due to the fact that two nitrogens and one 
carboxylic acid are present. The uptake of the drug by cancer cells after oral administration 
is controlled by an amino acid active transport system. A drawback to use of this drug is 
the build up of resistance due to a mutation that leads to a change in the transport system. 
Melphalan 4 is used to treat multiple myeloma, malignant myeloma and ovarian cancer. 
One  major  drawback  to  the  use  of  Chlorambucil  3  and  Melphalan  4  is  their  minimal 
specificity, which means that they can be very toxic to healthy cells in the body, e.g. bone 
marrow cells. 
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Cyclophosphamide
14 5 was one of the first nitrogen mustard prodrugs to be synthesised. It 
was thought that tumours were rich in phosphoramidase which would convert the drug into 
its active form.  
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Scheme 3 Jennifer M. Wilson, 2007     Chapter 1, 17 
Scheme 3 shows what actually happens. The drug 5 is oxidised by enzymes in the liver 
producing the active metabolite 4-hydroxycyclophosphamide 6 and its tautomer 7 which 
can react with aldehyde dehydrogenase (ALDH) forming phosphoramide mustard 8 that 
can  crosslink  with  DNA.  A  side  product  is  acrolein  9  which  is  toxic  to  the  bladder 
epithelium.  
1.2.1.2  Alkyl Sulfonates 
The most common alkyl sulfonate is Busulfan
15 10 which is also a bifunctional alkylating 
agent. It is used to treat chronic myeloid leukaemia (CML) and other cancers. It can be 
taken orally or intravenously.  
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1.2.1.3  Nitrosoureas 
The two main compounds that fall under this category are Carmustine (BCNU) 11 and 
Lomustine (CCNU) 12.
16 Decomposition occurs in aqueous conditions. 
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Scheme 4 
These  compounds  are  used  for  the  treatment  of  brain  tumours  as  they  are  extremely 
lipophilic so can easily pass through the blood-brain barrier (BBB).
17  
1.2.1.4  Ethyleneimines 
As the classification name suggests, these drugs contain the three-membered ring moiety 
that appears  as  an  intermediate  during  the  DNA  alkylation  process. TEPA  13 was  the 
initial  compound  synthesised  although  it  turned  out  to  be  chemically  unstable  so Jennifer M. Wilson, 2007     Chapter 1, 18 
ThioTEPA  14  was  produced.
18  ThioTEPA  is  used  to  treat  breast,  ovarian  and  bladder 
cancer and is given intravenously. 
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1.2.1.5  Triazenes 
Triazenes are used to treat malignant melanomas and Hodgkin’s lymphomas. This group of 
compounds  produces  the  same  intermediates  after  following  different  physiological 
pathways in the body. Scheme 5 shows two examples, temozolomide 15 and dacarbazine 
16  breaking  down  to  form  the  same  intermediate  5-(3-methyltriazen-1-yl)imidazole-4-
carboxamide (MTIC) 17 which then breaks down to form amine-imidazole-4-carboxamide 
(AICA) 18 and the DNA-alkylating methyldiazonium ion 19.
19 
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2  Hypoxia and Cancer 
The majority of solid human tumours contain areas deficient in oxygen and, cells in this 
condition are referred to as hypoxic.
20 Hypoxia occurs when there is an insufficient amount 
of oxygen reaching tissues. Hypoxic cells have been found in cervical cancers, squamous 
cell carcinomas of the head and neck, melanoma, breast and prostate cancers. There is no 
regularity  between  individual  tumours  and  there  is  no  way  of  predicting  the  levels  of 
hypoxia in a tumour.
21 
Hypoxia  is  associated  with  the  poor  prognosis  of  cancer.  Clinical  and  experimental 
evidence show that hypoxia is one of the major causes of resistance to treatment as well as 
encouraging tumour growth and possibly increasing malignant cell progression. In head 
and neck cancer there is evidence that the extent of hypoxia is associated with the overall 
survival of a patient.
20 
The detection of the level of hypoxia present in a cancer patient may be beneficial for 
designing a patient-specific treatment course. In particular the assessment of early tumour 
response to treatment as well as examining long-term tumour response is an important area 
of research. Unfortunately, data on hypoxia in human tumours is scarce due to technical 
and  experimental  limitations.  The  oxygenation  pattern  of  cells  and  the  occurrence  of 
hypoxia does not correlate with the stages of tumour growth.
21 It is impossible to predict 
the oxygenation status of individual cells in tumours before therapy. Therefore, to design 
tumour specific treatments the tissue oxygenation of individual tumours must be evaluated. 
Hypoxic  cells  are  intrinsically  more  resistant  to  treatment.  Generally  the  amount  of 
ionising  radiation  required  for  the  destruction  of  hypoxic  cells  is  three  times  that  for 
oxygenated  cancer  cells.
22  The  resistance  to  chemotherapy  in  hypoxic  cells  is  partially 
caused by reduced toxicity due to the absence of molecular oxygen. Some cancer agents, 
such as bleomycin
23 20, require free radicals for the cell killing mechanism to be activated. 
Without molecular oxygen this mechanism cannot occur. Other problems occur due to the 
hypoxia-induced inhibition of the cell cycle. Several chemotherapeutic agents target high-
proliferating cells. However the rate of proliferation decreases in hypoxic cells due to the 
reduction in oxygen concentration.
20 Toxicity of cancer agents also decreases the further 
the distance the tumour cells are from blood vessels. Simply put, the effective dose of a 
drug to hypoxic cells will be much less than that to other parts of the tumour. Jennifer M. Wilson, 2007     Chapter 2, 20 
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2.1 The Problems Hypoxia Creates 
2.1.1 Metastasis
20 
There is scientific evidence that shows the association of tumour hypoxia with metastasis – 
this is the spread of cancer from one part of the body to another. The promotion of tumour 
metastasis  by  hypoxic  cells  occurs  in  two  ways:  firstly  by  inducing  the  expression  of 
certain gene products involved in the metastatic cascade; and secondly by selecting a more 
aggressive phenotype. 
The initiation of metastasis occurs by three major processes.
24 The first step involves the 
degradation  of  the  basement  membrane  and  extra-cellular  matrix  of  the  cell.  This  is 
followed by the modulation of cell adhesion molecules resulting in cell migration - the 
cancer is now ‘moving’. 
2.1.2 Angiogenesis
20,25 
The  formation  of  new  blood  vessels,  known  as  angiogenesis  is  required  for  tumour 
progression to occur. The expanding tumour mass requires nutrients and the removal of 
catabolites,  which  are  produced  by  the  breakdown  of  complex  organic  molecules  into 
simpler components, accompanied by the release of energy. The process of angiogenesis is 
also required for the efficient dissemination of primary tumour cells during metastasis. 
The  initial  stages  of  both  metastasis  and  angiogenesis  are  almost  identical  as  both 
processes involve the degradation of the extra-cellular matrix and the directed migration of 
cells. Angiogenesis also requires proliferation of migrating endothelial cells. Therefore it Jennifer M. Wilson, 2007     Chapter 2, 21 
would be logical to think that molecules that aid tumour metastasis are also involved in 
angiogenesis and thus must also be regulated by hypoxia, i.e. matrix metalloproteinases, 
the urokinase-type plasminogen activator system and cell adhesion molecules. 
Tumours require an expansion of the blood supply to provide all nutritional requirements 
and  a  sufficient  oxygen  supply.  Tumour  cells  adjacent  to  capillaries  are  adequately 
oxygenated  and  are  therefore  capable  of  normal  aerobic  metabolism  and  cell  division. 
Oxygen must be carried by diffusion to cells not directly adjacent to a capillary and the 
oxygen tension diminishes with increasing distance from a blood vessel. Hypoxic cells 
present at the interface between well-oxygenated cells and necrotic tissue rely on anaerobic 
glycolysis
26 (the process by which the normal pathway of glycolysis is routed to produce 
lactate)  for  energy  production.  These  cells  are  ‘dormant’,  dividing  more  slowly  but 
remaining viable. 
Angiogenesis  in  a  tumour  produces  vessel  architecture  that  is  disproportionate  and 
inadequate  as  well  as  structurally  and  functionally  different  from  normal  tissue.    A 
consequence of this is the high rate of endothelial cell proliferation, which offers two ideas 
for  the  treatment  of  the  cancer  –  anti-angiogenesis  and  vascular  targeting.  Distorted 
vasculature is also a problem as the drug delivery to hypoxic areas is challenged. 
2.2 Strategies for the Treatment of Cancer by Exploiting 
Hypoxia 
It  has  already  been  established  that  hypoxia  is  detrimental  to  cancerous  cells  as  it 
encourages  metastasis  as  well as  other  processes  linked to  the  worsening  of  a  patient. 
However, hypoxia can be exploited to our advantage especially if a treatment can be found 
that will differentiate between hypoxic and normal cells. 
2.2.1 Anti-angiogenesis
27 
The idea behind this treatment is to stop the tumour developing new blood vessels. This is 
a  complex  biological  process  where  the  target  population  of  cells  consists  of  actively 
dividing and migrating vascular endothelial cells from established host and tumour vessels. 
Strategies  involve  the  blocking  of  angiogenic  growth  factors  and  the  suppression  of 
endothelial cell recruitment through small molecule receptor blockers, specific antibodies, 
or the use of inhibitors. Jennifer M. Wilson, 2007     Chapter 2, 22 
In 2004, Bevacizumab
28 (Avastin) became the first anti-angiogenesis drug to be approved 
for  the  treatment  of  cancer.  The  compound  is  a  monoclonal  antibody  directed  against 
vascular endothelial growth factor. The clinical trials carried out showed that people who 
took  the  drug  as  well  as  a  course  of  chemotherapy  lived  longer  (approximately  five 
months) than patients who were just following a course of chemotherapy. However this 
drug does not seem to be a cure for cancer. 
2.2.2 Vascular Targeting
29 
As explained before, solid tumours require a blood supply to provide oxygen and nutrients 
essential for growth. The growth of a tumour can be described as chaotic and the tumour 
vasculature results in the formation of subpopulations of hypoxic cells.  
Vascular targeting would use agents that exploit vasculature features that are unique within 
a tumour. There are advantages with this concept such as efficacy against any solid tumour 
because  the  endothelial  cell  lining  is  targeted,  as  well  as  no  resistance  being  built  up 
against the treatment – this is because endothelial cells are genetically stable. There is also 
easy  accessibility  of  the  drug  to  the  target  and  the  potential  exists  for  the  death  of 
thousands of tumour cells due to vessel damage and subsequent nutrient deprivation. It is 
hoped that this technique will result in the death of hypoxic cells at an intermediate level, 
particularly those resistant to classical treatments. 
Generally tumour hypoxia is an independent predictor of the outcome of a tumour, as it 
does not depend on tumour size, clinical stage, histological type, and extent of necrosis or 
haemoglobin levels in the patient.
20 Hypoxia has been assigned multiple roles in the whole 
process of cancer – it can induce angiogenesis, apoptosis and metastasis. The induction of 
these  chemical  changes  results  from  changes  in  the  gene  expression  that  accompany 
hypoxia. The body does try and fight back by expressing genes to counteract hypoxia by 
increasing oxygenation or by mediating cell death signals and inducing cell death. 
2.2.3 Improving Oxygenation 
The main interest in this area involves the administration of hyperbaric oxygen, hypoxic 
cell sensitisers and erythropoietin (EPO - Figure 2) to improve the haemoglobin level and 
avoid repeated blood transfusions.
30 Jennifer M. Wilson, 2007     Chapter 2, 23 
Mixed results have been achieved from these studies. The best result was in head and neck 
cancers  where  analysis  of  a  large  number  of  trials  showed  that  oxygen  modification 
resulted in a significant improvement in local control and survival. 
 
Figure 2 
Erythropoietin is a glycoprotein hormone that stimulates red blood cell production.  It is 
produced in the kidneys in response to tissue hypoxia in the bone marrow. The structure is 
made up of one hundred and sixty five amino acids in a circular form. Two disulfide bonds 
tether the molecule together between cysteines 29 and 33 and cysteines 6 and 161. Three 
N-linked sugars are present at asparagines 24, 38 and 83, and one O-linked sugar is present 
at serine 126.  
This protein can be applied to a tumour model especially in anaemic patients where tumour 
hypoxia  may  occur  due  to  low  haemoglobin  levels.
31  There  is  active  interest  in  using 
recombinant  human  EPO  in  order  to  improve  tumour  oxygenation.  Haemoglobin 
concentration has been shown to be an important factor for the outcome of various cancer 
types that are conventionally treated by radiotherapy.  
2.2.4 ARCON
32 
Accelerated  radiotherapy  combined  with  carbogen  and  nicotinamide  is  currently 
undergoing  clinical  assessment.  Both  agents  have  different  roles  for  the  treatment  of Jennifer M. Wilson, 2007     Chapter 2, 24 
cancer.  Carbogen  (95% O2  and  5%  CO2)  reduces  diffusion-limited  or  chronic  hypoxia 
whereas nicotinamide 21 reduces acute hypoxia from vascular shutdown. Simultaneous use 
of these agents has increased the radiation damaging effect in rodent models.
33 
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2.2.5 Exploitation of the Microenvironment 
There are three main ways that hypoxia can be exploited. Firstly the known molecular and 
cellular biological responses to hypoxia can be targeted. Secondly, the unique features of 
tumour vasculature (already discussed) which are responsible for, as well as a consequence 
of, tumour hypoxia, can also be exploited. Finally the lack of oxygen can be used to our 
advantage by the administration of bio-reductive drugs. 
2.2.5.1  Exploitation of Biological Responses
20 
Gene expression is altered by the presence of hypoxic cells. These changes in expression, 
in turn, cause a cellular and tissue response that affects the processes occurring in the cell, 
be it angiogenesis, metastasis or sensitivity to treatment. If the activation of the early steps 
of these processes can be targeted, specific and effective types of gene therapy can be 
developed. The idea of this concept is to transfer genetic material to the tumour cell in 
quantities sufficient to obtain a therapeutic level of expression. To date, research carried 
out has been unsuccessful due to deficiencies in the delivery systems being used. However 
a current area of research involves the targeting of anaerobic bacteria that will infect the 
hypoxic/necrotic areas of tumours. 
Various biological responses to hypoxia can be seen in a generalised pathway consisting of 
four steps. Firstly an oxygen sensor is activated – an oxygen sensor is capable of sensing 
and responding to reduced oxygen levels. Then the activation of this sensor leads to a 
molecular response, which is quickly followed by a cellular response. The culmination of 
these steps is a tissue or tumour response.  Jennifer M. Wilson, 2007     Chapter 2, 25 
2.2.5.2  Bio-reductive Drugs
34 
These are inactive compounds that can be reduced by enzymes in the body revealing toxic, 
active metabolites. They are designed so that this metabolism occurs preferentially in the 
absence of oxygen making them good agents for targeting hypoxic cancer cells. Used in 
combination  with  existing  cancer  treatments  this  strategy  has  potential  for  improving 
treatment outcome by targeting the hypoxic fraction of the tumour. Hypoxic cells are also 
found in a number of different medical conditions including rheumatoid arthritis, diabetes 
and stroke – thus non-cytotoxic delivery of the therapeutic agent would be preferred.  
Bio-reductive  drugs  are  also  known  as  hypoxia-selective  cytotoxins  (HSCs).
35  
Conceptually, HSCs consist of three domains: a trigger that undergoes hypoxia selective 
(oxygen inhibited) reduction;  an  effector  which  is  activated  following  reduction  of the 
trigger; and a linker which connects the other two domains and communicates the change. 
The  trigger  must  undergo  efficient  and  selective  metabolism  in  the  hypoxic  cells  to 
generate a toxic effector. Prodrugs are often classified by the nature of the trigger unit. The 
effector should be potent and able to kill cells in all proliferative states. Ideally it should be 
able  to  diffuse  back  to  kill  surrounding  cells.  Therefore,  the  effector  requires  good 
diffusion properties and an appropriate half-life. The linker deactivates the prodrug but 
must rapidly transmit an activating signal for the metabolism of the trigger. 
Bio-reductive  drugs  should  fulfil  several  requirements.  In  hypoxic  cells  the  compound 
should be converted into a stable persistent cytotoxin. The active product should bind non-
covalently to DNA  with a reasonable affinity to produce cytotoxicity but with  enough 
stability to allow slow diffusion and subsequent cytotoxicity in proximate tumour cells 
irrespective of the oxygen levels. The HSC must also be easily oxidised back to the parent 
compound if it comes into contact with an oxygenated cell. 
Nitro-aromatic heterocycles and indoloquinones have been studied for use as prodrugs.
36 
There is significant interest in the design of a prodrug that when reduced will release, as 
well  as  an  active  drug,  a  bioreductive  agent  that  itself  will  show  therapeutic  efficacy 
towards tumour cells (perhaps another population of tumour cells). Quinones release their 
active  drug  by  a  mechanism  involving  bio-reduction  followed  by  intramolecular 
cyclisation (Scheme 6). The benzoquinone acts as the trigger and the propionic moiety acts 
as the linker.
37 This effectively masks the drug until it is released in hypoxic tissues. The 
bulky  ‘dimethyl  lock’  imparts  steric  hindrance  upon  the  molecule  and  this  aids  the Jennifer M. Wilson, 2007     Chapter 2, 26 
lactonisation  (Thorpe-Ingold  effect
38).  After  reductive  activation,  intramolecular 
lactonisation occurs resulting in the elimination of the drug. 
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Scheme 6 
Bio-reductive drugs can also form adducts with DNA via attack by a nucleophilic moiety 
on DNA itself, i.e. the action of alkylating agents. This idea uses a synergistic approach for 
the killing of tumour cells – delivery of the drug as well as the concomitant activation of 
another cytotoxic agent. 
Another idea is to incorporate a nucleophile within the bio-reductive molecule that will 
react  intramolecularly  after  bio-reduction  and  drug  release,  effectively  inactivating  the 
compound (Scheme 7).
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Scheme 7 
Vitamin E (tocopheryl quinone TQ 22) can be cyclised in a redox driven manner (Scheme 
8).
40 The hydroxyl group is ejected upon reduction of TQ 22. Looking at this mechanism 
via  a  prodrug  approach, the  conjugation  of  a  chemotherapeutic  agent via  the  hydroxyl 
group would result in the ejection of the drug under favourable conditions.  Jennifer M. Wilson, 2007     Chapter 2, 27 
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Scheme 8 
Radio-sensitisers
20 such as gemcitabine 23,
41 are agents designed to mimic the effects of 
oxygen during radiation delivery. They perform two tasks – increasing DNA damage as 
well  as  restoring  radio-sensitivity  -  and  can  be  effective  as  this  type  of  cancer  agent. 
Unfortunately the compounds developed thus far could not be administered to patients at 
effective concentrations with acceptable toxicity. 
Two  of  the  best  ‘prodrugs’  are  Tirapazamine  24
42  (TPZ)  and  AQ4N  25
43.  TPZ  is  the 
leading compound in this class of drug and has been studied in clinical trials, especially the 
use of the drug in conjunction with cisplatin and/or radiotherapy. In fact a synergistic effect 
can be seen when the drug is used in conjunction with cisplatin. The release of the toxic 
moiety occurs by an enzymatically catalysed one-electron reduction of TPZ  yielding  a 
reactive hydroxyl radical capable of causing cell death through DNA damage.
44 A strong 
oxidising species must be formed as TPZ causes double-strand breakage of DNA under 
anoxic  conditions  and  these  effects  correlate  with  the  cytotoxicity.  In  the  presence  of 
oxygen,  this  radical  is  transformed  back  into  the  non-toxic  parental  compound  –  thus 
oxygenated tissues are protected and toxicity is minimised. 
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TPZ  causes  several  side  effects  including  neutropaenia  (an  abnormally  low  level  of 
neutrophils in the blood), fatigue, muscle cramps, nausea and vomiting. The mechanisms 
of these side effects are not fully understood. They could arise from aerobic redox cycling 
which leads to a reactive oxygen species or the TPZ radical forming in normal tissues. Jennifer M. Wilson, 2007     Chapter 2, 28 
In the case of AQ4N 25,
43 a stable product AQ4 27 is released from the compound by a 
reduction  process  (Scheme  9)  –  this  mechanism  occurs  via  an  obligate  mono-N-oxide 
intermediate,  AQ4M  26.  AQ4  intercalates  within  the  DNA  strand  and  blocks 
topoisomerase II action. The AQ4 released is stable and diffusion to oxygenated cells can 
occur  where  it  acts  producing  a  ‘bystander’  effect  –  this  occurs  when  cells  produce 
damage-response signals that are communicated to their unaffected neighbours.  
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Scheme 9 
AQ4N 25 is the N-oxide of AQ4 27. AQ4 27 has a high DNA affinity constant which 
stabilises  the  DNA  double  helix  as  measured by  a  large increase  in the  DNA  melting 
temperature.  The  DNA  binding  of  the  AQ4  chromophore  is  greatly  facilitated  by  the 
electropositive nature of the alkylamino side chains in the protonated form of the drug – 
this  allows  for  the  critical  electrostatic  interaction  with  the  phosphates  of  the  DNA 
backbone.  
Nitro-heterocycles can act as mimics of molecular oxygen and can be effective as radio-
sensitisers of hypoxic cells.
45 Although a correlation between the one-electron reduction 
potential of such compounds and their efficiency as sensitisers of hypoxic cells does exist, 
compounds  have  been  recently  identified  that  are  markedly  more  potent  than  their 
relatively negative one-electron reduction potentials would suggest. 
Misonidazole 28
46 was the first electron-affinic radio-sensitiser to receive extensive clinical 
study although it was established that it was not possible to administer a sufficient dose to 
achieve radio-sensitisation of tumours. 
The second  generation of this class of compounds were 1-substituted-2-nitroimidazoles 
such as etanidazole 29,
47 pimonidazole 30
48 and RSU 1069 31,
49 which are selectively toxic 
towards hypoxic cells because the 2-nitroimidazoles are bio-reduced in cancerous cells to 
form a specially designed electrophile that will avoid neuro-toxicity by being highly polar 
and thus less able to cross the ‘blood-brain barrier’. Pimonidazole 30 bears a tertiary amine Jennifer M. Wilson, 2007     Chapter 2, 29 
designed to  be  selectively  absorbed  by  acidic regions  of  tumour  tissue  and  thus has  a 
higher potency. RSU 1069 31 is a ‘dual-function’ agent with electrophilic groups. The 
compound proved potent as a radio-sensitiser in experimental systems but elicited dose-
limiting gastro-intestinal toxicity in clinical trials. RB6145 32
50 employs additional DNA-
alkylating  functionalities  in  order  to  produce  a  toxic  bi-functional  DNA  cross-linking 
species.
 At this point it could be seen that general toxicity of the compounds was hindering 
the development of a selectively bio-reductive cytotoxic species so attention was turned to 
producing bis(nitroimidazoles) - like compound 33.
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Using  bis(nitroimidazoles),  both  of  the  nitro  groups  could  be  reduced  providing  a  bi-
functional cytotoxin  which was more toxic than the non-reduced species. However the 
kinetic data collected although consistent with a bi-reduced cytotoxic species, showed that 
the compound does not act as a DNA cross-linking agent. There were also two important 
limitations with this class of agent. The dose range could not be evaluated properly due to 
lack of aqueous solubility and the full hypoxic selectivity was only seen after exposure of 
several  hours.  This  is  presumed  to  be  a  consequence  of  the  less  electrophilic  5-
nitroimidazole moiety. 
Nitro-benzyl mustard quaternary salts are a new class of HSCs, which show very high 
hypoxic selectivities in  vitro.
52 The proposed products for this class of  compounds  are 
shown  in  Scheme  10.  A  one–electron  reduction  of  the  nitro-aromatic  compounds  is 
induced by cellular enzymes to give the nitro radical anion. This mechanism is controlled 
primarily by the reduction potential of the compound and will occur in both oxygenated 
and hypoxic cells. The following step depends on the nature of the cell. In an oxygenated 
cell, molecular oxygen will re-oxidise the radical anion producing the parent compound. 
However,  if  the  cell  is  hypoxic,  fragmentation  of  the  initial  radical  anion  will  occur 
producing a benzyl radical and a reactive nitrogen mustard, such as mechlorethamine 2.  Jennifer M. Wilson, 2007     Chapter 2, 30 
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Scheme 10 
There  is  published  evidence  that  closely  related  nitro-benzyl  salts  and  nitro-benzyl 
quaternary salts do fragment following a one–electron reduction and that the nitro radical 
anions  of  such  compounds  are  readily  re-oxidised  by  oxygen.  Other  studies  involving 
cyclic voltammetry and direct observation of the absorption spectra of both the transient 
radical anion and the resulting benzyl radical provide further evidence for the suggested 
mechanism. The observation that these compounds fragment efficiently using radiolytic 
reduction also suggests  that the drugs could be reduced using  radiotherapy rather than 
enzymatic reduction. The only drawback to this idea would be the need to use more potent 
cytotoxins for the concept to be therapeutically useful. 
Radiation-activated prodrugs use the aquated electron from the radiolysis of water as the 
reducing agent.
53 The hypoxic selectivity is achieved by the redox cycling of the initial 
electron adduct in the presence of oxygen. Again it must be reinforced that highly potent 
cytotoxins are required to compete with endogenous electron acceptors in the body for the 
radiation-induced reductants.  
The positive charge on the quaternary salt ensures a high degree of deactivation of the 
mustard and excellent water solubility of the compound as well as a reduction potential 
within the range expected to be suitable for metabolic activation. It is now known that the 
extent to which toxicity is masked by a prodrug is not directly related to the reduction 
potential. However it is thought that the charge will slow the cellular uptake rate of the 
drug.
51 
Mechlorethamine 2
54 is the best mustard so far found to be formed from the fragmentation 
of the drug. It possesses a half-life long enough for back-diffusion into other tumour cells 
to  occur.  The  release  of  mechlorethamine  has  been  confirmed  by  the  trapping  of  the 
nitrogen mustard with diethyl dithiocarbamate and HPLC analysis. 
The main problem with nitro-benzyl quaternary salts is their aerobic toxicity as this totally 
negates the idea of a prodrug. Aerobic toxicity is not thought to be caused by the reductive Jennifer M. Wilson, 2007     Chapter 2, 31 
activation of the drug unless the reduced intermediate is not as stable as thought. Other 
possible theories indicate the slow release of the nitrogen mustard by direct nucleophilic 
displacement during the drug exposure phase. This potentially could occur chemically or 
enzymatically. Generation of a reactive oxygen species could also contribute to the aerobic 
toxicity through redox cycling. The main conclusion to be taken from these studies is that 
quaternising a mustard does not mask all its toxicity. 
Another potential strategy for the design and synthesis of prodrugs involves N-oxidation.
55 
The electron density on the nitrogen of the mustard is significantly decreased and the pKa 
value is lowered by about 5 log units. Molecular oxygen inhibits the metabolic reduction of 
the tertiary amine N-oxides and the N-oxide derivative of mechlorethamine, nitromin 34, 
has been reported to have modest hypoxia selectivity in cell cultures. 
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Several  different  nitrogen  mustards  that  were  already  used  as  therapeutic  agents  were 
transformed into their N-oxides using peracetic acid followed treatment with by sodium 
bicarbonate (Scheme 11).
56 
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Scheme 11 
However, aliphatic N-oxides can rearrange in aqueous solution via a cyclic intermediate to 
form tri-substituted hydroxylamines (Scheme 12).
57 Comparison of the 
1H
 NMR spectra of 
the product with 35 showed that the chlorambucil N-oxide had indeed rearranged. The 
decomposition products were also tested but chlorambucil N-oxide was the most cytotoxic 
species present. Jennifer M. Wilson, 2007     Chapter 2, 32 
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Scheme 12 
The development of related tetrahydroisoquinoline quaternary salts has also been carried 
out.
35 The provision of a second, non-cleavable linking  chain between  the nitro-benzyl 
chromophore and the quaternary leaving group ensures that the released mustard and the 
benzyl radical remain linked. A mono-functional mustard will be generated and it is hoped 
that the simultaneous generation of a linked reactive centre generated from the attached 
benzyl radical will not hinder the toxicity. 
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The three isomers of 36 that were synthesised were less toxic than mechlorethamine – this 
is due to the powerful deactivating effect of the permanent positive charge of the nitro 
group. Preliminary studies also show that these compounds inhibit [
14C]-choline uptake. 
This strongly suggests that the major mechanism for the uptake of these compounds is via 
the choline transport pathway instead of passive diffusion.
58 Further work is being carried 
out to study factors such as radical lifetime or the ability of the drugs to be transported via 
the choline carrier pathway. 
Carmethizole 37 is a novel bis-carbamate alkylating agent, which forms DNA-protein and 
DNA-DNA  crosslinks  in  vitro.
59  It  has  in  vivo  anti-tumour  activity  against  murine 
leukaemias, solid tumours and human tumour xenografts. 
N N
SMe
Me
O O
NH HN
O Me O Me
37
N N
R
Me
O O
NH HN
O Me O Me
38
R = NH2, N3, NHCO2R1  Jennifer M. Wilson, 2007     Chapter 2, 33 
By  adding  electron-donating  substituents  at the  2-position  the  anti-tumour  activity  was 
enhanced  whereas  with  electron-withdrawing  groups  the  compounds  became  inactive.  
This observation is probably explained by the stabilisation of the transition state of the 
SN1-type activation of the hydroxymethyl groups that will lead to DNA alkylation. Two 
different strategies could be employed. Firstly, the bis-hydroxymethylimidazole nucleus 
derived from carmathizole could be used as the alkylating unit with 2-nitrogen substituents 
added to deactivate the alkylating units. Secondly the substituted hydroxymethylimidazole 
ring could be used as a trigger unit rather than an alkylating unit. 
Using  the  first  strategy,  38  (when  R  =  NH2)  is  expected  to  be  more  reactive  than 
carmethizole. This is not useful for a prodrug so by changing the amino group to an azide 
or a carbamoyl group (i.e. considerably less electron donating substituents) a more useful 
compound  would  be  produced.  Azides  are  known  as  masked  amine  functions  and  the 
metabolism of aryl azides to amines has been demonstrated.
60 
The second approach involves the reduction of the trigger group leading to activation of a 
separate  alkylating  moiety  attached  via  a  deactivating  carbamoyl  linker.  The  electron-
withdrawing substituent on the imidazole ring could be bio-reduced to a more electron-
donating moiety that  would activate the carbamate unit to nucleophilic attack  with the 
subsequent fragmentation of the resulting carbamic acid, releasing a secondary amine as 
the  cytotoxic  effector.  The  alkylating  agent  selected  was  N,N-bis(2-chloroethyl)amine 
(BCEA)  and  nitro  and  sulfoxide  substituents  were  selected  as  suitable  electron 
withdrawing substituents to place in conjugation with the methyl carbamate. The results 
showed that there is potential in the further study of these compounds especially for the use 
as trigger units for the release of secondary amino cytotoxins.
59 
Transition  metal  complexes  have  demonstrated  cytotoxicity  in  cell  culture  and/or  anti-
tumour activity in tumour-bearing animals.
61 The metals used include Ag(I), Cu(I) and 
Cu(II),  Zn(II),  Hg(II),  Rh(II),  Ru(II)  and  Ru(III),  Pd(II),  Pt(II),  Co(III)  and  Fe(III). 
Platinum complexes are currently in routine clinical use.
62 
The classical inorganic anticancer agent cis-diaminedichloroplatinum(I), cisplatin 39 forms 
coordination  bonds  with  cellular  targets  and  is  classified  as  an  anti-tumour  alkylating 
agent.  Other  complexes  that  bind  specifically  to  sites  on  DNA  are  chiral  Co(III)  tris-
phenanthroline molecules. Jennifer M. Wilson, 2007     Chapter 2, 34 
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Cobalt (III) complexes are kinetically inert coordination complexes. The inertness is due to 
the d
6 low spin electron configuration of the trivalent cobalt. This inertness is the main 
reason why cobalt complexes have potential as prodrugs. The biological consequence of 
the inertness is that the complex will remain intact when added to a culture medium or 
injected as a drug. The drug should arrive at its cellular targets intact with its original 
ligand configuration.  
The complexes 40 and 41 are interesting as targets for bio-reductive drugs.
60 The bulky 
pyridine ligand in 41 is similar in size to the BCEA ligand possessed by many alkylating 
agents such as 40, although the bifunctional alkylating ability is not present. The Co(III) in 
both compounds could also be reduced to Co(II) thus releasing BCEA. The lone pairs on 
the  nitrogens  in  the  Co(III)  complexes  40  and  41  are  deactivated  because  they  are 
complexed to the metal. 
These drugs are known as HPDCs – hypoxia activated prodrugs of diffusible cytotoxins. 
They  are  used  as  a  solution  to  the  problem  of  cells  with  intermediate  oxygen 
concentrations. Bio-reductive drugs are only activated at very low oxygen concentrations 
and therefore many tumour cells are sufficiently hypoxic to be radio-resistant even though 
the  prodrug  will not  be activated.  Thus,  prodrugs  were  developed  with  an  appreciable 
diffusion range – HPDCs. Activation of the drug is confined to regions of very low oxygen 
tension. 
There are other strategies including ADEPT
63 and GDEPT,
64 which use prodrugs. ADEPT 
is antibody directed enzyme prodrug therapy and GDEPT is gene directed enzyme prodrug 
therapy.  
ADEPT involves a group of drugs called monoclonal antibodies, which recognise certain 
proteins that are found at the surface of some cancer cells. ADEPT is a targeted therapy – 
the antibody is attached to a specific enzyme. The monoclonal antibody recognises the 
protein and locks on to it. A prodrug is then given and cell death should occur. Jennifer M. Wilson, 2007     Chapter 2, 35 
GDEPT operates in the same way except that a gene for the expression of the prodrug 
activating enzyme is delivered to the cells. The prodrug becomes activated by the foreign 
enzymes present in the cancerous cells. 
2.3 Conclusion 
To  date,  there  is  no  prodrug  that  has  shown  sufficient  clinical  activity  to  achieve 
registration for general use. A drug has to be designed that will reach remote hypoxic cells, 
i.e. the diffusion of the drug should be more efficient. The activated effector must possess a 
better ‘bystander’ effect so that the ‘killing zone’ is expanded. A more deliberate design 
process must be developed allowing the synthesis and biological testing of a drug that will 
selectively kill cancer cells. 36 
3  Human African Trypanosomiasis
65 
3.1 Human African Trypanosomiasis 
Human African Trypanosomiasis (HAT) is more commonly known as African Sleeping 
Sickness. The disease is carried by parasites of the Trypanosoma genus and is transmitted 
by the bite of a tsetse fly (Glossina genus – Figure 3
66). The tetse flies themselves acquire 
the  infection  from  mammals  (human  beings  or  animals)  harbouring  the  pathogenic 
parasites. Tsetse flies are found exclusively in Africa in a belt that stretches south of the 
Sahara and north of the Kalahari desert. 
 
Figure 3 
The protozoa belong to a family comprised of parasites of insects, plants, fish, amphibians, 
reptiles, birds and mammals.
67 The parasites generally infect most vertebrate genera and 
are  likened  to  cancer  cells  due  to  their  capacity  for  growth.
68  Only  two  forms  of 
trypanosomes cause significant human disease. Trypanosoma brucei (Figure 4
69) is found 
in sub-Saharan Africa and causes HAT. The parasites are known as salivaria as the disease 
is transmitted in tsetse fly saliva. Trypanosoma cruzi is found in America, primarily in 
South  America,  but  it  presents  a  potential  hazard  in  Mexico  through  blood  and  organ 
donations.  T.  cruzi  causes  Chagas’  disease  and  the  parasites  are  known  as  stercoraria 
because  transmission  is  via  vector  faeces.  Both  forms  of  the  parasite  are  single-celled 
flagellates that are transmitted by insect vectors. The parasites undergo phases of local 
multiplication followed by dissemination and localisation in target organs where they cause 
lethal damage. Both vector groups that transmit the diseases are known as K-strategists.
70 
They have a low reproductive rate complemented by a high survival rate adapted to exploit 
their habitats. 
It  has  been  shown  that  humans  have  been  exposed  to  T.  brucei  during  the  course  of 
evolution whereas T. cruzi evolved independently, only coming into prominence with the 
appearance of man on the American continent within the past 12,000 years. 4000 year old Jennifer M. Wilson, 2007     Chapter 3, 37 
mummified  remains  from  South  America  have  been  identified  as  possessing  T.  cruzi 
DNA.
71 
 
Figure 4 
There is one reported case of HAT being transmitted sexually.
72 A 30 year old Portuguese 
woman presented herself at hospital with HAT symptoms. She had never visited Africa, 
although  her  Brazilian  partner  had  been  on  a  military  mission  to  Angola  three  years 
previously. He was identified as a symptom free carrier. Both were successfully treated for 
HAT. 
HAT affects 36 countries of sub-Saharan Africa (Figure 5
73) and occurs in remote rural 
areas where health systems are weak or non-existent and it mainly strikes the active adult 
population.  Epidemics  are currently  rife in  the  Democratic  Republic  of  Congo  (DRC), 
Angola and Sudan. Other infected countries include Uganda, Central African Republic, 
Congo Republic and Tanzania.
74 60 million people are at risk from HAT.
75 The number of 
cases is difficult to estimate. In 1998, 40,000 cases were reported but it is believed that the 
real  number  of  sufferers  was  in  the  region  of  300,000-500,000  due  to  cases  being 
undiagnosed and therefore untreated.  
 
Figure 5 Jennifer M. Wilson, 2007     Chapter 3, 38 
Surveillance of the disease is being reinforced and the number of cases reported has been 
substantially  reduced.  It  is  still  difficult  to  assess  the  current  situation  due  to  lack  of 
surveillance and diagnostic expertise. The disease was nearly eliminated during the 1960s. 
However the disease has recently been on the increase due to war, population movements 
and the collapse of health systems. The disease is the major cause of depopulation of large 
tracts  of  Africa.  Fear  has  led  to  abandonment  of  fertile  land  and  is  an impediment  to 
development.
65 
There are two stages to the disease.
65 After the host has been bitten by the tsetse fly, the 
parasites proliferate at the site of infection, leading to an inflammatory nodule or ulcer. The 
parasites then spread to the draining lymph node and reach the bloodstream, initiating the 
haemolymphatic  phase.  The  sufferer  will  experience  fever,  headaches,  joint  pains  and 
itching.  As  the  disease  progresses  past  the  blood-brain  barrier,  the  parasite  infects  the 
central nervous system and the second stage known as the neurological phase begins. The 
sufferer  will  experience  confusion,  sensory  disturbances,  poor  coordination  and 
disturbance of the sleep cycle – hence the common name of the disease. How and why the 
parasites infect the CNS is not clear. 
There  are  two  forms  of  HAT  depending  on  which  specific  parasite  is  involved. 
Trypanosoma brucei gambiense (T.b.g.) occurs in west and central Africa and accounts for 
90% of reported cases. The disease is a chronic infection and the patient can be infected for 
several months without showing any symptoms. As symptoms do appear the disease will 
be in the advanced stages with the central nervous system affected. The other form of the 
disease is Trypanosoma brucei rhodesiense (T.b.r.) which affects east and southern Africa, 
although this accounts for less than 10% of the reported cases. This form of the disease is 
acute and the first symptoms will appear after a few weeks. The disease will develop more 
rapidly in the later stages. Without treatment HAT is fatal. 
The diagnosis relies on detecting parasites in the patient’s blood or lymph nodes. If there is 
a positive test for parasites, a lumbar puncture is performed to identify if the disease has 
progressed onto the second stage. Current diagnostic methods  are invasive, difficult to 
carry out and require highly trained staff. Jennifer M. Wilson, 2007     Chapter 3, 39 
3.2 Trypanosomes’ Life Cycle
76 
The tsetse fly becomes infected when taking a blood meal from an infected mammalian 
host (Figure 6
76). The parasites transform into procyclic trypomastigotes and multiply. The 
parasites leave the midgut and transform into epimastigotes that reach the fly’s salivary 
glands and continue mulitiplying. 
The  infected  tsetse  fly  has a  blood  meal  on  a  mammalian  host  and  injects  metacyclic 
trypomastigotes into the skin tissue. The parasites enter the lymphatic system and pass into 
the bloodstream. Inside the host, they transform into bloodstream trypomastigotes and are 
carried to other sites of the body. Continuous replication occurs. 
 
Figure 6
76 
3.3 Treatment of HAT
77 
The type of treatment a patient receives depends on the stage of the disease. If caught early 
during the first stage, the drugs used are less toxic, easier to administer and more effective. 
However, if the disease has developed into the later stages the success of the treatment 
relies on the drug crossing the blood-brain barrier. Such drugs are toxic and complicated to 
administer. Jennifer M. Wilson, 2007     Chapter 3, 40 
3.3.1 Pentamidine 
Pentamidine 42 was first used in 1941 to treat first stage T.b.g. and is well tolerated by 
patients.
78 The aromatic diamidine must be injected into the muscles. Diamidines work 
directly against the parasites. 
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Pentamidine 42 was developed after the observation that a related compound, synthalin, 
that  induced  hypoglycaemia  in  mammals  also  displayed  trypanocidal  activity.
78  The 
diamidines are dications at physiological pH and they interact with a number of cellular 
anions.  They  are  known  to  bind  tightly  to  the  minor  groove  of  DNA  inhibiting 
replication.
79 
3.3.2 Suramin 
Suramin 43 was first developed in 1921 by German chemists and is used to treat T.b.r., 
although  the  drug  does  produce  undesirable  side  effects  in  the  urinary  tract  and  also 
stimulates allergic reactions.
80 The drug is given to humans and camels. The treatment 
course takes five weeks which causes problems due to the lack of resources in infected 
areas.  
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The  drug  is  a  colourless,  polysulfonated  symmetrical  naphthalene  derivative.  Other 
naphthalene  dyes  were  initially  developed  for  their  marked  trypanocidal  activity.  At 
physiological pH, the drug bears six negative charges and it inhibits many enzymes by 
electrostatic interactions. It has been shown to block the specific cell surface binding of 
various growth factors
81 and inhibits tyrosine phosphorylation.
82 Jennifer M. Wilson, 2007     Chapter 3, 41 
Suramin  43  inhibits  reverse  transcriptase  which  is  a  key  enzyme  of  the  human 
immunodeficiency virus (HIV).
83 The drug had no impact on the progression of AIDS. 
Suramin 43 has recently been used in clinical trials against hormone-refractory prostate 
cancer and other human malignancies as it inhibits angiogenesis.
82,83  
3.3.3 Melarsoprol 
Melarsoprol 44 was first used in 1949 and was developed from arsenic. It is known to 
corrode plastic syringes.
84 The compound 44 is synthesised by complexing melarsen oxide 
with the metal-chelating drug dimercaptol. In trypanosomiasis, 44 reversibly inhibits the 
cellular enzyme glutathione reductase and NADPH oxidase.
85 
The melaminophenyl-based organic arsenical 44 induces many different side effects. One 
of  the  more  serious  is  encephalopathic  syndrome  which  will  kill  3-10%  of  patients. 
Statistics show that one in 20 patients treated with melarsoprol will die.  
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One  Médecins  Sans  Frontières  doctor  working  in  Uganda  has  been  quoted  as  saying 
‘Melarsoprol is a terrible drug – you don’t feel proud injecting it. It is caustic, it burns and 
you don’t know if you are going to save your patient or kill him!’ 
The  disease  can also  build  up  resistance  against the  drug  and  around  30%  of  patients 
treated will not be cured. This resistance has mainly been observed in central Africa. The 
drug is accumulated by an unusual amino-purine transporter and loss of this transporter 
leads  to  drug  resistance.  T.  brucei  contain  multiple  purine  transporters  at  their  plasma 
membranes. Trypanosomes like all protozoan parasites are auxotrophic for purines and rely 
entirely on salvage from the host environment for their purine supply.
86  
It is generally accepted that the toxic species of the arsenicals is the trivalent oxidation 
state of  the  arsenic.  Trivalent  arsenicals react  quickly and  reversibly  with  vicinal thiol 
groups  in  proteins  such  as  trypanothione  and  so  many  enzymes  can  be  targeted  for 
inhibition. Cell death is rapid. Jennifer M. Wilson, 2007     Chapter 3, 42 
3.3.4 Eflornithine 
Eflornithine 45 was first registered in 1990 to treat T.b.g. although the drug was initially 
designed to be an anti-cancer agent. Clinicians are still deliberating about the malignancies 
for which it is best suited.
87 The compound is a derivative of ornithine. The regimen is 
extremely strict and difficult to apply as slow drip infusions are administered every six 
hours for fourteen days. 
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It is reported that uptake occurs via passive diffusion across the plasma membrane. The 
compound inhibits ODC. 
3.3.5 Nifurtimox 
Nifurtimox 46 is normally used to treat Chagas’ disease and has been used with limited 
success to treat arsenical-resistant HAT.
88 The drug contains a nitro group that is essential 
for activity. Uptake is reported to occur via passive diffusion. One electron reduction of the 
nitro group generates a free radical which in turn generates reduced oxygen metabolites 
such as superoxide, hydroxyl free radical and hydrogen peroxide all of which can cause the 
death of the parasite.
89 Mammalian cells have better protection against oxidative damage so 
the compound is generally parasite selective.  
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3.3.6 Megazol 
1.3.7Megazol 47 has shown good activity against T. brucei.
90 The 5-nitroimidazole possesses 
the same motif recognised by the transporter responsible for the uptake of several anti-
trypanosomal  drugs.  It  was  thought  that  megazol  47  would  be  of  limited  use  against 
arsenical-resistant trypanosomes. However it would appear that this drug enters the cell by 
passive diffusion as opposed to the transporter thus supplying an alternative drug to use 
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against arsenical-resistant parasites.
91 A combination treatment of megazol 47 and suramin 
43 appears to eliminate trypanosomiasis of the CNS.
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3.3.7 Treatment of Cattle 
Domestic cattle can be affected by the disease too although it is referred to as ‘Nagana’. 
This word literally means ‘depressed’. There are several drugs that can be used to treat 
infected livestock such as berenil 48 and cymelarsan 49.
78 These drugs are based on the 
human alternatives. Berenil like pentamidine has two positive charges at pH 7.4. 
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Once cured, the cattle must not be slaughtered for human consumption for several months 
to ensure that the drug is totally excreted. 
1.3.83.3.8  Vector Control 
During the colonial era, great efforts were made to eradicate HAT by clearing large areas 
of land of any vegetation and removing large wild mammals that would act as a reservoir 
for the disease.
92 This proved very effective but due to the huge resurgence of the disease 
this is now not practical. 
Nowadays, insecticides have proved very successful. The lower parts of trees are targeted 
for spraying as resting flies can be found there in infested areas.
93 Unfortunately ecological 
considerations mean that the use of insecticides is becoming more restricted. 
Tsetse traps and baits are very useful (Figure 7). Trap efficiency depends on the different 
species of tsetse fly. The traps are baited with odours and impregnated with insecticides. 
The flies are also attracted to visual aides such as large expanses of black or blue cloth. 
Acetone is sometimes used as this is the tsetse-atttracting component of cattle breath. 
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Figure 7 
A much publicised approach to controlling tsetse numbers involves the release of sterile 
male flies that will mate unproductively with females.
94 
3.4 Potential Drug Uptake Pathways
95 
Trypanosomes live freely in the bloodstream and cerebral spinal fluid of their mammalian 
hosts and not intracellularly. They are fully exposed to the host’s immune response. The 
parasite remains protected from the immune response by a dense, highly immunogenic 
glycoprotein coat.
96 Up to 1000 genes code for these surface glycoproteins and sequential 
expression  of  these  genes  produces  antigenically  distinct  parasite  populations  allowing 
survival in the mammalian host.
97 Due to this antigenic variation, the prospects of vaccine 
development are poor. 
Drugs need only cross one membrane in order to reach the trypanosomes’ interior which 
can offer a means of selectively targeting drugs to these cells. Potential drug targets could 
be designed from biochemical pathways common to the parasites but absent in mammalian 
hosts.
98 As explained before the only barrier between the parasite and its host is the plasma 
membrane.  Transporters  are  used  for  the  uptake  of  nutrients  by  the  parasites.  If  vital 
transporters were blocked the parasites would die. Nutrient transporters represent excellent 
drug targets.
99 
3.4.1 Glucose Metabolism 
Trypanosomes are dependent on glycolysis for energy production. The first seven enzymes 
found in this pathway reside within unusual organelles known as glycosomes.
100 There are 
several  structural  and  functional  features  of  trypanosome  glucose  transporters  that 
distinguish  them  from  mammalian  counterparts.
101  The  transporters  possess  a  relative 
insensitivity to various pharmacological reagents such as cytochalasin B. The transporters Jennifer M. Wilson, 2007     Chapter 3, 45 
also  have  a  substrate  recognition  profile  which  includes  the  ability  to  transport  D-
fructose.
102 
3.4.2 Pentose Phosphate Pathway 
Many enzymes of the pentose phosphate pathway (Figure 8) are related to cyanobacterial 
isoforms  rather  than  to  those  of  eukaryotes.
103  6-Phosphogluconate  dehydrogenase  (3
rd 
enzyme of the pathway) is essential for trypanosomal survival.  
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Figure 8 
There are specific structural differences when compared to the mammalian counterpart and 
this has been exploited in the design of new selective inhibitors.
104 Jennifer M. Wilson, 2007     Chapter 3, 46 
3.4.3 Thiol Metabolism 
The role of glutathione in trypanosomes is undertaken by trypanothione 50 (N,N-bis-gluta-
thionylspermidine) which is a low molecular weight thiol consisting of two glutathione 
molecules linked by spermidine.
105 Enzymes involved in trypanothione metabolism have 
been identified as good candidate targets.  
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Design of new targets should take into account that the interaction between trypanothione 
50 and the enzyme appears to occur via a heteroatom of the enzyme that bonds with the 
free thiol groups of the two cysteines present in the co-factor.
106 Therefore the central atom 
of any new lead compounds should show a great affinity towards sulfur. 
3.4.4 Polyamine Metabolism 
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Figure 9 
By synthesising synthetic analogues of key biosynthetic enzymes, drugs can be directed to 
specific targets. Ornithine and methionine are essential for the trypanosomes’ polyamine 
biosynthetic pathways (Figure 9).
107 Eflornithine 45 is the only drug used to treat HAT for Jennifer M. Wilson, 2007     Chapter 3, 47 
which  a mode of action has been identified. As explained before eflornithine 45 is an 
inhibitor of ornithine decarboxylase (ODC).  
The polyamine metabolic pathway is also a target for anti-cancer chemotherapy due to the 
central role of these metabolites in cell proliferation. 
3.4.5 Lipid and Sterol Metabolism 
Lipids  play  a  central  role  in  biological  membranes  as  well  as  participating  in  cell 
signalling. Sterol biosynthesis has been targeted for use against fungi which have similar 
pathways to trypanosomatids. Therefore drugs designed to use against fungi could also be 
potential anti-parasitic candidates.
108 
3.5 Future of HAT Treatments 
It is difficult to encourage pharmaceutical companies to carry out research on anti-parasitic 
agents  as  there  is  no  monetary  incentive  for  them.  Most  sufferers  live  in  developing 
countries. In May 2001, after pressure from several governments and non-governmental 
organisations,  Aventis,  MSF  and  WHO  set  up  a  project  to  produce  pentamidine  42, 
melarsoprol 44 and eflornithine 45 for at least five years. Bayer and Bristol-Myers Squibb 
also got involved in the production of sleeping sickness drugs.  
A  consortium  of  researchers  funded  by  the  Melinda  and  Bill  Gates  Foundation  have 
identified prodrug DB289 51 (2,5-bis[4-amidinophenyl]furan bis-O-methyl amidoximine) 
as a future HAT treatment.
109 The compound is absorbed across the intestinal epithelia and 
is converted into a trypanocidal dicationic form. 
O MeON
H2N
NOMe
NH2
51  
This is the first ‘new’ HAT drug for almost 50 years. More research is required to design 
better drugs. Major pharmaceutical companies must be encouraged to play a greater role in 
developing new drugs for this developing world disease. Meanwhile it is mainly University 
researchers who carry out research into the development of new and better anti-parasitic 
agents. 48 
4  Previous Work within the Robins Group 
4.1 Piperidines 
The Robins group first started researching alkylating agents in the early 1990s. Henderson 
synthesised a series of bifunctional mustards based on piperidine such as 52. The aim of 
the  research  was  to  investigate  whether  aziridinium  ion  formation  was  possible  if 
conformational restrictions were imposed on the molecule. Prodrugs were developed in the 
form  of  N-oxides  53.  The  free  bases  such  as  52  showed  good  activity  in  two  human 
carcinoma cell lines (IC50 values ~8 µM); however the N-oxides such as 53 were inactive 
in  oxic  and  hypoxic  conditions.
110  It  is  thought  that  the  reduction  potentials  of  the 
compounds were outside the range needed for bioreduction. 
N
Me
Cl Cl
N
Cl Cl
O Me
52 53  
4.2 Bispiperidines 
Henderson  then  investigated  variation  of  the  alkylation  selectivity  using  bispiperidines 
such as 54. The piperidines were separated by a chain of varying length to ascertain the 
optimum  distance  between  the  two  heterocycles.  The  derivatives  synthesised  showed 
greater selectivity of alkylation at N-7 of guanine over melphalan and were cytotoxic in 
three  cisplatin-resistant  cell  lines.
111  A  relationship  between  linker  chain  length  and 
compound reactivity was observed. When n = 2, compound 54 was twice as reactive as 
longer chain analogues. 
54
N N
X X
n
 
4.3 Bispyrrolidines 
Anderson carried out further investigation into the length of the linker chain and varied the 
size of the heterocycle by producing a series of homochiral bispyrrolidines such as 55. Jennifer M. Wilson, 2007     Chapter 4, 49 
Compound 55 with 2-, 5- and 6- carbon linker chains gave the best alkylating results. 
Examples of 55 with 3- and 4- carbon linker chains showed no cross-linking activity. A 
range  of  alkyl  linear  56  and  cyclic  mustards  57  were  also  prepared  but  showed  no 
cytotoxicity in a useful range (IC50 values > 100 µM) when tested against  human colon 
carcinoma cell lines.
112 
N N
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4.4 Azamacrocycles 
Robins’ group research then moved away from heterocyclic mustards towards macrocyclic 
nitrogen mustards. There were several reasons for this. Firstly the macrocycles would still 
allow  for  multiple  alkylating  arms  to  be  incorporated  into  the  drugs.  Secondly  the 
architecture of the compounds would be defined yet chain lengths could still be varied. 
Finally, and most importantly, bioreducible prodrugs could be synthesised due to metal ion 
chelation.  Inorganic  chemists  have  long  studied  macrocyclic  polyamines  as  ligands  for 
chelation.
113  
N N
N N
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58 R = H
59 R = Me
60 n = 1
61 n = 2 62  
Compound  % DNA cross-linking at 0.1 µM  IC50 µM 
58  100  22 
59  64  10 
60  94  8 
61  100  9 
62  30  13 
Table 1 
Lacy synthesised a cyclen derivative 58 which showed extremely promising cross-linking 
results compared to chemotherapeutic agents currently in use.
114 The compound was 10
4 
times more effective at DNA crosslinking than chlorambucil and 2000 times better than 
melphalan. IC50 values for the set of compounds ranged from 6 to 25 µM (chlorambucil – 
45 µM and melphalan – 8.5 µM). Anderson synthesised a range of poly-2-chloroethylated Jennifer M. Wilson, 2007     Chapter 4, 50 
azamacrocycles 59-62.
114 These compounds showed promising biological results. Table 1 
shows a summary of the biological results for this set of compounds. 
Due  to  difficulties  experienced  during  the  synthesis  of  the  previously  discussed 
azamacrocycles, Parker investigated the development of a flexible, reliable method for the 
synthesis of azamacrocycles with varying linker chain lengths. Parker also developed the 
synthesis  of  copper(II)  complexes  of  the  macrocycles  thus  producing  potentially 
bioreducible prodrugs.
115 Complex 63 showed no hypoxia selectivity, however complex 64 
displayed  reversible  redox  behaviour  and  showed  excellent  hypoxia  selectivity.  When 
tested against human chronic myeloid leukaemia cell line K562, complex 64 was 24 times 
more toxic under hypoxic conditions than in oxic conditions.  This provided the evidence 
that further investigation into this area of research would be beneficial. 
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Jones investigated the synthesis of oxaazamacrocycles and azamacrocycles of varying size 
and shape to discover if this affects their alkylating ability.
116 Compound 65 proved to be 
the most toxic (IC50 – 4.0 µM) of all the compounds prepared so far. It was unfortunate 
that it proved impossible to synthesise the corresponding copper complex.  
N O
N N
Cl
Cl Cl
65
.3HCl
 
Reid  developed  a  reliable  synthesis  of  substituted  tetraazamacrocycles  such  as  66.  R 
groups were aromatic or heteroaromatic producing a range of compounds with varying 
electronic demand.
117 However, it proved difficult to attach the alkylating arms onto the 
macrocycles so unfortunately the desired alkylating agents were not prepared. The parent 
macrocycles were tested against the parasite Trypanosoma brucei. Analogue 67 was the 
most  toxic  and  underwent  in  vivo  testing  although  a  dose  of  20  mg/kg  did  not  cure 
trypanosomiasis. Jennifer M. Wilson, 2007     Chapter 4, 51 
NH HN
NH HN
66
R NH HN
NH HN
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4.5 Aims of the Project 
It was thought that the favourable results from compounds 64 and 65 could be improved. 
So far only mustards bearing a 2-chloroethyl alkylating arm have been produced. It would 
be interesting to investigate varying the leaving group R (see 68). The aziridinium ion 
formation  could  turn  out  to  be  more  efficient  producing  better  biological  activity.  A 
selection of R groups attached to the cyclen skeleton would be desirable. These compounds 
would then  be  sent  for  biological  testing to  assess DNA  cross-linking  ability,  hypoxia 
selectivity and anti-parasite activity. 
N N
N N
68
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It  would  be  sensible  to  complete  the  ‘set’  of  heteroatom-containing  macrocycles  by 
synthesising thiaazamacrocycles containing N, O, and S such as 69. Multiple alkylating 
sites would still be available and there is literature evidence that sulfur binds to copper(II) 
more  strongly  than oxygen  which  may  overcome  the  problems  experienced  during the 
synthesis of the copper complexes of the oxaazamacrocycles. 
N S
N N
69
Cl
Cl Cl
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5  Synthesis  of  Azamacrocyclic  Mustard 
Derivatives 
5.1 Synthesis of Cyclen 
The first aim of the project was to investigate a quick and reliable synthesis for compound 
70  –  commonly  known  as  cyclen.  Cyclen  has  been  used  as  an  intermediate  for  the 
synthesis of diagnostic and therapeutic agents.
118 The tetraazamacrocycle is involved in the 
development  of  magnetic  resonance  imaging  contrast  agents
119  and  more  recently  as  a 
chelating  agent  for  use  against  targeted  cancer  agents.
120  Cyclen  70  is  commercially 
available but is expensive. There are several ways of synthesising cyclen but in each case 
reaction conditions favour intramolecular cyclisation over intermolecular cyclisation.  
HN NH
NH HN
70  
5.1.1 Template Synthesis
121 
This synthesis is an established procedure within the Robins Group, based on published 
work and can be carried out on a multigram scale (Scheme 13). The three step synthesis 
uses  a  carbon  template  around  which  the  macrocycle  is  built  and  the  two  carbon 
infrastructure  is  then  removed  leaving  the  tetraazamacrocycle.  Starting  from 
triethylenetetraamine  (TETA)  71,  this  synthesis  exploits  the  reactivity  of  formamide 
acetals  forming  bis-imidazoline  72.  Cyclisation  occurred  by  reacting  72  with  1,2-
dibromoethane to give the monoimidazolinium compound 73. The desired macrocycle 70 
was  obtained  after  alkaline  hydrolysis  with  potassium  hydroxide.  The  disadvantage  to 
template synthesis is that it cannot be used to  synthesise  a  range of  macrocycles with 
varying ring size and heteroatom content. It was decided to attempt other cyclen syntheses 
that could provide the opportunity to vary the range of compounds synthesised. Jennifer M. Wilson, 2007     Chapter 5, 53 
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Scheme 13 
5.1.2 Richman Atkins Cyclisation 
Before the 1970s, the most efficient method for the synthesis of polyazamacrocycles was 
by Stetter and Roos.
122 By combining terminal dihalides and bis-sulfonamide sodium salts 
under high dilution conditions, the protected product  was isolated in poor to moderate 
yields.  Although  this  procedure  was  versatile  with  respect  to  ring  size,  there  were 
disadvantages such as excessive use of solvent, poor yields and long reaction times. In 
1974  Richman  and  Atkins  published  a  letter  detailing  a  procedure  with  improved 
cyclisation yields without high dilution conditions (Scheme 14). Nine to 21 membered 
macrocycles could be prepared using DMF as a dipolar aprotic solvent.
123  
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Scheme 14 
More recently, this reaction was carried out between the dianion of bis-toluenesulfonamide 
and  bis-tosylated  derivatives  in  DMF.  The  dianion  was  created  either  by  addition  of 
sodium hydride or more recently in situ by addition of caesium carbonate.
124  
The tosyl groups are essential for the success of the reaction. Not only do they render the 
amine hydrogens  more  acidic to aid deprotonation but their steric bulk encourages the 
intermediate to undergo intramolecular cyclisation rather than oligomerisation by adopting 
a pseudo-Thorpe Ingold effect (Figure 10).
125 The distance between the reacting termini is 
decreased by the bulk of the tosyl groups pushing the termini closer together. Jennifer M. Wilson, 2007     Chapter 5, 54 
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Figure 10 
5.1.3 Phase Transfer Cyclisation 
Lukyanenko  published  work  describing  the  synthesis  of  azamacrocycles  and 
oxaazamacrocycles  using  a  biphasic  system.
126  Bis-sulfonamides  were  reacted  with 
dibromides or ethylene glycol bis-(toluene-4-sulfonyl) derivatives in a toluene and aqueous 
alkali mixture.  
Quaternary ammonium salts were used as phase transfer catalysts. The charged centre of 
the salt allows the compound to dissolve in an aqueous environment and the butyl groups 
permit  the  compound  to  solubilise  in  an  organic  medium.  Scheme  15  shows  the 
mechanism for the cyclisation. The alkali deprotonates a sulfonamide producing an anion 
that exchanges cations with the catalyst. The ionic species formed undergoes alkylation in 
the organic phase. The alkylated species then undergoes deprotonation once more forming 
another ionic precursor that undergoes intramolecular cyclisation completing the process. 
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Scheme 15 Jennifer M. Wilson, 2007     Chapter 5, 55 
5.1.4 Synthesis of Tosylated Cyclen 
5.1.4.1  Tosylation of Precursors 
The  starting  materials  for  both  the  Richman-Atkins  cyclisation  and  the  phase-transfer 
cyclisation require the corresponding amine or diol to be tosylated. Well known procedures 
previously used by members of the Robins group were applied successfully. 
Scheme 16 shows the reaction of diethylene triamine 77 with tosyl choride – these reaction 
conditions require vigorous stirring and product 78 was produced in very high yield.
127  
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Scheme 16 
Scheme 17 shows that different conditions were required when tosylating diethanolamine 
79.
128 Triethylbenzylammonium chloride (TEBA) was used as a phase transfer catalyst. 
Product 80 was prepared in good yield.  
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Scheme 17 
5.1.4.2  Cyclisation 
Both the Richman Atkins and the phase-transfer reactions were carried out to compare 
yields. As Scheme 18 shows both reactions produced the desired macrocycle 76 in good 
yield.  The  phase  transfer  procedure  does  have  advantages  over  the  Richman  Atkins 
cyclisation.  The  main  one  is  the  length  of  time  required  for  the  reaction  to  go  to 
completion. To achieve optimum yields with the Richman Atkins procedure the reaction 
mixture must be left stirring for two weeks as opposed to an overnight reaction using the 
phase transfer procedure.  Jennifer M. Wilson, 2007     Chapter 5, 56 
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Scheme 18 
5.1.5 Deprotection of Tosyl Groups 
The final step required to achieve cyclen 70 is the removal of the tosyl groups. There are 
many  examples  in  the  literature  that  include  conc.  sulfuric  acid,
129  sodium/mercury 
amalgam,
130  potassium  fluoride  on  alumina,
131  lithium  aluminium  hydride
132  and 
hydrobromic  acid  in  varying  concentrations  of  acetic  acid  solution.
125,133  All  of  these 
conditions are harsh and generally low yielding. 
Several procedures were investigated. The first reaction involved reacting the tosylated 
macrocycle  with  HBr-AcOH  45%  and  phenol  (Scheme  19).
133  The  protected  amine 
becomes protonated resulting in attack by a bromide ion producing tosyl bromide. In order 
to prevent this by-product from re-attaching to the macrocycle, phenol was added to ‘mop 
up’ any by-product. The intermediate formed at this point is the hydrobromide salt. The 
free base 70 was isolated either by using ion exchange chromatography or by using sodium 
hydroxide and a Dean-Stark apparatus. Although this reaction was successful, there were 
impurities present which could affect future reactions. 
The  second  method applied  involved  heating the  protected  macrocycle  under  reflux  in 
conc. sulfuric acid for 40 hours (Scheme 19).
133 Pure 70 was isolated, however the yield 
was poor. 
The final procedure attempted involved heating the macrocycle in conc. sulphuric acid at 
165 
oC  for  10  minutes  (Scheme  19).  This  black  solution  was  cooled  and  then  added 
dropwise to an ethanol/diethyl ether mixture from which a solid precipitated. This solid 
was dissolved in a minimum volume of water and an equivalent volume of hydrobromic 
acid was added dropwise until crystals were observed. This hydrobromide salt was heated 
under  reflux  overnight  with  sodium  hydroxide  solution  in  toluene  using  a  Dean-Stark 
apparatus producing the pure free base 70 in good yield.
134 Jennifer M. Wilson, 2007     Chapter 5, 57 
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Scheme 19 
5.2 Alkylation of Cyclen 
In order to synthesise the desired mustard pharmacophore, a two carbon chain must be 
added  to  the  amine  groups.  Parker  initially  synthesised  chloroacetamides  which  were 
subsequently  reduced  (Scheme  20)  and  this  method  was  particularly  effective  for 
triazamacrocycles.
135 However a more efficient route was then discovered using ethylene 
oxide.
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Scheme 20 
Alkylation  using  ethylene  oxide  is  clean  and  high  yielding  although  a  high  yield  is 
dependent on the purity of the parent macrocycle. Reaction conditions must be carefully 
monitored to prevent the formation of unwanted side-products such as over-alkylated and 
polymerised species. Optimum reaction conditions involve the use of water as the reaction 
solvent and the reaction temperature must be maintained for three hours at 0 
oC. Gaseous 
ethylene oxide was added to the reaction mixture with the use of a cold finger condenser 
and addition funnel to ensure accurate volumes of reactant were added. Once the reaction 
was complete excess ethylene oxide was removed by rotary evaporator yielding pure 83 – 
no further purification was required (Scheme 21). The 2-hydroxyethylated compound 83 
provides the precursor required to attempt the synthesis of a range of compounds with 
different leaving groups present on the mustard functionality.  Jennifer M. Wilson, 2007     Chapter 5, 58 
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Scheme 21 
In order to synthesise the chlorinated mustard 58, the 2-hydroxyethylated macrocycle 83 
was reacted  with thionyl chloride (Scheme 22).
115  The  mustard 58  was isolated as the 
corresponding stable dihydrochloride salt which prevents immediate activation as the lone 
pairs on the nitrogens are protonated and aziridinium ion formation cannot occur.  
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Scheme 22 
Copper complexation occurred quantitatively by treating the hydrochloride salt 58 with 
anhydrous copper (II) chloride in hot methanol.
115 The complex 64 precipitated from the 
solution upon cooling, producing the prodrug.  
5.3 Synthesis of Carbamates 
It was decided to form carbamate groups on the macrocyclic skeleton in the same way as 
the Robins group had previously synthesised carbamate derivatives that showed cytotoxic 
activity.
111 Carbamates are also generally crystalline so purification is easier and they are 
reasonably  stable  although  it  is  hoped  that  they  will  be  displaced  under  physiological 
conditions. 
5.3.1 Route I 
The phenyl carbamate 84 was synthesised in quantitative yield using a procedure involving 
the 2-hydroxylethylated macrocycle 83, pyridine and phenyl isocyanate (Scheme 23).
136 
This  compound  was  crystallised  and  an  X-ray  structure  was  obtained  (Figure  11). Jennifer M. Wilson, 2007     Chapter 5, 59 
Compound 84 crystallises in the monoclinic space group P21/a and the structure clearly 
shows the formation of the macrocyclic ring and four carbamate side-chains. 
N
N N
N
OH
OH
HO
HO
N
N N
N
O
O
O
O
N
O
H
N
O
H
N
O
H
N
O
H
PhNCO
pyr
2 d, RT
100%
83 84  
Scheme 23 
 
Figure 11 
Due to the success of this reaction, substituted phenyl carbamates were targeted, e.g. 4-
nitrophenyl, 4-bromophenyl and 4-methoxyphenyl. However it was impossible to isolate 
the desired compounds and the only products observed in the 
1H NMR spectra were the 
corresponding aromatic amines produced after hydrolysis of the isocyanates. 
The  synthesis  of  alkyl  carbamates  was  also  attempted  using  the  same  procedure.  The 
isopropyl derivative 85 was isolated in a poor yield (11%), however it proved impossible to 
synthesise the ethyl derivative. Jennifer M. Wilson, 2007     Chapter 5, 60 
5.3.2 Route II 
A different procedure was used to try and synthesise a range of carbamates. A method 
using  the  2-hydroxyethyl  precursor  83,  an  isocyanate  and  dibutyl  tin  diacetate  in 
dichloromethane was attempted (Scheme 24).
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Scheme 24 
The two previously obtained macrocyclic carbamates were synthesised again by stirring 
the reaction mixtures at room temperature for two days. The phenyl derivative 84 was 
again produced quantitatively and the isopropyl derivative 85 was obtained in a good 60% 
yield. It was also possible to crystallise 85 and an X-ray crystal structure was obtained 
(Figure 12). As before this compound crystallises in the monoclinic space group P21/a and 
shows successful formation of the macrocycle and four side-arms. 
 
Figure 12 
Using the same reaction conditions, it proved impossible to synthesise the propyl 86 and 
the  4-methoxyphenyl  87  analogues.  The  reactions  needed  to  be  heated  under  reflux 
conditions  overnight  and  these  two  compounds  were  successfully  isolated  in  moderate 
yields. By studying reaction conditions and the number of equivalents of isocyanate used, Jennifer M. Wilson, 2007     Chapter 5, 61 
it proved possible to synthesise a range of substituted carbamates. The reaction conditions 
required and yields are summarised in Table 2. 
Cpd No.  R  Eq. RNCO  T  Yield 
84 
 
40  RT  100% 
85 
 
40  RT  60% 
86    40  reflux  41% 
87 
OMe 
40  reflux  56% 
88 
Br 
40  reflux  64% 
89 
NO2
 
10  reflux  64% 
90 
NO2
 
10  reflux  46% 
91 
NO2 
10  reflux  60% 
Table 2 
The mechanism of the reaction is assumed to proceed as shown in Scheme 25.
137 A lone 
pair of electrons from the alcohol attacks the carbonyl of the isocyanate which in turn 
attaches itself onto the dibutyl tin diacetate with loss of an acetate group. The acetate group 
reattaches onto the tin moiety reforming the catalyst and resulting in the formation of the 
desired compound. 
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Scheme 25 
5.4 Synthesis of Copper Complexes 
In order to transform the macrocycles into prodrugs, copper complexes had to be formed. 
Using the same procedure previously described in Scheme 22,
115 eight copper complexes Jennifer M. Wilson, 2007     Chapter 5, 62 
were synthesised from the corresponding macrocyclic carbamates using one equivalent of 
copper(II) chloride (Scheme 26). Yields are summarised in Table 3.  
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Scheme 26 
Cpd No.  R  Yield 
92 
 
100% 
93 
 
58% 
94    64% 
95 
OMe 
23% 
96 
Br 
39% 
97 
NO2
 
18% 
98 
NO2
 
74% 
99 
NO2 
80% 
Table 3 
Characterisation  using  mass  spectrometry  and  UV-vis  spectrometry  proved  that  the 
complexes had been successfully formed. It has been reported that the λmax for the d to d 
transition of CuCl2 occurs at 810 nm. Upon complexation of amine ligands to the copper, 
the λmax for the d to d transition dropped to 690 nm.
138 Parker obtained a λmax of 622 nm for 
mustard  64.  Similar  results  were  obtained  for  the  macrocyclic  copper-complexed 
carbamates 92-99 and are detailed in the Experimental chapter. It was unfortunate that 
crystals of the complexes could not be grown as X-ray crystal structures would have been 
desirable. Jennifer M. Wilson, 2007     Chapter 5, 63 
5.5 Unsuccessful Attempts at Formation of Other Leaving 
Groups 
Although the carbamate synthesis was successful, many unsuccessful attempts were made 
to attach different leaving groups onto the cyclen macrocycle. 
5.5.1 Sulfonamides 
It  was  desirable  to  synthesise  a  mustard  derivative  with  tosyl  groups  attached  to  the 
alkylating arms as this functional group is considered to be a good leaving group. Several 
procedures were attempted using different solvents, bases and reaction conditions (Scheme 
27).
139 It proved difficult to produce the tetratosylated macrocycle. A mesylation was also 
attempted but again isolation of the desired compound was unsuccessful.
140  
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Scheme 27 
It is thought that the product is so reactive that aziridinium ion formation occurs and the 
molecule then breaks itself apart. In order to prevent this happening it was decided to form 
the copper complex of the 2-hydroxyethylated macrocycle 83 as the nitrogen lone pairs 
would  then  be  bound  to  the  copper  and  aziridinium  ion  formation  should  not  occur 
(Scheme 16). 
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Scheme 28 
The  copper  complex  100  was  successfully  synthesised  using  the  procedure  previously 
discussed. Tosylation was then attempted using tosyl chloride and pyridine (Scheme 28).
141 
Only starting material was recovered although there had been solubility issues with the Jennifer M. Wilson, 2007     Chapter 5, 64 
reaction.  The  reaction  was  modified  to  use  DMF  as  a  co-solvent  which  resulted  in 
complete dissolution of the starting material. Unfortunately the desired product was not 
produced and it was not possible to obtain starting material from the reaction mixture. 
5.5.2 Chloroacetamides and Bromoacetamides 
Parker  had  used  a  successful  strategy  for  the  alkylation  of  triazamacrocycles  using 
chloroacetyl chloride (Scheme 20).
142 The carbonyl groups could then be reduced leaving 
the  desired  alkylating  agent.  By  using  bromoacetyl  bromide  it  was  hoped  that  a 
bromosubstituent  could  be  synthesised  as  previous  work  carried  out  on  the  bromo-
derivative had been unsuccessful.
143 
Both the chloro- and the bromo-derivatives were synthesised using a mixture of cyclen 70 
in dichloromethane with triethylamine and the corresponding haloacetyl halide (Scheme 
29). The yields for both reactions were poor but the desired precursors were produced. 
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Scheme 29 
Reduction of the carbonyl groups was attempted using BH3.THF.
144 However the desired 
compounds appeared to have degraded and could not be isolated. A procedure involving 
lithium aluminium hydride was then tried although this resulted in the same conclusions 
that the product, if formed at all, had degraded.
145 
5.5.3 Finkelstein Reaction 
A  commonly  used  reaction  for  the  exchange  of  halides,  a  Finkelstein  reaction,  was 
attempted using 2-chloroethylated mustard 58, sodium bromide and acetone.
146 Again it 
appeared that there was degradation of the product. Perhaps the molecule is once again too 
reactive and aziridinium ion formation occurs. Jennifer M. Wilson, 2007     Chapter 5, 65 
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5.5.4 Carbonates 
As it had been possible to synthesise a range of carbamates 84-91, it was thought that it 
would be possible to synthesise a range of carbonates. These should be easier to cleave 
under  physiological  conditions  to  produce  aziridinium  ions.  The  precursor  is  the  2-
hydroxylethylated macrocycle 83. 
The first attempt involved the procedure used to synthesise the carbamates with phenyl 
chloroformate  used  instead  of  phenyl  isocyanate  (Scheme  31).
137  However  the  desired 
compound could not be isolated and it looked as though the starting material had degraded 
as seen before during the development of the carbamate synthesis. 
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Scheme 31 
The next protocol tried, used alkyl bromide, phase transfer catalyst, potassium carbonate as 
base and DMF under a carbon dioxide atmosphere that was obtained by dissolving dry ice 
in the reaction mixture and sealing the vessel.
147 It proved impossible to extract anything 
resembling the desired product. 
Several other attempts were made to synthesise a carbonate derivative. The first involved 
using phenyl chloroformate with pyridine as solvent and base.
148 The second used DCM as 
the solvent and this time no extra additives were added. The only reagents were the alcohol 
precursor and the phenyl chloroformate and the reaction was carried out at -40 
oC.
149 A 
final  attempt  used  sodium  methoxide  in  toluene  with  phenyl  chloroformate.
150 
Unfortunately the product was not obtained using any of these methods.  Jennifer M. Wilson, 2007     Chapter 5, 66 
5.6 Biological Results 
5.6.1 Anti-Cancer Test Results 
The series of carbamates 84-91 were sent to Prof. John Hartley at University College, 
London to establish the DNA-crosslinking and cytotoxicity of the uncomplexed mustards 
against the human chronic myeloid leukaemia cell line K562.
151 The copper complexes 92-
99  were  sent  to  Prof.  Ian  Stratford  at  the  University  of  Manchester  for  aerobic  and 
anaerobic testing against the lung-derived tumour cell line A549.
152 
Unfortunately the range of compounds 84-91 proved to be too stable to be efficient DNA 
cross-linkers. Aziridinium ion formation did not occur. There are no quantitative data for 
this range of compounds (XL50 > 1 mM and IC50 > 100 µM) but Figures 13 and 14 show 
that after one hour or two hour incubation with the drug, there is no significant cross-
linking even at high concentrations. No hypoxia selectivity was thus observed with the 
corresponding copper complexes due to the lack of activation of the prodrugs. The data for 
84-86 is not shown but similar results were obtained. 
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Figure 14 
5.6.2 Anti-Parasitic Test Results 
The carbamates 84-91 were sent to Dr Mike Barrett in the Department of Parasitology at 
the University of Glasgow for anti-parasitic testing against Trypanosoma brucei (Alamar 
Blue assay).
153 Polyamine analogues have shown the ability to disrupt natural polyamine 
metabolism and transport, thus inhibiting parasitic growth. As explained before Reid had 
synthesised a range of azamacrocycles which displayed good results (EC50 values as low as 
1.26 µM).
117 
The compounds were also tested against HEK cells which should show if the compound is 
selective towards the parasites.
154 A selective drug would show EC50 values of 1-2 µM 
against Trypanosoma brucei but would be inactive against the HEK cell lines. 
The Alamar blue results (Table 4) show that the ortho-, meta- and para-nitrocarbamates 
are the best trypanocides. The meta-derivative is also significantly less active against the 
HEK  cells  which  is  required  for  the  drug  to  be  useful  as  an  anti-parasitic  agent. 
Fluorescence  was  measured  for  the  three  best  compounds.  However  none  of  the 
compounds seemed to fluoresce. The compounds kill the cells but don’t rupture the cellular 
membrane. 
91 
88 
90 
89 
87 Jennifer M. Wilson, 2007     Chapter 5, 68 
 
Cpd no.  R  Est. log P  T. brucei 
EC50 (µM) 
HEK 
EC50 (µM) 
84 
 
4.66  9.22  56.6 
85 
 
1.11  16.9  152 
86    1.40  10.1  ≥200 
87 
OMe
 
4.98  4.00  20.4 
88 
Br
 
8.22  5.81  26.0 
89 
NO2
 
6.24  0.463  * 
90 
NO2 
6.24  2.00  79.1 
91 
NO2 
6.24  0.916  23.0 
Table 4 
*  shows  a  gradual  decreasing  of  fluorescence  with  a  biphasic  curve:  at  lower  drug 
concentrations (0.1-0.78 µM) there is a slight cytostatic effect, while at the higher doses 
there is a toxic effect. 
 
Log P is the ratio of concentrations of a compound in the two phases of a mixture of two 
immiscible solvents at equilibrium (octanol and water).
155 The estimated log P values are 
included in the table (obtained from an online programme
156) as Lipinski’s rules state that 
the  optimum  log  P  values  for  a  drug  should  be  between  1  and  3.
157  The  compounds 
synthesised by Reid that showed good activity all possessed log P values that fell into this 
category.
117 It should be noted that the compounds 89-91 that showed good activity all 
possess log P values greater then 3. These log P values mean that the drug structures would 
have to be modified for optimum uptake of the drug by the body. These compounds are 
quite insoluble and it was difficult to dissolve the compounds in DMSO to perform the 
assays. It is therefore unrealistic to expect that these compounds would be easily taken-up 
into the body and would cross the blood brain barrier. Jennifer M. Wilson, 2007     Chapter 5, 69 
5.7 Synthesis  of  Carbamates  to  Investigate  Structure- 
Activity Relationships 
It is unknown whether the mechanism of action of the drugs on the T. brucei involves the 
cyclen  moiety  or  the  carbamate  side  chain.  In  order  to  assess  the  structure-activity 
relationships,  it  was  decided  to  synthesise  a  set  of  carbamates  without  the  cyclen 
macrocycle.  These  contained  the  functional  groups  that  had  given  the  best  biological 
results from the macrocycles that had been tested – e.g. ortho-, meta- and para-nitrophenyl 
and para-methoxyphenyl derivatives.  
5.7.1 Piperazine Based Bis-Carbamates 
Henderson had previously synthesised a range of piperazine-based carbamates.
137 In fact it 
was a procedure developed by Henderson that had been used to synthesise the range of 
macrocyclic carbamates 84-91. It was decided to synthesise a range of piperazine-based 
carbamates. The compounds would still incorporate a heterocycle. They should be useful 
for comparison purposes with the macrocyclic carbamates. As the precursor to the desired 
compounds was commercial, only one synthetic step would be necessary (Scheme 32). 
Using the same general procedure described for the synthesis of the other carbamates, four 
piperazine derivatives 103-106 were successfully produced and the yields are summarised 
in Table 5.  
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Cpd no.  R  Yield 
103 
NO2 
68% 
104 
NO2 
55% 
105 
NO2
 
90% 
106 
OMe
 
99% Jennifer M. Wilson, 2007     Chapter 5, 70 
Table 5 
5.7.2 Linear Carbamates 
It was also decided to synthesise a linear compound that would have four arms, similar to 
the  tetraazamacrocyclic  cyclen  moiety.  2-Hydroxyethyl  arms  were  added  to  ethylene 
diamine 107 producing the tetraol 108 required for carbamate formation (Scheme 33). The 
next step was the addition of the carbamate functionality to the four side arms. The same 
procedure  and  reaction  conditions  were  attempted  as  for  the  macrocyclic  carbamates, 
unfortunately it proved impossible to form the desired compounds. It was decided to test 
biologically the four piperazine derivatives that had been successfully produced. 
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5.8 Biological Results 
The four piperazine based derivatives 103-106 were tested as before against Trypanasoma 
brucei and HEK cells. The results are summarised below (Table 6). 
Cpd no.  R  Est. log P  T. brucei 
EC50 (µM) 
HEK 
EC50 (µM) 
103 
NO2 
3.23  >100  >200 
104 
NO2 
3.23  16.6  14.1 
105 
NO2
 
3.23  1.31  >200 
106 
OMe
 
2.61  >100  >200 
Table 6 
The biological results show that 103 and 106 have no trypanocidal activity or any activity 
against the HEK cells. However the corresponding cyclen derivatives 87 and 89 with the 
same  functional  groups  in  the  same  positions  do  show  activity  against  trypanosomes, 
therefore the cyclen ring of the macrocycles is responsible for some of the activity. The Jennifer M. Wilson, 2007     Chapter 5, 71 
derivative 104 with the nitro group in the meta position displays low trypanocidal activity, 
however  this  compound  seems  to  be  toxic  to  HEK  cells.  It  appears  to  act  more  as  a 
cytostatic than  a toxic drug. The best results occur  with the para-nitro derivative 105. 
Strong trypanocidal activity is displayed however the compound does not seem toxic to 
HEK cells.  
It is not understood why moving the nitro group around the aromatic ring displays such an 
array of results. The results do not help explain the structure-activity relationship for the 
azamacrocycles in any more detail. 
5.9 Conclusions  
A short efficient synthesis of a range of eight macrocyclic carbamates was developed and 
the corresponding copper complexes were successfully synthesised as alkylating agents 
disguised as pro-drugs. Unfortunately the compounds synthesised proved to be too stable 
to be activated as aziridinium ions and the corresponding copper complexes were therefore 
unselective towards hypoxic cells. Further work is necessary to design successful anti-
cancer prodrugs. 
 It  would  appear  that  the  eight  macrocyclic  carbamates  provide  a  good  model  for  the 
development of anti-parasitic drugs as they gave promising results when tested against 
Trypanosoma  brucei.  The  structure-activity  relationship  for  the  eight  macrocyclic 
carbamates  was  unclear  so  a  range  of  piperazine  carbamates  were  synthesised  to 
investigate  whether  the  activity  of  the  compounds  is  due  to  the  cyclen  moiety  or  the 
carbamate functional group. Initial biological results show that the nitro group in the para-
position of the piperazine carbamates produces the best anti-parasitic  activity for these 
compounds.  Futhermore,  it  is  evident  that  the  macrocyclic  cyclen  ring  does  confer 
significant anti-parasitic activity. Futher work is required to determine the mode of action 
of  the  macrocyclic  compounds.  In  addition,  the  structures  of  the  compounds  needs 
modified to enhance their solubility. It is hoped that the transport of these compounds 
through the parasite plasma membrane will be better understood by studying the different 
carbamates that have been synthesised. There is a realisitic prospect of developing more 
potent and selective analogues. 72 
6  Synthesis of Thiaazamacrocycles 
As previous members of the Robins group had synthesised a range of azamacrocycles
115 
and  oxaazamacrocycles
116  such  as  58  and  65,  it  was  decided  to  synthesise  a  range  of 
thiaazamacrocycles to complete the set of macrocycles containing the common heteratoms 
of N, O and S.  
O N
N N
Cl
Cl Cl
N N
N N
Cl
Cl Cl
Cl
.2HCl .3HCl
58 65  
The  previously  synthesised  oxaazamacrocycles  were  promising  alkylating  agents,  and 
compound 65 displayed the  most potent cytotoxicity of any  macrocycle synthesised to 
date.
116 It was therefore planned to make a range of thiaazamacrocycles (Figure 15). They 
might display different biological results to the oxaazamacrocycles. It should be noted that 
it  was  impossible  to  synthesise  the  corresponding  pro-drug  of  65  by  complexing  the 
macrocycle to copper, although there is literature precedent for the complexation of copper 
to  ligands  containing  oxygen  and  nitrogen.
158  It  is  well-documented  that 
thiaazamacrocycles  complex  to  copper
159  and  the  proposed  thiaazamacrocycles  should 
form  the  desired  pro-drugs  with  copper(II)  and  might  produce  hypoxia  selective 
compounds. 
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Figure 15 
Extreme caution would have to be exercised during the synthesis of the thiaazamacrocycles 
to ensure that at no time would  a sulfur mustard be formed as an intermediate. If the 
pathway used to synthesise the azamacrocycles
115 and oxaazamacrocycles
116 was modified 
to synthesise the sulfur derivatives, several sulfur mustards might be required as precursors 
or  intermediates.  It  was  decided  that  it  would  be  prudent  to  find  a  synthesis  of  a Jennifer M. Wilson, 2007     Chapter 6, 73 
thiaazamacrocycle that was designed in such a way that epi-sulfonium ion formation could 
not occur – i.e. the C-2 of the 2-chloroethyl arm (or corresponding leaving group) was 
protected so that the lone pairs on the sulfur could not activate the mustard mechanism 
(Figure 16). 
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Figure 16 
6.1 Amide Strategy 
A  literature  search provided  the  necessary  solution  to  the  problem.  There  are  multiple 
examples  in  the  literature  of  the  synthesis  of  thiaazamacrocycles  by  forming  amide 
bonds.
160 The carbonyl group present on the β-carbon to the sulfur provides protection 
against epi-sulfonium ion activation. Once the macrocycle is formed, the carbonyl groups 
would be reduced leaving the desired parent macrocycle. At this stage epi-sulfonium ion 
formation cannot occur. There were many literature precedents available for the reduction 
of the carbonyl groups.
159,161 Not only would this pathway (Figure 17) to new macrocycles 
produce the desired compounds safely, it would also eliminate the difficult low yielding 
de-tosylation  step  and  reduce  the  number  of  synthetic  steps  required  to  synthesise  the 
compounds.  Once  the  reduced  macrocycle  was  obtained,  the  alkylating  arms  of  the 
compound  would  be  added  using  ethylene  oxide.  Again,  there  are  literature  examples 
detailing the 2-hydroxyethylation of thiaazamacrocycles.
162 Chlorination would then take 
place producing the desired mustard. Copper complexation would be the final synthetic 
step required to produce the prodrug. 
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Figure 17 Jennifer M. Wilson, 2007     Chapter 6, 74 
6.1.1 Formation of Amide-Protected Macrocycles 
The first step of the reaction involves the synthesis of the sulfur-containing acid chloride 
that is the precursor for the amide bond formation. This was simply prepared by stirring 
thiodiglycolic acid 109 in thionyl chloride at room temperature overnight (Scheme 34).
160c 
The acid chloride 110 was isolated by removing the excess thionyl chloride under vacuum. 
This  product  was  not  purified  but  used  directly  in  the  next  reaction.  Quantitative 
conversion was assumed. 
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Scheme 34 
Formation  of  the  macrocycles  occurred  using  a  high  dilution  simultaneous  drop-wise 
addition of thiodiglycolic acid chloride 110 and a diamine.
160c The product precipitated 
from the reaction mixture. Three macrocycles 111-113 were synthesised using commercial 
diamines  (Scheme  35).  These  reactions  work  very  well  and  quantitative  yields  were 
achieved for the three macrocycles 111-113. 
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Scheme 35 
In one case, it was necessary to synthesise the diamine precursor 116 required to carry out 
the  cyclisation.  There  are  several  procedures  in  the  literature  to  synthesise  sulfur-
containing diamines.
163 It was decided to use a process that involved reacting cysteamine 
hydrochloride  114  with  2-chloroethylamine  hydrochloride  115  in  a  sodium  ethoxide 
solution.
164 The desired amine 116 was successfully formed and was subsequently reacted 
with  the  thiodiglycolic  acid  chloride  110  producing  the  desired  macrocycle  117  in 
excellent yield (Scheme 36). Jennifer M. Wilson, 2007     Chapter 6, 75 
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Scheme 36 
It should be noted that NMR spectroscopic characterisation carried out on the macrocycles 
corresponded  to  literature  data.  However  it  proved  very  difficult  to  obtain  any  mass 
spectrometry data for any of these macrocyclic amides (111-113, 117). 
6.1.2 Reduction of Carbonyl Groups 
Four amide-protected macrocycles (111-113, 117) had been successfully synthesised. The 
next  step  involved  reducing  the  amide  functional  groups.  The  use  of  1M  borane  in 
tetrahydrofuran  solution  as  the  reducing  agent  was  reported  in  the  literature.
160 
Macrocycles  111  and  112  were  heated  under  reflux  in  borane  solution  for  four  hours 
(Scheme 37). The compounds did not dissolve and grey suspensions were observed. The 
excess borane was quenched and the reaction mixtures were concentrated. The resulting 
residues were heated under reflux in 6M hydrochloric acid for two hours. However, after 
basification  and  extraction  according  to  literature  procedures,  only  trace  amounts  of 
material were isolated. The aqueous phases were concentrated and re-extracted but nothing 
was recovered. It was assumed that the borane solution had degraded or that the starting 
materials had broken apart due to harsh reaction conditions.  
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Scheme 37 
The reactions  were repeated using new borane  reagent and the reaction mixtures were 
vigorously stirred to aid dissolution of the starting materials. Again only small amounts of 
crude material were recovered. Perhaps heating the compound under reflux in acid during 
the work-up was too harsh and the macrocycle was degrading. Jennifer M. Wilson, 2007     Chapter 6, 76 
The  solubility  of  the  starting  materials  could  be  an  issue.  The  reaction  mixture  was 
sonicated in an attempt to encourage the starting material to dissolve in the tetrahydrofuran  
solution. The macrocycles 111 and 112 are extremely insoluble so that no common organic 
solvents  can  be  used  ruling  out  the  use  of  other  well-known  reducing  agents  such  as 
lithium aluminium hydride.  
It was decided to continue developing the borane reduction and instead of heating under 
reflux in 6M hydrochloric acid as a work-up, the corresponding hydrobromide salt was 
formed. No basic work-up was performed as it was felt that the free base could be isolated 
by  carrying  out  anion  exchange  column  chromatography.  Preliminary  results  looked 
promising but the isolated material was a mixture of compounds which proved difficult to 
purify.  In  certain  cases  the  recovered  products  were  the  diamines  used  to  form  the 
macrocycle. Thus, the skeleton of the macrocycle had broken apart into several fragments. 
Dean-Stark conditions were also applied to isolate the free base from the hydrobromic salt 
but no product was isolated. 
Different extraction conditions involving heating the quenched mixture under reflux in a 
methanol,  water  and  hydrochloric  acid  mixture  were  attempted  but  again  the  desired 
products  were  not  isolated.  Different  work-up  conditions  were  tried  including 
concentrating the quenched reaction mixtures and extracting the product into chloroform 
and ethyl acetate but nothing was recovered.  
When the reaction was carried out on macrocycles 113 and 117, complete decomposition 
of the starting materials was observed. 
It  was  decided  that  the  best  course  of  action  could  be  to  do  no  work-up  at  all.  After 
quenching the excess borane, the reaction mixture was concentrated. 
1H NMR spectra for 
the desired products showed the expected peaks although not necessarily at the expected 
frequency (Figures 18 and 19 – some impurities are present as these are crude reaction 
mixtures). For compound 111, the expected 
1H NMR signals of the corresponding amine 
would be a singlet corresponding to a CH2N peak and two triplets corresponding to  a 
CH2N peak and a CH2S peak. For compound 112, the expected 
1H NMR signals for the 
corresponding amine would be three triplets corresponding to two CH2N peaks and a CH2S 
peak as well as a quintuplet/multiplet signifying the CH2. It should be pointed out that it 
was impossible to obtain mass spectra for these supposedly reduced macrocycles.  Jennifer M. Wilson, 2007     Chapter 6, 77 
Figure 18 
Figure 19 
The next step of the reaction sequence was carried out. Using ethylene oxide, the addition 
of the 2-hydroxyethyl arms was attempted.
115 Again 
1H NMR spectra suggested that the Jennifer M. Wilson, 2007     Chapter 6, 78 
desired  2-hydroxyethylated  compounds  may  have  been  synthesised  yet  it  was  still 
impossible to obtain mass spectra. It was decided to try and chlorinate the 2-hydroxyethyl 
arms  using  thionyl  chloride  –  this  should  produce  a  solid  that  could  be  purified  by 
recrystallisation.  However  when  this  procedure  was  carried  out  on  the  supposed  2-
hydroxyethylated  thiaazamacrocycles,  no  product  was  isolated.  It  appeared  that  the 
reaction components had completely degraded. 
At this point it was decided to change the synthetic pathway. There was no proof that the 
intermediates  were  being  produced.  It  was  disappointing  that  this  pathway  resulted  in 
failure as there does appear to be literature precedent. 
6.2 Tosyl-protected Macrocycle Strategy 
It  was  decided  to  try  and  synthesise  some  tosyl-protected  thiaazamacrocycles  as  this 
synthesis pathway had been highly successful for the production of the azamacrocycles
115 
and the oxaazamacrocycles.
116 Characterisation of intermediates should confirm or exclude 
the  presence  of  the  desired  compounds  from  the  previous  pathway.  As  explained 
previously,  extreme  care  would  need  to  be  exercised  to  ensure  that  no  sulfur  mustard 
intermediates were formed (Figure 20). 
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6.2.1 Formation of Tosyl-protected Macrocycles 
In  order  to  synthesise  the  tosyl-protected  macrocycles  the  precursors  needed  to  be 
prepared. To produce the two thia-diazamacrocycles (S,N,N), the diaminothiol 116 which 
was  synthesised  for  the  amide  synthetic  pathway  and  the  necessary  diols  were  tosyl-Jennifer M. Wilson, 2007     Chapter 6, 79 
protected using standard conditions (Scheme 38). 1,2-Ethanediol 118 and 1,3-propanediol 
119 were protected using tosyl chloride and pyridine.
128 The protection of diaminothiol 116 
required  a  vigorously  stirred  reaction  mixture  of  toluene-4-sulfonyl  chloride  in  diethyl 
ether and sodium hydroxide solution.
165 For the thia-triazamacrocycle (S,N,N,N), the tosyl 
protected  diethanolamine  80  synthesised  in  Chapter  5  was  used  as  well  as  the  tosyl 
protected diaminothiol 122. 
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Scheme 38 
For the ‘pseudo-cis’-dithia-diazamacrocycles (S,S,N,N), a new diaminodithiol 123 required 
to be synthesised but there was literature precedent for the synthesis of this compound.
166 
Cysteamine hydrochloride 114 was reacted with 1,2-dichloroethane in a sodium butoxide 
solution (Scheme 39). This dithiadiamine 123 was then tosyl protected using the same 
conditions described for 122.
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Scheme 39 
The cyclisations took place under the phase-transfer conditions previously described in 
Chapter 5 (Scheme 40 and 41).
126 Jennifer M. Wilson, 2007     Chapter 6, 80 
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Scheme 41 
For the ‘pseudo-trans’-dithia-diazamacrocycle (S,N,S,N), a different approach was required 
to avoid using a sulfur mustard. The precursor was prepared by reacting the corresponding 
tosyl protected diol 80 with thiourea producing the dithiol 130
160a that reacted with the 
tosyl protected  diaminothiol  122  (Scheme  42). The  cyclisation  was  unsuccessful  using 
phase-transfer conditions
126 but a trace amount of desired product 131 was obtained using 
standard Richman-Atkins conditions.
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Scheme 42 
Therefore it was decided to carry on with the other five macrocycles (125-129) to complete 
the synthesis pathway. It should be noted that the yields for cyclisation to 128 and 129 Jennifer M. Wilson, 2007     Chapter 6, 81 
were  disappointing  when  compared  to  those  for  the  azamacrocycles  and 
oxaazamacrocycles. 
6.2.2 Tosyl Deprotection of Macrocycles 
As explained before, the procedures used to de-tosylate macrocycles are harsh and low 
yielding.  It  was  decided  to  investigate  the  reaction  conditions  for  de-tosylating 
thiaazamacrocycles. There was literature precedent for the removal of tosyl groups from 
thiaazamacrocycles.
133 The first method attempted used Birch reduction conditions. The 
tosyl-protected  macrocycle  126  was  reacted  with  a  lithium  and  ammonia  mixture  in 
tetrahydrofuran (Scheme 43). Unfortunately no product was isolated. 
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Scheme 43 
It  was  then  decided  to  use  the  HBr-AcOH  mixture  discussed  previously.
133  The  tosyl-
protected macrocycle 126 was heated under reflux for two days in an HBr-AcOH and 
phenol mixture (Scheme 44). The free amine was isolated in a number of ways. The first 
involved  an  ion-exchange  column,  however  this  was  extremely  low  yielding  and  the 
product  was  not  pure.  The  product  could  not  be  separated  from  the  crude  mixture  by 
Kugelrohr distillation. Dean-Stark conditions were employed and the hydrobromide salt 
and sodium hydroxide were heated under reflux overnight in toluene. Upon concentration 
of the solvent the product 132 was obtained.  
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Scheme 44 
However the crude mixture appeared to contain more than one product. As the compound 
is very polar, purification is difficult. Compound 132 is so polar that it would not pass 
through a silica column. Alumina column chromatography would be a good alternative as 
the concept of reverse phase chromatography is used. The product was separated quickly Jennifer M. Wilson, 2007     Chapter 6, 82 
and  efficiently  providing  the  desired  compound.  This  technique  proved  extremely 
successful for obtaining the pure free amine macrocycle 132. 
Figure 21 shows the yields achieved for the five substrates (132-136). This reaction is 
generally not high yielding and starting materials (tosylated macrocycle) were sometimes 
recovered. However it was felt that as long as the desired free bases were obtained in pure 
form, the yields were sufficient. 
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It should be pointed out that 
1H NMRs collected for the free bases (132 and 133) were 
compared with the 
1H NMRs shown in Figures 18 and 19. It was determined that the 
desired compounds had not been synthesised using the amide synthetic pathway and wny 
further research hwould involve the tosyl-protected macrocycles. 
6.2.3 Addition of 2-Hydroxyethyl Arms 
The next step of the synthesis involved the addition of the carbon chain that would make 
up  the  2-carbon  link  required  for  optimum  DNA  cross-linking.  This  was  achieved  by 
reacting the free amines (132-136) with ethylene oxide as described before although it was 
necessary  to  change  the  reaction  conditions  required  for  the  azamacrocycles  and 
oxaazamacrocycles.
115 Instead of carrying out the reaction in water, ethanol was used as the 
reaction solvent (Scheme 45). Although the reaction mixture was initially cooled to 0 
oC, it 
was allowed to return to room temperature and the mixture  was stirred overnight in  a 
sealed reaction vessel. Jennifer M. Wilson, 2007     Chapter 6, 83 
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When  this  reaction  was  carried  out  for  the  synthesis  of  the  azamacrocycles  and  the 
oxaazamacrocycles,  no  purification  was  required  as  the  desired  pure  compounds  were 
isolated  with  no  by-products  present.  In  the  case  of  the  thiaazamacrocycles, 
1H  NMR 
spectra showed the presence of other peaks. It is likely these are polymerised or over-
alkylated products. Alumina column chromatography was used once again to purify the 
compounds and all five substrates (137-141) were successfully isolated (Figure 22). 
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6.2.4 Chlorination of Macrocycles – Mustard Formation 
All that remained was the final chlorination step that would produce the desired alkylating 
agents as  hydrochloride  salts.  The  protonated  nitrogens  should  prevent  aziridinium  ion 
formation. 
The 2-hydroxyethylated macrocycles (137-141) were reacted overnight in thionyl chloride 
at 50 
oC (Scheme 46).
115 Normally a white solid is isolated after extraction and purification 
but with every reaction attempted, a brown viscous oil was recovered. Numerous attempts 
were made to try and isolate a pure product but nothing was successful. 
1H NMR spectra 
showed  that  no  expected  peaks  were  present,  and  it  appeared  that  degradation  had 
occurred. Jennifer M. Wilson, 2007     Chapter 6, 84 
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It  was  extremely  disappointing  to  discover  that  the  chlorinations  were  unsuccessful, 
particularly as the synthesis pathway to the 2-hydroxyethylated thiaazamacrocycles had 
been arduous and difficult throughout with unexpected purification required at each step. 
The  synthesis  of  the  azamacrocycles  and  the  oxaazamacrocycles  had  been  less 
complicated. Without the chlorinated mustards it was clearly impossible to synthesise the 
desired alkylating agents and corresponding prodrugs. 
6.2.5 Carbamate Formation 
It  was  decided  to  try  and  synthesise  a  selection  of  carbamates  from  the  range  of  2-
hydroxyethylated thiaazamacrocycles (137-141) that had been successfully synthesised.
137 
Although it was highly probable that the carbamates would be too stable to be efficient 
alkylating agents due to biological testing carried out previously, synthesis of copper(II) 
complexes could be attempted to see if the sulfur coordinates to the copper better than with 
the  oxygen-containing  macrocycles.  Anti-parasite  testing  would  also  be  carried  out  to 
determine  whether  the  thiaazamacrocycles  (137-141)  are  more  cytotoxic  than  the 
azamacrocyclic  carbamates  (84-91)  thus  providing  the  prospect  of  a  new  molecular 
skeleton to develop anti-parasitic drugs. 
The  2-hydroxyethylated  macrocycle  137  was  heated  under  reflux  with  4-nitrophenyl 
isocyanate and dibutyl tin diacetate in DCM overnight (Scheme 47).
137 Unfortunately the 
only product that was isolated was the corresponding hydrolysed isocyanate as seen before 
during  the  azamacrocyclic  carbamate  (84-91)  synthesis.  Several  different  reaction 
conditions were investigated as had been required during the synthesis of azamacrocyclic 
carbamates but nothing proved successful. 
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It  was  decided  to  leave  this  area  of  the  project  and  concentrate  on  the  synthesis  of 
compounds that would prove to be biologically active. 
6.3 Conclusions 
It was extremely frustrating that none of the desired final compounds could be synthesised. 
A  possible  explanation  to  the  problem  was  discovered;  Hartley  and  co-workers  had 
investigated  the  synthesis  of  thioacetals  as  pathway  intermediates  due  to  the  fact  that 
carbonyl groups can be successfully masked to allow synthetic change to other parts of the 
molecule.
167  It  was  discovered  that  a  1,3-dithiane  displaces  tosylate  by  a  5-exo-tet 
cyclisation to give a bicyclic sulfonium salt which was isolable (Scheme 48).
168 This was 
verified by X-ray crystallography. 
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It  was  suggested  that  a  similar  mechanism  could  be  occurring  with  the  chlorinated 
thiaazamacrocyclic mustards. A favoured 6-exo-tet cyclisation mechanism could happen 
forming  a  strained  structure  that  then  broke  apart  resulting  in  the  degradation  of  the 
macrocycle. 
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Scheme 49 
Despite  not  achieving  the  aims  of  the  project,  a  reliable  synthetic  pathway  has  been 
developed  that  allows  the  preparation  of  pure  thiaazamacrocycles  as  free  bases. 
Functionalisation  has  also  been  added  to  the  thiaazamacrocycles  in  the  form  of  2-
hydroxyethyl arms. 86 
7  Synthesis of Substituted Macrocycles 
As  stated  before,  Reid  had  investigated  the  synthesis  of  aromatic-substituted 
azamacrocycles.
117 By using a two-step iron templated synthesis (Figure 23),
169 a range of 
20 compounds was produced and several of these compounds displayed excellent results 
when tested against Trypanosoma brucei. 
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Figure 23 
7.1 Synthesis of an Alkyl Substituted Azamacrocycle 
It would be beneficial to synthesise an alkyl substituted macrocycle to discover whether it 
possesses different biological activity as this would aid the design and development of new 
anti-parasite drugs. It was decided to attempt the synthesis of a macrocycle 142 with a 
methyl group attached as this is the simplest alkyl group and if the synthesis was successful 
it would provide a pathway for the synthesis of a range of compounds with different alkyl 
substituents. 
HN NH
NH HN
142  
7.1.1 Template Synthesis 
It was decided to attempt a template synthesis as discussed previously in Chapter 5 for the 
synthesis of cyclen 70.
121 If successful this would provide a short route for the multigram 
preparation of the susbstituted macrocycle. 
The  first  step  of  the  reaction  was  the  synthesis  of  bisimidazoline  72  by  treating 
triethylenetetraamine 71 (TETA) with dimethylformamide dimethyl acetal (Scheme 50). 
The desired product 72 was obtained in crystalline form in moderate yield and was reacted 
with 1,2-dibromopropane to form the carbon skeleton of the macrocycle. The 
1H NMR Jennifer M. Wilson, 2007     Chapter 7, 87 
spectrum showed the disappearance of the bisimidazoline so the reaction was carried onto 
the next step. Alkaline hydrolysis should remove the two carbon infrastructure leaving the 
desired product 142. Unfortunately no product 142 or any starting material was recovered; 
the harsh reaction conditions must have broken down the reagents. It is unknown whether 
the macrocyclic skeleton was formed at all. 
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Scheme 50 
7.1.2 High Dilution Amide Synthesis 
7.1.2.1  Formation of Macrocycle 
Reid also carried out some research into the synthesis of enantiomerically pure substituted 
macrocycles.
117 By adapting this line of research, the synthesis of the methyl substituted 
macrocycle 142 should be possible. Stetter and Mayer in 1961 had synthesised dione 144 
by reacting diacid chloride 143 with ethylenediamine (Scheme 51).
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By  substituting  1,2-diaminopropane  for  the  ethylenediamine,  it  would  be  possible  to 
synthesise  a  compound  with  the  molecular  skeleton  of  the  desired  target  compound. 
Reduction  of  the  carbonyl  groups  and  removal  of the  tosyl  groups  would  produce  the 
methyl-susbtituted macrocycle 142 as a free base (Figure 24). Jennifer M. Wilson, 2007     Chapter 7, 88 
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The first stage of the reaction pathway was the synthesis of the diacid chloride 143.
170 This 
was achieved in a four step process (Scheme 52). Tosyl-protected ethylenediamine 145 
(prepared  quantitatively  from  ethylenediamine  using  toluene-4-sulfonyl  chloride  and 
pyridine), was reacted with methyl bromoacetate in a sodium methoxide solution to give 
diester 146. The diacid 147 was obtained by heating 146 under reflux with acetic acid and 
hydrochloric acid. The desired intermediate 143 was obtained by heating diacid 147 under 
reflux in thionyl chloride. 
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Scheme 52 
The next step of the pathway was the key cyclisation reaction.
170 The original procedure 
used benzene as the solvent for this reaction. However this reaction requires high dilution 
conditions  so  for  health  and  safety  reasons  dichloromethane  was  substituted  for  the 
benzene.  The  diacid  chloride  143  and  1,2-diaminopropane  were  added  dropwise 
simultaneously  and  the  desired  product  148  precipitated  from  the  reaction  mixture 
(Scheme 53). Jennifer M. Wilson, 2007     Chapter 7, 89 
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7.1.2.2  Formation of Free Base 
The next step of the pathway required the removal of the tosyl groups and the reduction of 
the carbonyl groups. A procedure was found that claimed to use lithium aluminium hydride 
to remove tosyl protecting groups from cyclen 70.
171 It was thought that this method could 
be  used  to  reduce  the  carbonyl  groups  and  remove  the  tosyl  groups  in  one  step.  The 
reaction was carried out by heating the macrocycle 148 under reflux in THF with lithium 
aluminium hydride for three days (Scheme 54). However the conditions were too harsh 
and the macrocycle was destroyed. 
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Scheme 54 
It was decided to use milder conditions to reduce the carbonyl groups and then the tosyl 
groups would be removed using de-tosylation methods well known in the Robins group. 
The  carbonyl  groups  were  successfully  reduced  using  a  1M  borane  in  tetrahydrofuran 
solution  followed  by  hydrolysis  using  conc.  hydrochloric  acid  yielding  the  desired 
compound 149 (Scheme 55).
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Scheme 55 Jennifer M. Wilson, 2007     Chapter 7, 90 
Only one step remained to complete the synthesis of the methyl-substituted macrocycle 
142. The de-tosylation step used to obtain cyclen 70 was attempted. The hydrobromide salt 
was  formed  followed  by  formation  of  the  free  base  under  Dean-Stark  conditions  but 
attempts to isolate the desired compound were unsuccessful.
173 Use of other established de-
tosylation techniques were also unsuccessful (e.g. HBr-AcOH 45%).
133 
It was decided to abandon this synthesis as the desired alkylated compound had not been 
produced and other areas of research were producing better results. It was hoped that more 
success would be had synthesising substituted thiaazamacrocycles. 
7.2 Synthesis  of  Aromatic-Substituted  Thiaaza-
macrocycles 
Reid had synthesised a range of azamacrocycles based on the cyclen skeleton.
117 It would 
be interesting to investigate whether the cytotoxicity of the compounds changes depending 
on the presence of different heteroatoms in the macrocyclic structure. As work was already 
being carried out trying to synthesise thiaazamacrocycles for use as alkylating agents, it 
seemed prudent to synthesise a range of substituted thiaazamacrocycles (Figure 25). 
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Figure 25 
It was decided to attempt the synthesis of the substituted thiaazamacrocycles using the iron 
templated  synthesis  that  had  been  successful  for  Reid.
169  It  is  well-documented  that 
triethylene  tetraamine  (TETA)  71  can  form  complexes  (cis-[MLCl2])  with  first-row 
transition metals.
174 It was unknown whether the iron would complex to the ligand if any 
sulfur atoms were present.  
7.2.1 Synthesis of a Substituted Dithia-diazamacrocycle 
7.2.1.1  Iron Templated Synthesis 
The reaction was attempted using the dithiadiamine 123 synthesised previously (Chapter 
6).  Diamine  123  was  reacted  with  ferric  chloride  and  methanol  to  form  the  diimine Jennifer M. Wilson, 2007     Chapter 7, 91 
(Scheme 56). Commercial phenyl glyoxal monohydrate was added. In order to isolate the 
desired compound, sodium borohydride was added to reduce the iron(III) to iron(II). An 
acidic  work-up  removed  the  coordinated  iron  leaving  the  free  base.
169  When  Reid 
synthesised the azamacrocycles, there were specific colour changes associated with the 
different stages of the reaction, however these  were not observed  when attempting the 
synthesis of the thiaazamacrocycle. The 
1H NMR spectrum of the crude product looked 
promising. However it was soon discovered that cyclisation had not occurred and reduced 
starting materials were obtained from the mixture, thus explaining the ‘positive’ 
1H NMR 
spectrum. 
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7.2.1.2  Future Work - High Dilution Amide Synthesis 
It was disappointing that the iron templated synthesis was unsuccessful and due to time 
constraints more research was not carried out in this area of the project. However upon 
reflection, there is another route that could be followed to synthesise a substituted dithia-
diazamacrocycle. 
The  high  dilution  route  described  previously  to  synthesise  the  methyl-substituted 
azamacrocycle 142 failed due to the presence of the tosyl-protecting groups which could 
not be removed under standard conditions. However if the same pathway was applied in 
the  instance  of  the  dithia-diazamacrocycles,  there  would  be  no  tosyl  groups  present 
(Scheme 57). 
The dithia-diacid 150 is commercially available. This would be transformed to the diacid 
chloride 151 which should then undergo cyclisation under high dilution conditions to form 
the  macrocycle  152.
170  Reduction  conditions have  already been  investigated  during the 
synthesis  of  the  methyl-substituted  azamacrocycle,
172 so  the  carbonyl  groups  should be 
reduced leaving the desired substituted thiaazamacrocycle 153 as the free base. Jennifer M. Wilson, 2007     Chapter 7, 92 
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This three step synthesis if successful would provide a means to synthesise a range of 
substituted dithia-diazamacrocycles simply and quickly, allowing an investigation into the 
development of better and more potent anti-parasitic drugs. 
7.2.2 Synthesis of a Substituted Thia-triazamacrocycle 
It is thought that one of the reasons the iron templated synthesis was unsuccessful for the 
dithia-diaazamacrocycles was that the two sulfur atoms did not coordinate strongly to the 
iron centre. It was hoped that if only one sulfur was present, coordination would still occur 
with the three nitrogen atoms (Scheme 58). 
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In order to test this theory, the sulfur-containing triamine 154 needed to be synthesised. 
There is literature precedent for the synthesis of this compound.
163c,175 A procedure was 
attempted  using  the  thia-diamine  116  already  synthesised  (Scheme  59).  2-
Chloroethylamine hydrochloride and caesium hydroxide monohydrate were reacted with 
the thia-diamine 116 in DMF – the literature quoted good yields for this reaction.
175 Jennifer M. Wilson, 2007     Chapter 7, 93 
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Several attempts were made to reproduce the literature results but unfortunately it was 
impossible  to  synthesise  the  thia-triamine  154.  Without  this  intermediate  the  reaction 
pathway could not be continued. 
7.3 Conclusions 
The desired substituted macrocycles could not be obtained by the routes and procedures 
tried. Further research needs to be carried out to obtain the desired target compounds. As 
discussed  previsouly  it  is  thought  that  the  substituted  dithiadiazamacrocycle  (S,S,N,N) 
would  be  synthesised  using  the  pathway  discussed.  These  compounds  would  allow  an 
investigation  into  cytotoxicity  and  a  structure-activity  relationship  could  be  established 
leading to a better understanding of the drug’s interactions in the body as well as allowing 
the design and development of more potent and efficient anti-parasitic agents.  94 
8  Synthesis of HDM2 Inhibitors 
8.1 Introduction – p53: ‘Guardian of the Genome’ 
p53  was  discovered  in  1979
176  and  voted  ‘molecule  of  the  year  1993’  by  Science 
magazine.
177  It  has  been  identified  as  an  important  tumour  suppressor  gene,  hence  the 
description ‘guardian of the genome’.
178 50% of all tumours possess a mutated form of the 
p53 protein – it is the most frequently altered gene in cancers. The other 50% of tumours 
possess ‘wild-type’ p53 which is inactivated by a variety of methods.  p53 stands for the 53 
kDa gene product found in cells that are infected with a virus.
179 
In the body, the p53 protein activates the transcription of specific  genes by forming a 
tetramer that binds to the DNA sequence.  p53 uses two different mechanisms for tumour 
suppression although both processes produce the same result which is the prevention of 
harmful gene mutations being passed onto daughter cells. Firstly, p53 responds to DNA-
damaging environmental stresses by stopping the cell cycle; DNA replication is halted 
allowing the  damaged  DNA to  be  repaired.   Secondly,  p53  can  also  initiate  apoptosis 
(programmed cell death) as shown in Figure 26.
180 
 
Figure 26 - Roles of p53
180 
Cancer can occur in cells where mutated p53 exists and apoptosis cannot occur – thus the 
damaged DNA replication occurs resulting in the development of a tumour.  p53 mutations 
are  largely  found  in  the  hydrophobic  region  of  the  protein  which  is  the  site  of  DNA 
binding.  Due to the loss of active p53, the cancer is also less responsive to radiotherapy or 
chemotherapy. This genetic mutation can be inherited as a disease known as Li-Fraumeni 
syndrome – the sufferer inherits only one functional copy of p53.
181 
However, in healthy cells, the levels of p53 have to be kept to a minimum to allow the 
normal running of the cell, e.g. growth and replication.  This function is carried out by the Jennifer M. Wilson, 2007     Chapter 8, 95 
HDM2 protein (Human Double Minute-2), which forms an auto-regulatory feedback loop 
with  p53.    HDM2  is  the  product  of  a  p53  inducible  gene.
182  p53  initiates  HDM2 
transcription and HDM2 inhibits p53 in three ways.  HDM2 can bind to the transactivation 
domain of p53, which blocks the transcription of genes. Also HDM2 contains a sequence 
of amino acids that is similar to the nuclear export ‘signal’ that exists in vital proteins. 
Therefore binding the HDM2 to p53 induces the eviction of the complex from the nucleus 
to the cytoplasm where normal cell functions cannot be carried out.  Finally, HDM2 is also 
an ubiquitin ligase protein – p53 becomes ‘tagged’  with a ubiquitin molecule and this 
targets p53 for degradation by proteasomes in the cell.  It can be seen that HDM2 regulates 
the stability of p53 as in Figure 27 (HDM2 is represented by MDM2 – Mouse Double 
Minute-2).
183 
 
Figure 27 - Regulation of p53 by MDM2 
However in certain circumstances, e.g. when a cell is put under oncogenic stress, HDM2 
activity must be inhibited to allow p53 levels to increase and the cell will undergo DNA 
repair or apoptosis.  This can be achieved in several ways. The DNA damage can initiate 
phosphorylation  of  several  amino  acids  in  p53,  which  prevents  binding  with  HDM2.  
Secondly, the activation of oncogenes (cancer causing cells) results in the expression of a 
protein  known as Auxin Response Factor (ARF). This ADP ribosylation factor protein 
binds to HDM2 using a site remote from the p53 binding site resulting in a conformational 
change in the HDM2 protein preventing binding and ubiquitylation on p53.
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8.1.1 Using HDM2 As A Therapeutic Target 
In some tumours, the p53 function is disrupted due to genetic mutations of p53.  However 
other tumours possess ‘wild type’ p53 – this type of p53 has lost the ability to respond to 
oncogenic stress due to over-expression of HDM2.  Thus the chance of forming a tumour 
is  increased  by  the  inhibition  of  p53  stabilisation.  Generally  soft  tissue  tumours, 
osteocarcinomas and oesophagal carcinomas demonstrate the highest frequency of HDM2 
amplification.
184  In  fact  it  is  thought  that  these  types  of  cancers  require  HDM2  over-
expression  for  tumour  survival.  Therefore,  HDM2-inhibiting  drugs  should  cause 
stabilisation of p53 and induce apoptosis in cancer cells. 
Past investigation into inhibitors of non-enzyme protein-protein interactions has not proved 
successful.
185 An investigation into the p53-HDM2 complex had to be carried out before 
inhibitors of HDM2 could be developed.
186 Protein crystallography was used to determine 
the structure of the complex of HDM2 with peptides of the p53-binding domain.  The 
results showed that HDM2 has a deep hydrophobic cleft constructed of α-helices and β-
sheets. The HDM2 cleft is filled with three amino acid side chains from the hydrophobic 
face of p53 (Phe 19, Try 23 and Leu 26) – the p53 forms an amphipathic α-helix with one 
side  hydrophobic  and  one  hydrophilic.    Van  der  Waals  interactions  and  steric 
complementarity constitute the main sources of attraction between p53 and HDM2. 
 
Figure 28 - Hydrophobic Pocket in HDM2 
Figure 28 shows the HDM2 NH2 terminal in blue with its twisted ‘trough’ type structure. 
The p53 peptide, shown in yellow, may bind to the HDM2 as an α-helix. A shows the 
HDM2-p53 complex with the floor of the HDM2 cleft in the plane of the picture. B shows 
the  complex  rotated  90
o,  looking  down  the  helical  axis  of  p53.  C  shows  the  complex 
rotated 90
o from the vertical axis of B.
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8.1.2 Inhibitors Of The HDM2-p53 Complex 
p53 derived peptides inhibit the interaction between p53 and HDM2.  However peptides 
are not useful as drugs as stomach acid and hydrolytic enzymes hydrolyse the peptides too 
easily.
187  
Inhibitors should be designed to mimic p53.  The reason for this is that only HDM2 has 
structurally  well-defined  binding  sites  whereas  p53  can  undergo  structural change,  e.g. 
phosphorylation or change of conformation can occur due to stress and p53 is composed of 
a single short stretch of amino acids.  The interactions between p53 and HDM2 consist of 
three hydrogen bonds and the contact surface area is small.  Therefore a low molecular 
weight inhibitor may work which also favours an oral administration for the drug. 
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Several  compounds  have  been  identified  as  small  molecule  HDM2  antagonists.  These 
include  the  chalcones  155  that  are  based  on  phenoxy-acetic  acid  derivatives  and 
phenoxymethyl tetrazole derivatives.
188 The chalcones were first reported in 1999 and  bind 
in the hydrophobic pocket of HDM2 showing IC50 values within the µM range. Zhao and 
co-workers prepared non-peptidic polycyclic antagonists 156 which have shown moderate 
affinity for HDM2 and initiate p53-controlled apoptosis in tumour cell lines.
189 During a 
library screening, the nonapeptide chlorofusin 157 was identified as an inhibitor but due to 
the  high  molecular  mass  and  complex  structure  it  is  an  unsuitable  drug  candidate.
190 Jennifer M. Wilson, 2007     Chapter 8, 98 
However, the molecule could prove useful for future drug design. The stereochemistry of 
C-4, C-8 and C-9 is as shown or inverted and the asterisks denote two stereocentres where 
one is R and the other is S. 
Three years ago, Roche published the structure of three cis-imidazoline based compounds 
158-160, known as the Nutlins – named after the Nutley inhibitor.
185 The compounds were 
synthesised as racemic mixtures and were separated using chiral columns.  One enantiomer 
of  the  products  formed  had potent  binding  activity,  whereas the  other  enantiomer  was 
found to be 150 times less active. 
Bindings  of  these  compounds  to  the  p53  binding  site  were  proven  by  X-ray  crystal 
structures.  An in vivo study of these compounds on mice with human tumour xenografts 
showed 90% inhibition of tumour growth after 20 days compared to the control.  More 
importantly no side effects such as weight loss or abnormalities were observed.
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At the same time a small molecule called RITA 161 (Reactivation of p53 and Induction of 
Tumour cell Apoptosis) was discovered by workers at the Karolinska Institute in Sweden 
during a library screen.
191 Again this compound could serve as a lead compound for future 
drug design. 
O
S S
OH HO
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8.2 Aims Of The Project 
A  high  throughput  assay  to  identify  low  molecular  weight  inhibitors  of  HDM2  was 
developed by Professor Karen Vousden FRS and her team from the Cancer Research UK 
Beatson laboratories together with Dr Allan Weissman from the National Cancer Institute 
and Igen Pharmaceuticals in the USA.
192 The screen was carried out in tumours containing 
wild-type p53 and a library of 10,000 compounds was tested. Forty compounds were found Jennifer M. Wilson, 2007     Chapter 8, 99 
to inhibit HDM2 autoubiquitylation by more than 50%. The compounds 162-164 were 
identified  after  additional  in vitro  gel-based  assays.
193  The  compounds  all  contain  a  5-
deazaflavin structural motif. 
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A  ‘library’  of  new  analogues  of  these  compounds  has  already  been  synthesised  and 
tested.
194 The biological results showed that the para-substituted compounds are favoured 
over the meta-substituted. 
As work has been carried out concerning the phenyl substituent,
194 it was decided to focus 
on the 7-position of the heterocycle (Scheme 60).  An amino group instead of the nitro 
group at C-7 on compound 165 would produce a more water-soluble compound 166, which 
should be more suited for a drug that has to be taken orally or intravenously. This amino 
group could then be treated with sodium nitrite and acid to form a diazonium salt 167 
which should lead to the synthesis of further compounds such as the cyano derivative 168. 
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Scheme 60 
All compounds synthesised up to this point had contained a 7-nitro group.
194 It could not be 
ruled out that part of the mechanism of action of these compounds involved the nitro group 
and oxidative stress processes.
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of  the  5-deazaflavins,  compounds  containing  different  functional  groups  would  be 
prepared.  The  size  of  the  binding  pocket  could  also  be  investigated  by  synthesising 
deazaflavins with different aromatic rings such as quinoline. 
8.3 Synthesis of Deazaflavins 
Retrosynthesis  of  the  5-deazaflavin  skeleton  165  by  disconnection  of  the  central  ring 
produces two fragments consisting of a 6-anilinouracil compound 169 and a substituted 
nitrobenzaldehyde  170.  Further  disconnection  of  169  produces  6-chlorouracil  171  and 
aniline 172 (Scheme 61). Analogues are easily prepared by using substituted derivatives of 
these synthons. 
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Scheme 61 
6-Chlorouracil 171 is a commercial compound, however due to problems with the supplier 
it was necessary to synthesise the starting material. This was successfully achieved from 
2,4,6-trichloropyrimidine 173 as shown in Scheme 62.
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Scheme 62 
The first coupling reaction involved reacting 6-chlorouracil 171 with aniline 172 (Scheme 
63).  Diversity  can  be  added  to  the  synthesis  by  using  substituted  anilines.  The  two 
reactants were melted together at 170 
oC for 20 minutes producing a white solid in good 
yield.
197 Nucleophilic substitution occurs at the 6-position of the uracil – the presence of the Jennifer M. Wilson, 2007     Chapter 8, 101 
chlorine  encourages  this  reaction.  The  reaction  is  similar  to  nucleophilic  aromatic 
substitution as the intermediate formed is stabilised by the presence of the electronegative 
element. However the reaction is more like a 1,4-carbonyl addition. The second step of the 
synthesis  involved  the  condensation  of  the  secondary  amine  169  with  2-chloro-5-
nitrobenzaldehyde 170 (Scheme 63).
197 Water was then added resulting in the precipitation 
of the desired product 165.  
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Scheme 63 
The mechanism of the reaction is shown in Scheme 64. Nucleophilic aromatic substitution 
occurs before the condensation reaction takes place.
198 SNAr occurs because SN2 will not 
occur at sp
2 hybridised orbitals and it highly unlikely that an SN1 reaction would occur as it 
would involve unaided loss of the leaving group and the formation of an aryl cation with 
an empty sp
2 hybridised orbital outside of the benzene ring and a full p-orbital inside the 
ring. SNAr involves addition of the nucleophile followed by loss of the leaving group. The 
presence of an electron withdrawing group positioned ortho- or para- to the ring aids the 
reaction  as  electrons  can  be  delocalised  around  the  aromatic  ring.  2-Chloro-5-
nitrobenzaldehyde possesses two electron withdrawing groups, therefore it reacts readily 
with the secondary amine. Jennifer M. Wilson, 2007     Chapter 8, 102 
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Scheme 64 
A small library of derivatives was synthesised using the previously discussed method.
197 
The results are summarised in Figure 29. The quoted yields are for the two successive 
steps. 
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Figure 29 
It was possible to grow crystals of 181 and an X-ray crystal structure was obtained (Figure 
30). As expected the lower aromatic ring is twisted out of the plane of the deazaflavin 
system. Jennifer M. Wilson, 2007     Chapter 8, 103 
 
Figure 30 
As discussed previously it was desirable to synthesise an amino derivative 166 as this 
would produce a precursor to many different analogues. Unfortunately it was not possible 
to reduce the nitro compound 165 although several different methods were tried. Firstly a 
reduction using iron powder and hydrochloric acid
199 was attempted but the desired product 
was undetectable in the 
1H NMR spectrum. A radical method using samarium and 1,1’-
dioctadecyl-4,4’-bipyridinium  dibromide
200  also  failed  –  the  starting  material  was 
recovered. A method using formic acid, triethylamine and 10% palladium on carbon
201 also 
proved  unsuccessful.  It  was  thought  that  these  reactions  were  unsuccessful  due  to  the 
limited solubility of the nitro compound 165. 
It was then decided to use Buchwald-Hartwig aminations
202 to introduce the amino moiety 
using compound 179 which had been synthesised using the established pathway previously 
discussed.  Compound  179  was  reacted  with  diethylamine,  palladium  diacetate,  tri-tert-
butylphosphine, sodium tert-butoxide and toluene (Scheme 65). 
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Scheme 65 
Unfortunately only starting material was recovered. It was decided to attempt a microwave 
technique using diethylamine, potassium tert-butoxide and DMSO.
203 Again only starting 
material was recovered. Jennifer M. Wilson, 2007     Chapter 8, 104 
It was then thought that the chlorine atom of 179 could be substituted with an azide anion 
(Scheme 66). This involves nucleophilic aromatic substitution as discussed previously.
198 
The  azide  would  provide  the  opportunity  to  add  functionality  onto  the  molecule. 
Unfortunately this reaction was not successful.
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Scheme 66 
As attempts to reduce the nitro group on the 5-deazaflavin had proved unsuccessful it was 
decided  to  use  a  preformed  amino-chlorobenzaldehyde  (Scheme  67).  This  compound 
should react with the anilinouracil to produce the desired compound although it would 
have to be prepared as there are no commercial amino-chlorobenzaldehydes available.  
5-Amino-2-chlorobenzoic acid 183 was transformed into 184 using a one-pot procedure to 
add the methyl ester group and Boc protect the amine.
205 Conditions for the reduction of 
184 to 185 were investigated.
206 A procedure using lithium aluminium hydride and THF 
was successful. 
At first it had been assumed that the methyl ester 184 could be directly reduced to form the 
aldehyde  compound  186,  however  it  was  impossible  to  isolate  the  pure  aldehyde.
205 
Therefore it was decided to form the alcohol 185 and then oxidise the primary alcohol to 
the corresponding aldehyde 186. Jennifer M. Wilson, 2007     Chapter 8, 105 
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Scheme 67 
Unfortunately, it proved impossible to oxidise the alcohol 185 to aldehyde 186. Numerous 
attempts  were  made,  none  of  which  produced  the  desired  compound.
207  This  was 
disappointing as there only remained two steps to produce the desired amino compound – 
the coupling of 168 and 186 followed by Boc-deprotection should produce 166. 
8.4 Biological Test Results 
All synthesised compounds were tested at the Beatson Oncology Laboratories, Glasgow. 
All the compounds were analysed for their ability to stabilise endogenous HDM2 and p53 
in  primary  human  pigment  epithelial  cells  (RPE).  Several  of  the  compounds  showed 
activity in the stabilisation of p53 comparable to compound 162. Three of the analogues, 
174,  177  and  178  demonstrated  stronger  p53  stabilisation  and  activity  at  lower 
concentrations than compound 162. Generally stabilisation of p53 is accompanied by the 
activation of DNA damage-induced kinases – p53 becomes phosphorylated at serine 15. 
However in this case there was no clear indication that phosphorylation had occurred on 
the p53 stabilised by the 5-deazaflavins. This shows that the compounds stabilise p53 by 
inhibition of HDM2 as opposed to the activation of a DNA damage response.  
The original lead compounds 162-164 contain a nitro group that could be reduced to a nitro 
anion radical in biological systems. This radical then interacts with DNA to induce DNA 
damage. However the results from compounds 174, 177 and 178 argue against this notion. 
More interesting was the fact that analogues without the nitro group retained biological 
activity. The results are summarised in Table 7. These compounds 176-178 contained a 6-
chloro group instead of the 7-nitro group. Jennifer M. Wilson, 2007     Chapter 8, 106 
Compound  1 µM  5-10 µM 
165  ND  - 
174  +  ++ 
175  ND  - 
176  -  + 
177  +  ++ 
178  +  ++ 
179  ND  - 
180  -  - 
181  -  - 
182  ND  - 
Table 7. Stabilisation of p53 measured by Western blotting in RPE cells treated with the 
analogues at the indicated concentrations for 24 hours. Results of the three experiments are 
summarised to indicate no elevation of p53 levels (-); increase in p53 with that seen with 5 
µM  compound  162  (+);  or  increase  in  p53  levels  in  excess  of  that  seen  with  5  µM 
compound 162 (++). ND, not determined. 
8.5 Conclusions 
By consideration of the test results obtained, it has been determined that the compounds 
must have certain structural characteristics in order to be good inhibitors of HDM2. For 
example there must be a substituent on the aromatic ring of the fused cyclic system. 
The  most  important  new  finding  is  that  the  nitro  group  present  in  the  three  original 
compounds 162-164 is not essential for stabilisation and activation of p53.  
The R substituent on the phenyl ring must be in the ortho or para position and requires 
some bulk, e.g. a methyl group or a chlorine atom is adequate although a bromine atom 
appears to be too big. This work has been published as part of a wider study of these types 
of compounds.
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Figure 31 
If any further work is carried out on this project it would be beneficial to complete the 
synthesis of the amino-derivative as this compound would allow an investigation into the 
mode of action of the deaazaflavins. 
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9  Experimental 
9.1 General Experimental Details 
All reactions were carried out under an inert atmosphere unless otherwise stated, using 
oven-dried or flame-dried glassware. Solutions were added via syringe unless otherwise 
stated.  Tetrahydrofuran  and  diethyl  ether  were  freshly  distilled  from  sodium-
benzophenone; dichloromethane, toluene, dimethylformamide and pyridine were distilled 
from calcium hydride prior to use. Petroleum ethers refer to the fraction boiling at 40-60 
oC.  Brine refers  to  a  saturated  sodium chloride  solution.  Reagents  were obtained  from 
Aldrich Chemical Company (Gillingham, Dorset, UK), Alfa Aesar Lancaster (Morecambe, 
Lancs,  UK)  or  Alfa  Aesar  Avocado  (Heysham,  Lancs,  UK)  and  used  without  further 
purification unless otherwise stated. Purification by column chromatography was carried 
out  using  Fischer  Silica  60A  silica  gel  (mesh  size  35-70  µm)  as  the  stationary  phase. 
Melting points were measured using Gallenkamp apparatus and are uncorrected. IR spectra 
were recorded using Golden Gate, nujol or KBr on a JASCO FT/IR 410 spectrometer. 
NMR spectra were recorded using a Bruker AV400 or DPX/400 spectrometer. Chemical 
shifts are given in ppm relative to trimethylsilane. Chemical shifts in 
13C NMR spectra are 
given in ppm relative to CDCl3 as internal standard (77.0 ppm). All NMR J values are 
given in Hz. Mass spectra were recorded on a JEOL JMS700 spectrometer.  
9.2 Experimental to Chapter 5 
9.2.1 General Procedures (A-C) 
General procedure A – Copper complex formation: A stirred solution of macrocycle (1 
eq) and methanol/water mixture (5:1) was added to a round-bottomed flask fitted with a 
water-cooled condenser. Anhydrous copper (II) chloride (1 eq) was added and the reaction 
mixture was heated to 50 
oC for 10 min. A blue or green solid precipitated on cooling and 
was collected by filtration. 
General  procedure  B  –  Method  1  for  synthesis  of  carbamates:  A  stirred  solution  of 
1,4,7,10-tetra(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane (1 eq) and pyridine (5 mL) 
was prepared. Isocyanate (eq) was added and the reaction mixture was stirred for 18 h at 
RT. The pyridine was removed by rotary evaporator and the beige solid was filtered and Jennifer M. Wilson, 2007     Chapter 9, 109 
washed with diethyl ether (20 mL). White crystals were obtained by recrystallising from 
hot methanol. 
General  procedure  C  –  Method  2  for  synthesis  of  carbamates:  A  stirred  solution  of 
alcohol (1 eq), dibutyl tin diacetate (3 drops) and dichloromethane (10 mL) was prepared. 
Isocyanate (0.88 mL, 9.28 mmol)  was added and the reaction mixture was stirred and 
heated under reflux for 24 h. The solvent was concentrated and the residue was filtered and 
washed with diethyl ether (20 mL). The crude product was recrystallised from ethyl acetate 
and hexane. 
General procedure D – Acylation of azamacrocycles: A stirred solution of cyclen (1 eq) 
and dichloromethane (5 mL) was prepared and cooled to 0 
oC in an ice bath. Triethylamine 
(4  eq)  was  added.  Once  all  the  reactants  had  dissolved,  chloroacetyl  chloride  or 
bromoacetyl bromide (4 eq) was added. The reaction mixture was stirred for 20 min at 0 
oC 
then allowed to return to RT and stirred for 16 h. The dark brown solution was washed 
with water (2 x 25 mL). The organic layer was dried (MgSO4) and concentrated leaving a 
dark  brown  oil  that  was  purified  by  column  chromatography  (eluant: 
dichloromethane/methanol 97/3). 
9.2.2 Experimental Details 
N,N’,N’’-Tri(toluene-4-sulfonyl)diethylene triamine 78
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A stirred solution of diethylene triamine (21.7 mL, 0.20 mol) and distilled water (125 mL) 
was prepared. Sodium hydroxide pellets (24.0 g, 0.6 mol) were added and the temperature 
was kept below 40 °C. Diethyl ether (125 mL) was added and the reaction mixture was 
stirred  vigorously.  Toluene-4-sulfonyl  chloride  (114.5  g,  0.6  mol)  was  added,  the 
temperature was kept below 20 °C during addition. The reaction mixture was cooled to 0 
°C and stirred for one hour. The white precipitate was filtered and washed with diethyl 
ether  (250  mL).  Recrystallisation  from  chloroform  gave  the  desired  product  (112.6  g, 
99%). mp 176-178 °C (lit. 177-179 °C); 
1H NMR (400 MHz, CDCl3): 2.50 (9H, s, CH3), 
2.63 (2H, t, J 6.0 Hz, 2 x NH), 3.14-3.22 (8H, m, 4 x CH2), 7.29-7.38 (6H, m, 6 x ArH), 
7.64 (2H, d, J 8.4 Hz, 2 x ArH), 7.77-7.87 (4H, m, 4 x ArH); m/z (FAB): 566 (MH
+, 99%), 
412 (71), 227 (53), 154 (50), 136 (35), 92 (31). Jennifer M. Wilson, 2007     Chapter 9, 110 
N,O,O’-Tri(toluene-4-sulfonyl)diethanolamine 80
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A stirred solution of toluene-4-sulfonyl chloride (114.5 g, 0.6 mol) and dichloromethane 
(140  mL)  was  prepared  and  cooled  to  0  °C.  Diethanolamine  (19.2  mL,  0.2  mol), 
benzyltriethylammonium chloride (18.2 g, 80.0 mmol) and 30% NaOH solution (24.0 g in 
150 mL distilled water) were added whilst stirring vigorously. The reaction mixture was 
allowed  to  return  to  room  temperature  and  was  stirred  for  another  hour.  The  reaction 
mixture was poured onto distilled water (300 mL). The organic phase was separated and 
washed with distilled water (3 x 150 mL). The organic phase was dried (MgSO4), filtered 
and concentrated. The viscous oil was placed on a vacuum line to eliminate any presence 
of solvent. The product crystallised over a period of 2 weeks (102.9 g, 91%). mp 97-99 °C 
(lit. 101-103 °C); 
1H NMR (400 MHz, CDCl3): 2.45 (3H, s, CH3), 2.49 (6H, s, 2 x CH3), 
3.40 (4H, t, J 6.0 Hz, 2 x CH2N), 4.14 (4H, t, J 6.0 Hz, 2 x CH2O), 7.31-7.34 (2H, m, 2 x 
ArH), 7.38 (4H, d, J 8.0 Hz, 4 x ArH), 7.63 (2H, d, J 8.4 Hz, 2 x ArH), 7.78 (4H, d, J 8.0 
Hz, 4 x ArH); m/z (CI): 568 (MH
+, 13%), 432 (12), 396 (12), 242 (100), 157 (35). 
1,4,7,10-Tetra(toluene-4-sulfonyl)-1,4,7,10-tetraazacyclododecane 76
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Method  1:  A  mixture  of  toluene  (200  mL),  tetrabutylammonium  bromide  (0.81  g,  2.5 
mmol) and 2.5% LiOH solution (2.56 g in 100 mL distilled water) was heated under reflux 
conditions.  N,N’,N’’-Tri(toluene-4-sulfonyl)diethylene  triamine  (5.65  g,  10  mmol),  
N,O,O’-tri(toluene-4-sulfonyl)diethanolamine  (5.68  g,  10  mmol)  and  toluene  (400  mL) 
were added in small portions. The reaction mixture was heated under reflux overnight. The 
reaction  mixture  was  cooled  and  the  white  precipitate  was  filtered  and  washed  with 
methanol (100 mL) giving a white solid. (5.42 g, 69%). mp 276-279 
oC (lit. 278-280 
oC); 
1H NMR (400 MHz, CDCl3): 2.47 (12H, s, 4 x CH3), 3.45 (16H, bs, 8 x CH2), 7.34 (8H, d, 
J 7.0 Hz, 8 x ArH), 7.66 (8H, d, J 7.0 Hz, 8 x ArH); m/z (FAB): 789  (MH
+, 99%), 633 
(40), 477 (16), 323 (20), 253 (37), 154 (38), 92 (54). 
Method 2: A stirred solution of N,N’,N’’-tri(toluene-4-sulfonyl)diethylene triamine (8.0 g, 
11  mmol),  caesium  carbonate  (13.68  g,  42  mmol)  and  DMF  (300  mL)  was  prepared. Jennifer M. Wilson, 2007     Chapter 9, 111 
N,O,O’-Tri(toluene-4-sulfonyl)diethanolamine (5.68 g, 11 mmol) was dissolved in DMF 
(125 mL) and added to a dropping funnel. The contents of the dropping funnel were added 
dropwise  over  a  period  of  3  h.  The  reaction  mixture  was  stirred  for  5  d  at  room 
temperature. The DMF was removed using a pump-assisted rotary evaporator. The residue 
was taken up in dichloromethane (150 mL) and distilled water (150 mL). The aqueous 
layer was extracted with dichloromethane (100 mL). The combined organic phases were 
washed with brine (150 mL), dried (MgSO4) and concentrated. The light brown residue 
was recrystallised from methanol (5.25 g, 47%). Spectroscopic data as described above.  
1,4,7,10-Tetraazacyclododecane 70 – Cyclen
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Method  1:  A  stirred  solution  of  1,4,7,10-tetra(toluene-4-sulfonyl)-1,4,7,10-
tetraazacyclododecane (5.42 g, 6.87 mmol), phenol (12.80 g, 0.14 mol) and HBr-AcOH 
45% (270  mL)  was prepared.  The  round bottomed  flask  was  fitted  with  a  water-filled 
condenser and an air condenser. This allows the evolving HBr gas to escape to the top of 
the fume hood. The reaction mixture was heated under reflux for 3 d. The reaction mixture 
was cooled and the acetic acid was removed under vacuum. The residue was taken up in 
toluene (4 x 30 mL) to azeotrope off all traces of acetic acid on the rotary evaoporator. The 
dark purple residue was dissolved in distilled water (150 mL) and dichloromethane (75 
mL)  was  added.  The  layers  were  separated  and  the  aqueous  layer  was  washed  with 
dichloromethane  (4  x  75  mL).  The  aqueous  layer  was  concentrated  yielding  a  brown 
residue which was purified by an anion exchange column. The column was prepared using 
Amberlite IRA-400 resin. Distilled water (200 mL), potassium hydroxide (50 mL, 10 % 
solution)  and  distilled  water  (350  mL)  were  passed  down  the  column  until  pH  7  was 
achieved. The crude residue was dissolved in a minimum volume of distilled water and 
loaded onto the column. Water was eluted through the column until the pH dropped from 
11  to  7.  The  aqueous  eluant  was  concentrated.  Methanol  (4  x  25  mL)  was  added  to 
azeotrope off all traces of water. The product was recrystallised from hot toluene yielding a 
white powder (0.54 g, 46%). mp 98-100 
oC (lit. 110-113 °C); 
1H NMR (400 MHz, D2O): 
2.48 (16H, bs, 8 x CH2); m/z (CI): 173 (MH
+, 61%), 113 (8), 97 (9), 79 (100). 
Method  2:  A  stirred  solution  of  1,4,7,10-tetrakis-(toluene-4-sulfonyl)-1,4,7,10-
tetraazacyclododecane (9.66 g, 12.66 mmol) and conc. sulfuric acid (25 mL) was prepared Jennifer M. Wilson, 2007     Chapter 9, 112 
and stirred at 110 
oC for 40 h. The brown/black solution was poured into a conical flask 
and cooled in an ice bath. Distilled water (20 mL) was added slowly. Potassium hydroxide 
(45  g)  pellets  were  added  until  the  pH was  13.  Ethanol (150  mL)  was  added  and the 
mixture was filtered. The solid residue was washed with ethanol (5 x 20 mL) and the 
filtrate  was  concentrated.  The  residue  was  taken  up  in  the  minimum  volume  of  1  M 
hydrochloric  acid  (40  mL)  and  dichloromethane  (30  mL)  was  added.  The  layers  were 
separated and the aqueous layer was washed with dichloromethane (4 x 30 mL). The pH 
was  raised  to  13  by  adding  potassium  hydroxide  pellets.  This  was  extracted  with 
chloroform  (4  x  25  mL).  The  organic  layers  were  combined,  dried  (K2CO3)  and 
concentrated yielding a yellow solid (0.28 g, 13%). Spectroscopic data as described above. 
Method 3 : Conc. sulphuric acid (11 mL) was heated to 165 °C. 1,4,7,10-Tetra(toluene-4-
sulfonyl)-1,4,7,10-tetraazacyclododecane  (1.20  g,  2.42  mmol)  was  added  in  a  single 
portion  and  the  solution  was  stirred  until  the  reaction  mixture  had  turned  black.  The 
reaction  mixture  was  cooled  by  transferring  the  mixture  into  a  Buchner  flask  and 
submersing this flask in cold water. This mixture was added dropwise to ethanol (36 mL) 
that was stirred. The precipitate was the polyhydrosulfate salt. Diethyl ether (27 mL) was 
added and the solution  was cooled to 0 °C in  an ice bath. The solid was filtered and 
dissolved in the minimum volume of hot water (7 mL), and an equivalent volume of HBr 
(48% aq, 7 mL) was added. Overnight the tetrahydrobromide salt crystallised. This was 
filtered and washed with hydrobromic acid (5 mL) and ethanol (5 mL). The white crystals 
were dried under high vaccuum. The crystals were then added to a round-bottomed flask 
charged with toluene (20 mL), distilled water (5 mL) and sodium hydroxide pellets (0.4 g, 
10 mmol). Dean-Stark  apparatus was fitted and the reaction mixture  was heated under 
reflux for 24 h. The toluene solution was then filtered and concentrated yielding white 
crystals. (0.97 g, 88%). Spectroscopic data as described above. 
1,4,7,10-Tetra(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane 83
115 
N N
N N
OH HO
HO OH 
1,4,7,10-Tetraazacyclododecane (0.97 g, 5.63 mmol) and  distilled water (9.7 mL) were 
added  to  a  round-bottomed  flask  fitted  with  an  dropping  funnel  and  a  cooling  finger. 
Ethylene oxide (2.48 g, 56.3 mmol) and distilled water (1.9 mL) were added to the reaction Jennifer M. Wilson, 2007     Chapter 9, 113 
mixture dropwise. The reaction mixture was stirred for 2 h and the temperature was kept 
below 5 °C. The water and excess ethylene oxide were removed by rotary evaporator, 
yielding white crystals (2.10 g, 100%). mp 67-69 °C (no lit. mp available); 
1H NMR (400 
MHz, CDCl3): 2.42 (8H, t, J 4.8 Hz, 4 x CH2N), 2.46 (16H, bs, 8 x CH2N), 3.55 (8H, t, J 
4.8 Hz, 4 x CH2O); m/z (FAB): 349 (MH
+, 99%), 305 (18), 248 (4), 175 (9), 154 (14), 89 
(15). 
1,4,7,10-Tetra(2-chloroethyl)-1,4,7,10-tetraazacyclododecane dihydrochloride 58
115  
N N
N N
Cl Cl
Cl Cl
.2HCl
 
1,4,7,10-Tetra(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane  (100  mg,  1.43  mol)  and 
thionyl chloride (25 mL, 5 mL/100 mg tetraol) were added to a round-bottomed flask fitted 
with a water-cooled condenser and this was heated at 50 
oC overnight. The excess thionyl 
chloride was removed by rotary evaporator. The desired product was recrystallised from 
hot propan-2-ol (48 mg, 34%). mp 206-208 
oC (no lit. mp available); 
1H NMR (400 MHz, 
D2O): 3.28 (16H, bs, 8 x CH2N), 3.38 (8H, bs, 4 x CH2N), 3.84-3.90 (8H, m, 4 x CH2Cl); 
m/z (FAB): 423 [(M-2Cl)H
+, 
35Cl, 100%], 421 (79), 387 (22), 359 (17), 211 (26), 106 (38). 
1,4,7,10-Tetra(2-chloroethyl)-1,4,7,10-tetraazacyclododecane [Cu(II)]Cl2 64
115 
N N
N N
Cl Cl
Cl Cl
+Cl-
Cu
Cl  
Using  general  procedure  A,  64  was  synthesised  from  1,4,7,10-tetra(2-chloroethyl)-
1,4,7,10-tetraazacyclododecane dihydrochloride 58 (20 mg, 40 mmol), as blue crystals (21 
mg, 100%), m/z (FAB): 483 [(M-2Cl)
+, 
35Cl, 60%].  
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1,4,7,10-Tetra(phenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 84 
N N
N N
O O
O O
N
O
H
N
O
H
N
O
H
N
O
H  
Using  general  procedure  B,  84  was  synthesised  from  1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and phenyl isocyanate (1.09 mL, 10 
mmol), as white crystals (0.24 g, 100%). mp 150-152 
oC; νmax (KBr)/cm
-1: 3296 (NH), 
2944 (CH), 1696 (CO), 1228, 797;
 1H NMR (400 MHz, D6-DMSO): 2.62 (24H, bs, 12 x 
CH2N), 4.10 (8H, t, J 6.0 Hz, 4 x CH2O), 6.50 (4H, t, J 8.0 Hz, 4 x ArH), 7.24 (8H, t, J 8.0 
Hz, 8 x ArH), 7.45 (8H, d, J 8.0 Hz, 8 x ArH), 9.56 (4H, bs, 4 x NH); 
13C NMR (100 MHz, 
D6-DMSO): 52.4 (CH2), 53.8 (CH2), 62.1 (CH2), 122.3 (CH), 128.6 (CH), 128.7 (CH), 
128.8 (CH), 129.0 (CH), 134.8 (C), 153.5 (C); m/z (FAB): 825.4296 (MH
+, C44H57N8O8 
requires 825.4299), 511 (4), 358 (95), 307 (11), 155 (100), 109 (29).  
1,4,7,10-Tetra(isopropylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 85 
N N
N N
O O
O O
N
O
H
N
O
H
N
O
H
N
O
H  
Using  general  procedure  B,  85  was  synthesised  from  1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.2 g, 0.58 mmol) and isopropyl isocyanate (0.91 mL, 
9.28 mmol), as white crystals (0.24 g, 60%). Found: C, 55.8; H, 9.4; N, 16.3. C36H64N8O8 
requires C, 55.8; H, 9.5; N, 16.1%; mp 141-143 
oC; νmax (KBr)/cm
-1: 3279 (NH), 2969 
(CH) 1684 (CO), 1539; 
1H NMR (400 MHz, D6-Acetone): 1.00 (24H, d, J 6.8 Hz, 8 x 
CH3), 2.45 (24H, bs, 12 x CH2N), 3.59-3.64 (4H, m, 4 x CH), 3.94 (8H, t, J 6.0 Hz, 4 x 
CH2O); 
13C NMR (100 MHz, D6-DMSO): 22.5 (CH3), 42.2 (CH), 52.7 (CH2), 54.0 (CH2), 
61.6 (CH2), 155.3 (C); m/z (FAB): 689 (MH
+, 100%), 586 (10), 503 (18), 331 (85), 174 
(54), 131 (100), 90 (79), 72 (37).  
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1,4,7,10-Tetra(propylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 86 
N
N N
N
O
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O
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O
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H  
Using  general  procedure  C,  86  was  synthesised  from  1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.2 g, 0.58 mmol) and propyl isocyanate (0.88 mL, 
9.28 mmol), as white crystals (0.16 g, 41%). mp 142-144 
oC; νmax (KBr)/cm
-1: 3312 (NH), 
2960 (CH), 1686 (CO), 1548, 1272, 1008, 668;
  1H NMR (400 MHz, D6-Acetone): 0.91 
(12H, t, J 7.4 Hz, 4 x CH3), 1.48-1.57 (8H, m, 4 x CH2), 2.65 (24H, bs, 12 x CH2N), 3.09 
(8H, t, J 7.0 Hz, 4 x CH2N), 4.10 (8H, t, J 6.0 Hz, 4 x CH2O); 
13C NMR (100 MHz, D6-
DMSO): 11.2 (CH3), 22.7 (CH2), 42.0 (CH2), 52.6 (CH2), 54.0 (CH2), 61.8 (CH2) 156.2 
(C); m/z (FAB): 689.4922 (MH
+, C32H65N8O8 requires 689.4925), 433 (4%), 331 (2), 289 
(20), 146 (100).  
1,4,7,10-Tetra(4-methoxyphenyl)aminocarbonyloxyethyl-1,4,7,10-
tetraazacyclododecane 87 
N N
N N
O
N
O
H
O
N
O
H
O
N
O
H
O
N
O
H
MeO
MeO OMe
OMe
 
Using  general  procedure  C,  87  was  synthesised  from  1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83  (0.2 g, 0.58 mmol) and 4-methoxyphenyl isocyanate 
(3.0 mL, 23.2 mmol), as white crystals (0.55 g, 56%). mp 166-168 
oC; νmax (KBr)/cm
-1: 
3294 (NH), 2957 (CH), 1698 (CO), 1509, 1240, 827; 
1H NMR (400 MHz, D6-DMSO): 
2.06 (24H, bs, 12 x CH2N), 3.24 (12H, bs, 4 x OCH3), 3.65 (8H, bs, 4 x CH2O), 6.38 (8H, 
d, J 9.0 Hz, 8 x ArH), 6.90 (8H, d, J 9.0 Hz, 8 x ArH), 8.89 (4H, bs, 4 x NH); 
13C NMR 
(400 MHz, D6-DMSO): 52.5 (CH2), 53.8 (CH2), 55.1 (CH3), 62.0 (CH2), 113.8 (CH), 119.9 
(CH), 132.2 (C), 153.7 (C), 154.7 (C); m/z (FAB): 945.4724 (MH
+, C48H65N8O12 requires 
945.4722), 779 (4%), 695 (3), 459 (4) 338 (5), 238 (22), 170 (51), 87 (100).  Jennifer M. Wilson, 2007     Chapter 9, 116 
1,4,7,10-Tetra(4-bromophenyl)aminocarbonyloxyethyl-1,4,7,10-
tetraazacyclododecane 88 
N N
N N
O
N
O
H
O
N
O
H
O
N
O
H
O
N
O
H
Br
Br Br
Br
 
Using  general  procedure  C,  88  was  synthesised  from  1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and 4-bromophenyl isocyanate (2.30 
g, 11.6 mmol), as white crystals (0.21 g, 64%). mp 212-214 
oC; νmax (KBr)/cm
-1: 3303 
(NH), 2833 (CH), 1709 (CO), 1393, 1227, 820; 
1H NMR (400 MHz, D6-DMSO): 2.50 
(24H, bs, 12 x CH2N), 4.11 (8H, t, J 6.0 Hz, 4 x CH2O), 7.41-7.46 (16H, m, 16 x ArH), 
8.86 (4H, s, 4 x NH); 
13C NMR (100 MHz, D6-DMSO): 52.4 (CH2), 53.8 (CH2), 62.3 
(CH2) 113.4 (C), 120.2 (CH), 131.5 (CH), 138.9 (C), 153.4 (C); m/z (FAB): 1143 [MH
+ 
(
81Br), 4%], 1141 [MH
+ (
79Br), 5%], 371 (5), 253 (9), 170 (100), 87 (95).  
1,4,7,10-Tetra(2-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
89 
N N
N N
O
N
O
H
O
N
O
H
O
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O
H
O
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H
NO2 O2N
O2N NO2  
Using  general  procedure  C,  89  was  synthesised  from  1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and 2-nitrophenyl isocyanate (0.48 
g, 2.90 mmol), as a pale yellow solid (0.18 g, 64%). mp 82-84 
oC; νmax (KBr)/cm
-1: 3350 
(NH), 2359 (CH), 1718 (CO), 1428, 1237, 743; 
1H NMR (400 MHz, D6-DMSO): 2.59 
(24H, bs, 12 x CH2N), 4.11 (8H, bs, 4 x CH2O), 7.28 (4H, t, J 8.0 Hz, 4 x ArH), 7.66 (4H, 
t, J 8.0 Hz, 4 x ArH), 7.73 (4H, d, J 8.0 Hz, 4 x ArH), 7.96 (4H, d, J 8.0 Hz, 4 x ArH), 9.77 
(4H, bs, 4 x NH); 
13C NMR (100 MHz, D6-DMSO): 52.6 (CH2), 53.6 (CH2), 63.2 (CH2), 
123.8 (CH), 124.2 (CH), 125,7 (CH), 132.5 (C), 134.4 (CH), 140.7 (C), 153.4 (C); m/z 
(FAB): 1006 (MH
+, 97%), 842 (100), 826 (13), 678 (43), 660 (16), 490 (18), 326 (12), 232 
(32), 158 (48), 81 (100).  Jennifer M. Wilson, 2007     Chapter 9, 117 
1,4,7,10-Tetra(3-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
90 
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NO2 O2N  
Using  general  procedure  C,  90  was  synthesised  from  1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and 3-nitrophenyl isocyanate (0.48 
g, 2.9 mmol), as a pale yellow solid (0.14 g, 46%). mp 151-153 
oC; νmax (KBr)/cm
-1: 3389 
(NH), 2797 (CH), 1720 (CO), 1526, 1081, 735; 
1H NMR (400 MHz, D6-DMSO): 2.61 
(24H, bs, 12 x CH2N), 4.14 (8H, t, J 6.0 Hz, 4 x CH2O), 7.47-7.56 (4H, m, 4 x ArH), 7.80-
7.96 (12H, m, 12 x ArH), 10.09 (4H, bs, 4 x NH); 
13C NMR (100 MHz, D6-DMSO): 52.6 
(CH2), 53.7 (CH2), 62.6 (CH2), 121.9 (CH), 122.3 (CH), 128.9 (CH), 133.7 (CH), 146.4 
(C),  146.7  (C),  151.4  (C);  m/z  (FAB):  1005.3709  (MH
+,  C44H53N12O16  requires 
1005.3702), 391 (3), 322 (3), 238 (30), 170 (64), 87 (100).  
1,4,7,10-Tetra(4-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
91 
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Using  general  procedure  C,  91  was  synthesised  from  1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and 4-nitrophenyl isocyanate (0.48 
g, 2.9 mmol), as a bright yellow solid (0.18 g, 60%). mp 179-181 
oC; νmax (KBr)/cm
-1: 
3323 (NH), 2831 (CH), 1728 (CO), 1329, 855; 
1H NMR (400 MHz, D6-DMSO): 2.60 
(24H, bs, 12 x CH2N), 4.14 (8H, bs, 4 x CH2O), 7.64 (8H, d, J 8.8 Hz, 8 x ArH), 8.12 (8H, 
d, J 8.8 Hz, 8 x ArH), 10.30 (4H, s, 4 x NH); 
13C NMR (100 MHz, D6-DMSO): 52.6 
(CH2), 53.7 (CH2), 62.6 (CH2), 117.5 (CH), 124.9 (CH), 141.5 (C), 145.7 (C), 153.1 (C); 
m/z (FAB): 1005.3697 (MH
+, C44H53N12O16 requires 1005.3702), 990 (3), 824 (2), 782 (1), 
628 (1), 560 (1), 475 (1), 322 (3), 238 (17), 170 (100), 87 (100). Jennifer M. Wilson, 2007     Chapter 9, 118 
1,4,7,10-Tetra(phenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 92 
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Using  general  procedure  A,  92  was  synthesised  from  1,4,7,10-
tetra(phenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane  84  (0.24  g,  0.29 
mmol), as light blue crystals (0.28, 100%). mp 176-178 
oC; νmax (KBr)/cm
-1: 3185 (NH), 
2291, 1716 (CO), 1270, 1086; m/z (FAB): 887 ([M-2Cl]
+, 100%), 826 (8), 768 (18), 750 
(8), 410 (14), 367 (11), 185 (33), 94 (89), 71 (22). UV(H2O): λmax - 616 nm, εcoeff - 202 L 
cm
-1 mol
-1. 
1,4,7,10-Tetra(isopropylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 93 
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Using  general  procedure  A,  93  was  synthesised  from  1,4,7,10-
tetra(isopropylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane  85  (0.24  g,  0.35 
mmol), as green crystals (0.17 mg, 58%). mp 201-203 
oC; νmax (KBr)/cm
-1: 3341 (NH), 
2968  (CH),  1699  (CO),  1250,  1094;  m/z  (FAB):  751.4142  ([M-2Cl]
+,  C32H64N8O8Cu 
requires 751.4143), 688 (15%), 331 (13), 221 (15), 174 (17), 131 (100), 90 (38), 72 (20); 
UV(H2O): λmax - 614 nm, εcoeff - 375 L cm
-1 mol
-1.  
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1,4,7,10-Tetra(propylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 94 
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Using  general  procedure  A,  94  was  synthesised  from  1,4,7,10-
tetra(propylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane  86  (0.16  g,  0.24 
mmol), as green crystals (0.13 g, 64%). mp 66-67 
oC; νmax (KBr)/cm
-1: 3336 (NH), 2964 
(CH), 1706 (CO), 1539, 1263; m/z (FAB): 752 ([M-2Cl]
+, 100%), 688 (10), 667 (8), 221 
(12), 131 (20); UV(H2O): λmax - 614 nm, εcoeff - 375 L cm
-1 mol
-1.  
1,4,7,10-Tetra(4-methoxyphenylaminocarbonyloxyethyl)-1,4,7,10-
tetraazacyclododecane [Cu(II)]Cl2 95 
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Using  general  procedure  A,  95  was  synthesised  from  1,4,7,10-tetra(4-
methoxyphenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane  87  (0.3  g,  0.32 
mmol), as green crystals (78.0 mg, 23%). mp 186-188 
oC; νmax (KBr)/cm
-1: 3234 (NH), 
2942  (CH),  1721  (CO),  1511,  1221,  827;  m/z  (FAB):  1042.2632  ([M-Cl]
+, 
C48H64N8O12Cu
35Cl requires 1042.2628), 307 (22%), 155 (100), 109 (20); UV(H2O): λmax - 
604 nm, εcoeff - 381 L cm
-1 mol
-1.  
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1,4,7,10-Tetra(4-bromophenyl)aminocarbonyloxyethyl-1,4,7,10-
tetraazacyclododecane [Cu(II)]Cl2 96 
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Using  general  procedure  A,  96  was  synthesised  from  1,4,7,10-tetra(4-
bromophenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 88 (0.1 g, 80 µmol), 
as blue crystals (40 mg, 39%). mp 212-214 
oC; νmax (KBr)/cm
-1: 3333 (NH), 3102 (CH), 
1723 (CO), 1537, 1219, 881; m/z (FAB): 1238 [(M-2Cl)
+, 
79Br2, 
81Br2, 100%], 1002 (5), 
557 (10), 336 (15); UV(H2O): λmax: 786 nm, εcoeff: 1793 L cm
-1 mol
-1.  
1,4,7,10-Tetra(2-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 97 
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Using  general  procedure  A,  97  was  synthesised  from  1,4,7,10-tetra(2-
nitrophenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 89 (0.1 g, 90 µmol), 
as green crystals (40 mg, 39%). mp 149-151 
oC; νmax (KBr)/cm
-1: 3363 (NH), 1735 (CO), 
1512, 1340, 739; m/z (FAB): 1102 [(M-Cl)
+, 
35Cl, 3%], 903 (5), 209 (20), 158 (100), 81 
(55); UV(H2O): λmax - 623 nm, εcoeff - 1026 L cm
-1 mol
-1. 
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1,4,7,10-Tetra(3-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 98 
N N
N N
O
N
O
H
O
N
O
H
O
N
O
H
O
N
O
H
Cu
Cl
+Cl- O2N NO2
NO2 O2N
 
Using  general  procedure  A,  98  was  synthesised  from  1,4,7,10-tetra(3-
nitrophenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 90 (0.1 g, 90 µmol), 
as turquoise crystals (76 mg, 74%). mp 222-223 
oC; νmax (KBr)/cm
-1: 2959 (NH), 1718 
(CO), 1427, 1089, 735; m/z (FAB): 1102 [(M-Cl)
+, 
35Cl, 1.7%] 235 (8), 158 (100), 81 
(100); UV(H2O): λmax - 623 nm, εcoeff - 935 L cm
-1 mol
-1. 
[1,4,7,10-Tetra(4-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 99 
N N
N N
O
N
O
H
O
N
O
H
O
N
O
H
O
N
O
H
O2N
O2N NO2
NO2
Cu
Cl
+Cl-
 
Using  general  procedure  A,  99  was  synthesised  from  1,4,7,10-tetra(4-
nitrophenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 91 (0.1 g, 90 µmol), 
as green crystals (81 mg, 80%). mp 156-157 
oC; νmax (KBr)/cm
-1: 2448, 1734 (CO), 1508, 
1111, 853. m/z (FAB): 1102 [(M-Cl)
+, 
35Cl, 1.3%], 232 (22), 81 (100); UV(H2O): λmax - 
623 nm, εcoeff - 935 L cm
-1 mol
-1. 
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1,4,7,10-Tetra(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane [Cu(II)]Cl2 100 
Cl-
N
N N
N
OH
OH
HO
HO
Cu
Cl  
Using  general  procedure  A,  100  was  synthesised  from  1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.2 g, 0.57 mmol), as bright blue crystals (49.0 mg, 
18%) mp 234-236 
oC; νmax (KBr)/cm
-1: 3554, 3235, 1621, 1440, 1085, 1015; m/z (FAB): 
411.2036  [(M-2Cl)
+,  C16H36N4O4Cu  requires  411.2033],  349  (6%),  247  (5),  90  (5); 
UV(H2O): λmax – 602 nm, εcoeff – 371 L cm
-1 mol
-1. 
1,4,7,10-Tetrachloroacetyl-1,4,7,10-tetraazacyclododecane 101 
N
N N
N
Cl
Cl
Cl
Cl
O
O O
O
 
Using  general  procedure  D,  101  was  synthesised  from  1,4,7,10-tetraazacyclododecane 
(0.50 g, 2.9 mmol) and chloroacetyl chloride (1.39 mL, 17 mmol), as a beige solid (0.11 g, 
10%). mp 72-74 
oC; νmax (KBr)/cm
-1: 3450, 1786, 1653 (CO), 1423, 1131, 791. 
1H NMR 
(400 MHz, CDCl3): 3.74 (8H, s, 4 x CH2), 4.26 (16H, s, 8 x CH2N); 
13C NMR (100 MHz, 
CDCl3):  39.7  (CH2),  52.5  (CH2),  170.5  (C);  m/z  (FAB):  477.0612  (MH
+, 
35Cl, 
C16H25N4O4Cl6 requires 477.0630), 441 (22), 401 (7), 281 (12), 256 (8), 207 (11), 179 
(66), 148 (15), 75 (100). 
1,4,7,10-Tetrabromoacetyl-1,4,7,10-tetraazacyclododecane 102 
N
N N
N
Br
Br
Br
Br
O
O O
O
 
Using  general  procedure  D,  102  was  synthesised  from  1,4,7,10-tetraazacyclododecane 
(0.50 g, 2.9 mmol) and bromoacetyl bromide (1.51 mL, 17 mmol), as a brown oil (0.18 g, Jennifer M. Wilson, 2007     Chapter 9, 123 
11%). νmax (KBr)/cm
-1: 3444, 2957 (CH), 1732, 1645 (CO), 1174; 
1H NMR (400 MHz, 
CDCl3): 3.64 (8H, s, 4 x CH2), 3.88 (16H, s, 8 x CH2N). 
13C NMR (100 MHz, CDCl3): 
25.7 (CH2), 53.5 (CH2), 171.3 (C); m/z (FAB): 652.8601 (MH
+, C16H25
79Br4N4O4 requires 
652.8609), 577 (20%), 329 (15), 219 (20), 165 (28), 71 (47). 
1,4-Bis(2-o-nitrophenylaminocarbonyloxyethyl)piperazine 103 
N N
O
N
O
H O
N
O
H
O2N NO2
 
 
Using general procedure C, 103 was synthesised from 1,4-bis(2-hydroxyethyl)piperazine 
(0.2 g, 1.15 mmol) and 2-nitrophenyl isocyanate (0.57 g, 3.45 mmol), as white crystals 
(0.36 g, 68%). mp 134-136 
oC; νmax (KBr)/cm
-1: 3072 (NH), 2826 (CH), 1742 (CO), 1236, 
785; 
1H NMR (400 MHz, D6-DMSO): 2.50 (8H, s, 4 x CH2N), 2.55 (4H, t, J 5.5 Hz, 2 x 
CH2N), 4.17 (4H, t, J 5.5 Hz, 2 x CH2O), 7.30-7.34 (2H, m, 2 x ArH), 7.62-7.71 (4H, m, 4 
x ArH), 7.95 (2H, dd, J 8.2, 1.4 Hz, 2 x ArH), 9.91 (2H, bs, 2 x NH); 
13C NMR (100 MHz, 
D6-DMSO): 52.8 (CH2), 56.3 (CH2), 62.3 (CH2), 124.3 (CH), 124.5 (CH), 125.2 (CH), 
132.0 (C), 134.1 (CH), 141.5 (C), 153.5 (C); m/z (FAB): 503.1886 (MH
+, C22H27N6O8 
requires 503.1890), 238 (9%), 170 (71), 87 (100).  
1,4-Bis(2-m-nitrophenylaminocarbonyloxyethyl)piperazine 104 
N N
O
N
O
H O
N
O
H
O2N NO2 
 
Using general procedure C, 104 was synthesised from 1,4-bis(2-hydroxyethyl)piperazine 
(0.20 g, 1.15 mmol) and 3-nitrophenyl isocyanate (0.57 g, 3.45 mmol), as a yellow solid 
(0.30 g, 55%). mp 152-154 
oC; νmax (KBr)/cm
-1: 3385 (NH), 2821 (CH), 1742 (CO), 1277, 
779; 
1H NMR (400 MHz, D6-DMSO): 2.47 (8H, s, 4 x CH2N), 2.59 (4H, t, J 5.4 Hz, 2 x 
CH2N), 4.23 (4H, t, J 5.4 Hz, 2 x CH2O), 7.58 (2H, t, J 8.2 Hz, 2 x ArH), 7.80-7.88 (4H, 
m, 4 x ArH), 8.47 (2H, s, 2 x ArH), 10.26 (2H, bs, 2 x NH); 
13C NMR (100 MHz, D6-
DMSO): 52.8 (CH2), 56.4 (CH2), 61.7 (CH2), 112.0 (CH), 116.9 (CH), 124.1 (CH), 130.2 
(CH), 140.5 (C), 148.1 (C), 153.5 (C); m/z (FAB): 503.1891 (MH
+, C22H27N6O8 requires 
503.1890), 238 (14%), 170 (78), 87 (100). Jennifer M. Wilson, 2007     Chapter 9, 124 
1,4-Bis(2-p-nitrophenylaminocarbonyloxyethyl)piperazine 105
137 
N N
O
N
O
H O
N
O
H
O2N NO2 
 
Using general procedure C, 105 was synthesised from 1,4-bis(2-hydroxyethyl)piperazine 
(0.20 g, 1.15 mmol) and 4-nitrophenyl isocyanate (0.57 g, 3.45 mmol), as a yellow solid 
(0.49 g, 90%). mp 212-214 
oC (lit. m.p. 215-217
  oC); 
1H NMR (400 MHz, D6-DMSO): 
2.33-2.37 (8H, m, 4 x CH2N), 3.46 (4H, t, J 5.2 Hz, 2 x CH2N), 4.37 (4H, t, J 5.2 Hz, 2 x 
CH2O), 7.73 (4H, d, J 9.4 Hz, 4 x ArH), 8.22 (4H, d, J 9.4 Hz, 4 x ArH), 9.74 (2H, bs, 2 x 
NH); m/z (FAB): 503 (MH
+, 20%), 238 (11), 170 (75), 87 (100). 
1,4-Bis(2-p-methoxyphenylaminocarbonyloxyethyl)piperazine 106 
N N
O
N
O
H O
N
O
H
MeO OMe 
 
Using general procedure C, 106 was synthesised from 1,4-bis(2-hydroxyethyl)piperazine 
(0.20 g, 1.15 mmol) and 4-methoxyphenyl isocyanate (0.44 mL, 3.45 mmol) as a white 
solid (0.51 g, 99%). mp 155-157 
oC; νmax (KBr)/cm
-1: 3323 (NH), 2812 (CH), 1690 (CO), 
1219, 826; 
1H NMR (400 MHz, D6-DMSO): 2.44 (8H, bs, 4 x CH2N), 2.55 (4H, t, J 5.6 
Hz, 2 x CH2N), 3.69 (6H, s, 2 x OCH3), 4.15 (4H, t, J 5.6 Hz, 2 x CH2O), 6.85 (4H, d, J 9.0 
Hz, 4 x ArH), 7.35 (4H, d, J 9.0 Hz, 4 x ArH), 9.48 (2H, bs, 2 x NH); 
13C NMR (100 MHz, 
D6-DMSO): 52.9 (CH2), 55.1 (CH3), 56.6 (CH2), 61.1 (CH2), 113.9 (CH), 119.8 (CH), 
132.2  (C),  132.9  (C),  153.6  (C);  m/z  (FAB):  473.2398  (MH
+,  C24H33N4O6  requires 
473.2400), 238 (11%), 170 (68), 87 (100). 
1,2-Tetra(2-hydroxyethyl)ethylenediamine 108
212 
N
N
HO
HO
OH
OH
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Ethylenediamine  (0.56  mL,  8.32  mmol)  and  water  (50  mL)  were  added  to  a  round-
bottomed flask fitted with an dropping funnel and a cooling finger. Ethylene oxide (9.11 
mL,  0.17  mol)  and  water  (20  mL)  were  added  to  the  reaction  mixture  dropwise.  The 
reaction stirred for two hours with the temperature kept under 5 
oC. The water and excess 
ethylene oxide were removed by rotary evaporator, yielding a colourless oil (1.43 g, 73%). 
1H NMR (CDCl3, 400 MHz): 2.64 (8H, t, J 4.7 Hz, 4 x CH2N), 2.68 (4H, s, 2 x CH2N), 
3.68 (8H, t, J 4.7 Hz, 4 x CH2N), 3.76 (4H, s, 4 x OH); m/z (FAB): 237 (MH
+, 100%), 177 
(5), 155 (32), 133 (40), 119 (22), 90 (8). 
9.3 Experimental to Chapter 6 
9.3.1 General Procedures (A-F) 
General  procedure  A  –  Synthesis  of  macrocycles  (amide  bond  formation):  A  stirred 
solution of triethylamine (2 eq) and dichloromethane (100 mL) was prepared. Diamine (1 
eq) in dichloromethane (50 mL) and thiodiglycolic acid chloride (1 eq) in dichloromethane 
(50  mL)  were  added  dropwise  using  syringe  pumps  over  a  period  of  5  h.  The  beige 
precipitate was filtered off, washed with dichloromethane (100 mL) and recrystallised from 
methanol. 
General  procedure  B  –  Tosylation  of  diols:  A  stirred  solution  of  toluene-4-sulfonyl 
chloride (2 eq) and dry pyridine (10 mL) was prepared in an ice bath at 0 
oC. Diol (1 eq) 
and dry pyridine (25 mL) were added dropwise. The reaction mixture was stirred for 1 h at 
0 
oC then allowed to return to RT and stirred for 3 h. The reaction mixture was poured onto 
distilled water (150 mL). The white precipitate was filtered off and yielded white crystals 
from hot ethanol. 
General procedure C – Tosylation of diamines: A solution of diamine (1 eq), sodium 
hydroxide (2.1 eq) and distilled water (100 mL) was prepared. A solution of toluene-4-
sulfonyl chloride (2.1 eq) and diethyl ether (100 mL) was added. The reaction mixture was 
stirred at room temperature for 24 h. The layers were separated and the aqueous layer was 
washed  with  chloroform  (2  x  75  mL).  The  organic  layers  were  combined,  dried  and 
concentrated  yielding  a  brown  viscous  oil  which  was  purified  using  column 
chromatography (eluant: dichloromethane/methanol 95/5). Jennifer M. Wilson, 2007     Chapter 9, 126 
General  prodecure  D  –  Synthesis  of  tosyl-protected  macrocycles  (phase  transfer 
cyclisation  conditions):  A  mixture  of  toluene  (200  mL),  tetrabutylammonium  bromide 
(0.25 eq) and 2.5% lithium hydroxide solution solution (50 mL) was heated under reflux. 
Tosyl-protected diamine (1 eq) and tosyl-protected diol (1 eq) and toluene (400 mL) were 
added in small portions. The reaction mixture was heated under reflux overnight. After 
cooling, the organic layer was separated and concentrated and the white solid was filtered 
and recrystallised from methanol. 
General  procedure  E  –  Detosylation  of  macrocycles:  A  solution  of  tosyl-protected 
macrocycle (1 eq), phenol (10 eq) and HBr-AcOH 45% (5 mL per 100 mg) was prepared 
and stirred at 80 
oC for 3 d. An air condenser was placed on top of the water condenser to 
ensure safe passage of the evolved HBr to the top of the fumehood. The reaction mixture 
was cooled and concentrated. The dark brown residue was azeotroped using toluene (4 x 
15  mL)  to  remove  all  traces  of  acetic  acid.  The  dark  brown  residue  was  dissolved  in 
dichloromethane  (30  mL)  and  distilled  water  (30  mL)  was  added.  The  layers  were 
separated  and  the  aqueous  layer  was  washed  with  dichloromethane  (4  x  15  mL).  The 
aqueous layer was concentrated. The resulting orange residue was dissolved in distilled 
water (5 mL) and sodium hydroxide (10 eq) was added. The flask was topped up with 
toluene and the resulting mixture was azeotroped using Dean-Stark apparatus until all the 
water  had  been  removed.  The  toluene  was  decanted  off  and  concentrated.  The  crude 
product  was  purified  using  alumina  column  chromatography  (eluant: 
dichloromethane/methanol 95/5) yielding a transparent oil. 
General  procedure  F  –  Hydroxyethylation  of  macrocycles:  A  stirred  solution  of 
macrocycle (1 eq) and ethanol (5 mL) was prepared and cooled to 0 
oC using an ice bath. 
Ethylene oxide (5 eq per NH) was added dropwise using a cooling finger and addition 
funnel. The reaction mixture was sealed, allowed to return to room temperature and stirred 
overnight. The reaction mixture was concentrated. The crude product was purified using 
alumina column chromatography (eluant: dichloromethane/methanol 95/5). 
9.3.2 Experimental Details 
Thiodiglycolic acid chloride 110 
Cl
S
Cl
O O
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A mixture of thiodiglycolic acid (15.0 g, 0.1 mol) and thionyl chloride (150 mL, 2.1 mol), 
was stirred overnight at RT. Excess thionyl chloride was removed under  vacuum. The 
cream coloured solid was used in the next reaction without purification assuming 100% 
conversion. 
1-Thia-4,7-diazacyclononane-3,7-dione 111 
HN NH
S O O
 
Using general procedure A, 111 was synthesised from ethylene diamine (1.78 mL, 26.7 
mmol) and thiodiglycolic acid chloride 110 (5.0 g, 26.7 mmol), as a beige solid (4.65 g, 
100%). mp 162-164 
oC; νmax (KBr)/cm
-1: 2930 (NH), 1661 (CO), 1249, 794; 
1H NMR (400 
MHz, D2O): 3.08 (4H, s, 2 x CH2N), 3.19 (4H, s, CH2S); 
13C NMR (100 MHz, D2O): 36.6 
(CH2), 37.3 (CH2), 177.8 (C).  
1-Thia-4,8-diazacyclodecane-3,9-dione 112
160c 
HN NH
S O O
 
Using general procedure A, 112 was synthesised from 1,3-diaminopropane (2.23 mL, 26.7 
mmol) and thiodiglycolic acid chloride 110 (5.0 g, 26.7 mmol), as a beige solid (5.03 g, 
100%). mp 188-189 
oC (lit. > 200 
oC); νmax (KBr)/cm
-1: 2365 (NH), 1700 (CO), 1206, 814; 
1H NMR (400 MHz, D2O): 1.87-1.95 (2H, m, CH2), 2.95 (4H, t, J 7.8 Hz, 2 x CH2N), 3.19 
(4H, s, CH2S); 
13C NMR (100 MHz, D2O): 24.9 (CH2), 36.6 (CH2), 37.3 (CH2), 177.8 (C). 
1-Thia-4,7,10-triazacyclododecane-3,11-dione 113 
HN S
NH HN
O
O
 
Using general procedure A, 113 was synthesised from diethylene triamine (1.73 mL, 16.0 
mmol) and thiodiglycolic acid chloride 110 (3.0 g, 16.0 mmol), as white crystals (3.49 g, 
100%). mp 49-51 
oC; νmax (KBr)/cm
-1: 2922 (NH), 2121, 1601 (CO), 1218, 872; 
1H NMR 
(400 MHz, D2O): 2.76 (4H, t, J 6.2 Hz, 2 x CH2N), 2.96 (4H, t, J 6.2 Hz, 2 x CH2N), 3.10 Jennifer M. Wilson, 2007     Chapter 9, 128 
(4H, s, 2 x CH2S); 
13C NMR (100 MHz, D2O): 37.3 (CH2), 38.8 (CH2), 45.1 (CH2), 177.7 
(C). 
Bis(2-aminoethyl)sulfide 116
164 
H2N
S
NH2 
A stirred solution of sodium (0.60 g, 25.9 mmol) and ethanol (100 mL) was prepared. 
Cysteamine hydrochloride (1.0 g, 8.62 mmol) was added and the reaction mixture was 
heated under reflux for 30 min. 2-Chloroethylamine hydrochloride (0.98 g, 8.62 mmol) 
was added. The reaction mixture was heated under reflux for a further 2 h. The reaction 
mixture was cooled and the precipitated sodium chloride was filtered off and the filtrate 
was concentrated yielding the product as a pale yellow oil (0.92 g, 89%). 
1H NMR (400 
MHz, CDCl3): 1.21 (4H, bs, 2 x NH2), 2.55 (4H, t, J 6.5 Hz, 2 x CH2S), 2.82 (4H, t, J 6.5 
Hz, CH2N); m/z (EI): 121 (MH
+, 100%), 104 (60), 71 (33). 
1,7-Dithia-4,10-diazacyclododecane-3,11-dione 117 
HN S
NH S
O
O
 
Using general procedure A, 117 was synthesised from bis(2-aminoethyl)sulfide (1.29 g, 
10.7 mmol) and thiodiglycolic acid chloride 110 (2.0 g, 10.7 mmol), as white crystals (2.37 
g, 94%). mp 131-133 
oC; νmax (KBr)/cm
-1: 3567 (NH), 1595 (CO), 1388 (CH); 
1H NMR 
(400 MHz, D2O): 2.65 (4H, t, J 6.6 Hz, 2 x CH2N), 2.99-3.02 (8H, m, 4 x CH2S); 
13C 
NMR (100 MHz, D2O): 27.8 (CH2), 37.3 (CH2), 38.1 (CH2), 177.6 (CO). 
1,2-Ethanediol ditosylate 120
213 
TsO
OTs 
Using general procedure B, 120 was synthesised from 1,2-ethanediol (3.14 mL, 56 mmol), 
as white crystals (19.16 g, 92%). mp 122-124 
oC (lit. 123-125 
oC); 
1H NMR (400 MHz, 
CDCl3): 2.45 (6H, s, 2 x CH3), 4.18 (4H, s, 2 x CH2), 7.33 (4H, d, J 8.4 Hz, 4 x ArH), 7.72 
(4H, d, J 8.4 Hz, 4 x ArH); m/z (FAB): 371 (MH
+, 57%). Jennifer M. Wilson, 2007     Chapter 9, 129 
1,3-Propanediol ditosylate 121
214 
OTs TsO  
Using  general  procedure  B,  121 was  synthesised  from  1,3-propanediol  (4.75  mL,  65.7 
mmol), as white crystals (19.3 g, 83%). mp 90-92 
oC (lit. 91-93 
oC); 
1H NMR (400 MHz, 
CDCl3): 2.01 (2H, quin, J 6.0 Hz, CH2), 2.47 (6H, s, 2 x CH3), 4.07 (4H, t, J 6.0 Hz, 2 x 
CH2N), 7.36 (4H, d, J 8.0 Hz, 4 x ArH), 7.76 (4H, d, J 8.0 Hz, 4 x ArH); m/z (FAB): 385 
(MH
+, 100%). 
N,N’-Bis(toluene-4-sulfonyl)-bis(2-aminoethylsulfide) 122
165 
S
NHTs TsHN
 
Using general procedure C, 120 was synthesised from bis(2-aminoethylsulfide) 116 (4.0 g, 
33 mmol), as a brown viscous oil (12.7 g, 89%). 
1H NMR (400 MHz, CDCl3): 2.45 (6H, s, 
2 x CH3), 2.57 (4H, t, J 6.4 Hz, 2 x CH2S), 3.09 (4H, q, J 6.4 Hz, 2 x CH2N), 5.28 (2H, t, J 
6.4 Hz, 2 x NH), 7.37 (4H, d, J 6.2 Hz, 4 x ArH), 7.76 (4H, d, J 6.2 Hz, 4 x ArH); m/z 
(FAB): 429 (MH
+, 100%), 386 (5), 258 (4), 199 (35), 156 (25), 140 (15), 93 (12). 
1,8-Diamino-3,6-dithiaoctane 123
166 
S
S
NH2
H2N
 
 
A stirred solution of sodium (4.14 g, 0.18 mol) and tert-butanol (100 mL) was prepared 
and heated under reflux. Cysteamine hydrochloride (10.00 g, 88.0 mmol) was added and 
the reaction mixture was stirred for 30 min. 1,2-Dichloroethane (3.47 mL, 44.0 mmol) and 
tert-butanol (25 mL) were added dropwise and the reaction mixture was stirred for 3 h. 
After  cooling,  the  precipitated  NaCl was  filtered off  and  the filtrate  was concentrated. 
Kugelrohr distillation isolated the pure product as a pale yellow oil that solidified upon 
standing (7.31 g, 92%). 
1H NMR (400 MHz, CDCl3): 1.33 (4H, bs, 4 x NH), 2.65 (4H, t, J 
6.5 Hz, 2 x CH2N), 2.74 (4H, s, 2 x CH2S), 2.87 (4H, t, J 6.5 Hz, 2 x CH2S). m/z (CI): 181 
(MH
+, 100%), 164 (9), 136 (33), 104 (70), 76 (7). 
1,8-Bis(toluene-4-sulfonyl)-1-8-diamino-3,6-dithiaoctane 124 
S
S
NHTs
TsHN
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Using general procedure C, 124 was synthesised from 1,8-diamino-3,6-dithiaoctane 123 
(5.0 g, 27.7 mmol), as a brown solid (13.0 g, 96%). mp 87-88 
oC; νmax (KBr)/cm
-1: 3239 
(NH), 2922 (CH), 1596, 1424; 
1H NMR (400 MHz, CDCl3): 2.41 (6H, s, 2 x  CH3), 2.66-
2.99 (8H, m, 2 x CH2S, 2 x CH2S), 3.14 (4H, q, J 6.2 Hz, 2 x CH2N), 5.28 (2H, t, J 6.2 Hz, 
2 x NH), 7.34 (4H, d, J 8.1 Hz, 4 x ArH), 7.78 (4H, d, J 8.1 Hz, 4 x ArH); 
13C NMR (100 
MHz, CDCl3): 21.6 (CH3), 31.6 (CH2), 32.1 (CH2), 42.5 (CH2), 127.1 (CH), 129.8 (CH), 
126.8 (C), 143.7 (C); m/z (FAB): 489.1006 (MH
+, C20H29N2O4S4 requires 489.1010), 258 
(100%), 199 (40). 
4,7-Bis(toluene-4-sulfonyl)-1-thia-4,7-diazacyclononane 125
165 
TsN NTs
S
 
Using general procedure D, 125 was synthesised from N,N’-bis(toluene-4-sulfonyl)-bis(2-
aminoethyl)sulfide (2.0 g, 4.67 mmol) 122 and 1,3-ethanediol ditosylate 120 (1.8 g, 4.67 
mmol), as a white solid (1.6 g, 74%). mp 270-272 
oC (lit. 276-279 
oC); 
1H NMR (400 
MHz, CDCl3): 2.43 (6H, s, 2 x CH3), 3.13 (4H, bs, CH2N), 3.37 (4H, s, CH2N), 3.51 (4H, 
bs CH2S), 7.53 (4H, d, J 8.4 Hz, 4 x ArH), 7.73 (4H, d, J 8.4 Hz, 4 x ArH); m/z (FAB): 455 
(MH
+, 100%), 395 (3), 299 (35), 199 (4), 155 (32), 137 (32), 93 (35), 90 (34). 
4,8-Bis(toluene-4-sulfonyl)-1-thia-4,8-diazacyclodecane 126
160a 
TsN NTs
S
 
Using general procedure D, 126 was synthesised from N,N’-bis(toluene-4-sulfonyl)-bis(2-
aminoethylsulfide) 122 (2.0 g, 4.67 mmol) and 1,3-propanediol ditosylate 121 (1.8 g, 4.67 
mmol), as a white solid (2.2 g, 100%). mp 204-205 
oC (lit. 285-287 
oC – large difference 
could be due to different polymorph); 
1H NMR (400 MHz, CDCl3): 2.36-2.42 (2H, m, 
CH2), 2.44 (6H, s, 2 x CH3), 3.08 (4H, t, J 4.8 Hz, 2 x CH2N), 3.14 (4H, t, J 6.0 Hz, 2 x 
CH2N), 3.33 (4H, t, J 4.8 Hz, 2 x CH2S), 7.34 (4H, d, J 8.0 Hz, 4 x ArH), 7.67 (4H, d, J 8.0 
Hz, 4 x ArH); m/z (FAB): 469 (MH
+, 100%), 313 (55), 242 (100), 199 (14), 156 (20), 143 
(14), 93 (27). 
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4,7,10-Tris(toluene-4-sulfonyl)-1-thia-4,7,10-triazacyclododecane 127 
TsN
TsN NTs
S
 
 
Using general procedure D, 127 was synthesised from N,N’-bis(toluene-4-sulfonyl)-bis(2-
aminoethyl)sulfide  122  (2.0  g,  4.67  mmol)  and  N,O,O’-tris(toluene-4-
sulfonyl)diethanolamine 80 (2.7 g, 4.67 mmol), as white crystals (2.5 g, 82%). mp 184-186 
oC; νmax (KBr)/cm
-1: 3433, 2924 (CH2), 1334, 1150; 
1H NMR (400 NMR, CDCl3): 2.45 
(9H, s, 3 x CH3), 3.00 (4H, t, J 5.2 Hz, 2 x CH2S), 3.43 (12H, bs, 6 x CH2N), 7.34 (6H, d, J 
8.0 Hz, 4 x ArH), 7.68 (6H, d, J 8.0 Hz, 6 x ArH); 
13C NMR (100 MHz, CDCl3): 21.6 
(CH3), 31.7 (CH2), 50.9 (CH2), 52.2 (CH2), 127.6 (CH), 129.9 (CH), 134.2 (C), 144.1 (C); 
m/z (FAB): 652.1647 (MH
+, C29H38N3O6S4 requires 652.1643), 592 (20%), 496 (40), 253 
(73), 156 (40), 93.0 (85). 
7,10-Bis(toluene-4-sulfonyl)-1,4-dithia,7,10-diaazacyclododecane 128 
S S
NTs TsN
 
Using  general  procedure  D,  128  was  synthesised  from  1,8-bis(toluene-4-sulfonyl)-1,8-
diamino-3,6-dithiaoctane 124 (2.0 g, 4.09 mmol) and 1,2-ethanediol ditosylate 120 (1.52 g, 
4.09 mmol), as white crystals (0.70 g, 33%). mp 176-178 
oC; νmax (KBr)/cm
-1: 3088, 2893 
(CH), 1536, 1333, 1166; 
1H NMR (400 MHz, CDCl3): 2.38 (6H, s, 2 x CH3), 2.78 (4H, s, 2 
x CH2S), 2.83 (4H, t, J 6.2 Hz, 2 x CH2S), 3.33 (4H, t, J 6.2 Hz, 2 x CH2N), 3.42 (4H, s, 2 
x CH2N), 7.24 (4H, d, J 8.0 Hz, 4 x ArH), 7.63 (4H, d, J 8.0 Hz, 4 x ArH); 
13C NMR (100 
MHz, CDCl3): 21.6 (CH3), 31.8 (CH2),  43.9 (CH2),  50.7 (CH2), 52.2 (CH2), 127.6 (CH), 
129.9 (CH), 134.4 (C), 143.9 (C); m/z (FAB): 515.1159 (MH
+,  C22H31N2O4S4 requires 
515.1167), 487 (84%), 455 (100), 395 (28), 359 (28), 116 (37), 88 (94). 
7,11-Bis(toluene-4-sulfonyl)-1,4-dithia-7,11-diazacyclotridecane 129 
NTs TsN
S S
 Jennifer M. Wilson, 2007     Chapter 9, 132 
Using  general  procedure  D,  129  was  synthesised  from  1,8-bis(toluene-4-sulfonyl)-1,8-
diamino-3,6-dithiaoctane 124 (2.0 g, 4.09 mmol) and 1,3-propanediol ditosylate 121 (1.57 
g, 4.09 mmol), as a white solid (0.97 g, 45%). mp 52-54 
oC; νmax (KBr)/cm
-1: 3435, 2924 
(CH), 1597, 1339, 1157; 
1H NMR (400 MHz, CDCl3): 1.89-1.95 (2H, m, CH2), 2.38 (6H, 
s, 2 x CH3), 2.68 (4H, s, 2 x CH2S), 2.76-2.80 (4H, m, 2 x CH2S), 3.10-3.18 (8H, m, 4 x 
CH2N), 7.27 (4H, d, J 8.2 Hz, 4 x ArH), 7.61 (4H, d, J 8.2 Hz, 4 x ArH); 
13C NMR (100 
MHz, CDCl3): 19.7 (CH3), 26.6 (CH2), 28.5 (CH2), 29.3 (CH2), 46.5 (CH2),  47.5 (CH2), 
125.2 (CH), 128.0 (CH), 133.1 (C), 141.2 (C); m/z (FAB): 529.1326 (MH
+, C23H33N2O4S4 
requires 529.1323), 469 (44%), 409 (25), 373 (40), 214 (50), 156 (35), 93 (100). 
N-(Toluene-4-sulfonyl)-3-azapentane-1,5-dithiol 130
160a 
N
Ts
SH HS
 
 
A stirred solution of N,O,O’-tris(p-tolylsulfonyl)diethanolamine (5.85 g, 10.3 mmol) and 
anhydrous ethanol (40 mL) was prepared. Thiourea (1.72 g, 22.6 mmol) was added and the 
mixture  was  heated  under  reflux  conditions  overnight.  The  reaction  mixture  was 
concentrated and taken up in saturated sodium hydrogen cabronate solution (20 mL) and 
heated under reflux conditions for 3 h. After cooling, 6 N hydrochloric acid was added 
dropwise until the pH of the reaction mixture was 7. The aqueous solution was extracted 
with dichloromethane (3 x 50 cm
3). The organic layers were combined, dried (MgSO4) and 
concentrated. The crude product was purified using flash column chromatography (eluant: 
dichloromethane/methanol 99:1) yielding a transparent oil (1.98 g, 66%). 
1H NMR (400 
MHz, CDCl3): 1.36 (2H, t, J 8.5 Hz, 2 x SH), 2.37 (3H, s, CH3), 2.64-2.69 (4H, m, 2 x 
CH2S), 3.21 (4H, t, J 7.5 Hz, 2 x CH2N), 7.26 (2H, d, J 8.1 Hz, 2 x ArH), 7.63 (2H, d, J 8.1 
Hz, 2 x ArH); m/z (FAB): 292 (MH
+, 100%), 258 (95), 244 (47), 232 (22), 199 (13), 173 
(36), 156 (47), 140 (15), 104 (25), 93 (91).  
4,10-Bis(toluene-4-sulfonyl)-1,7-dithia-4,10-diaazacyclododecane 131 
NTs S
S TsN
 
Using general procedure D, 131 was synthesised from N,N’-bis(toluene-4-sulfonyl)-bis(2-
aminoethyl)sulfide 122 (3.41 g, 6.0 mmol) and N-(toluene-4-sulfonyl)-3-azapentane-1,5-
dithiol  130  (1.75g,  6.0  mmol),  as  white  crystals  (0.07  g,  3%).  mp  164-166 
oC;  νmax Jennifer M. Wilson, 2007     Chapter 9, 133 
(KBr)/cm
-1: 3417, 1667, 1327, 1077; 
1H NMR (400 MHz, CDCl3): 2.36 (6H, s, 2 x CH3), 
2.86 (8H, t, J 6.6 Hz, 4 x CH2S), 3.28 (8H, t, J 6.6 Hz, 4 x CH2N), 7.25 (8H, d, J 8.2 Hz, 8 
x ArH), 7.61 (8H, d, J 8.2 Hz, 8 x ArH); 
13C NMR (100 MHz, CDCl3): 21.6 (CH3), 31.5 
(CH2),  50.6 (CH2), 127.3 (CH), 129.9 (CH), 135.1 (C), 143.9 (C); m/z (FAB): 515.1178 
(MH
+, C22H31N2O4S4 requires 515.1167), 359 (13%), 258 (17), 199 (28), 155 (85), 137 
(58). 
1-Thia-4,8-diazacyclodecane 132
215 
NH HN
S
 
 
Using general procedure E, 132 was synthesised from 4,8-bis(toluene-4-sulfonyl)-1-thia-
4,8-diazacyclodenane 126 (0.5 g, 1.07 mmol), as a transparent oil (25.3 mg, 93%). 
1H 
NMR (400 NMR, CDCl3): 1.51-1.62 (2H, m, CH2), 2.59-2.81 (12H, m, 4 x CH2N, 2 x 
CH2S); m/z (CI): 161 (MH
+, 100%), 135 (22), 127 (18), 101 (17), 87 (10), 75 (5). 
1-Thia-4,7-diazacyclononane 133
162 
NH HN
S
 
 
Using general procedure E, 133 was synthesised from 4,7-bis(toluene-4-sulfonyl)-1-thia-
4,7-diazacyclononane 125 (0.5 g, 1.10 mmol), as a transparent oil (0.04 g, 31%). 
1H NMR 
(400 NMR, CDCl3): 1.96 (2H, bs, 2 x NH), 2.67-2.71 (8H, m, 2 x CH2N, 2 x CH2S), 2.87 
(4H, t, J 5.2 Hz 2 x CH2N); m/z (CI): 147 (MH
+, 100%), 145 (7), 113 (4), 85 (4), 69 (4). 
1-Thia-4,7,10-triazacyclododecane 134 
NH
NH HN
S
 
 
Using general procedure E, 134 was synthesised from 4,7,10-tris(toluene-4-sulfonyl)-1-
thia-4,7,10-triazacyclododecane 127 (0.5 g, 0.77 mmol), as a white solid (0.04 g, 32%). mp 
58-60 
oC;  νmax  (KBr)/cm
-1:  3405  (NH),  2923  (CH),  1576,  1457; 
1H  NMR  (400  NMR, 
CDCl3): 2.62-2.65 (4H, m, 2 x CH2), 2.68-2.71 (4H, m, 2 x CH2), 2.74-2.80 (8H, m, 4 x Jennifer M. Wilson, 2007     Chapter 9, 134 
CH2); 
13C NMR (100 MHz, CDCl3): 32.4 (CH2), 45.7 (CH2), 45.9 (CH2), 47.4 (CH2); m/z 
(FAB): 190.1376 (MH
+, C8H19N3S requires 190.1378), 113 (12%), 85 (50), 69 (72).  
1,4-Dithia-7,10-diazacyclododecane 135
159 
S S
NH HN
 
Using  general  procedure  E,  135  was  synthesised  from  7,10-bis(toluene-4-sulfonyl)-1,4-
thia-7,10-diazacyclododecane 128 (0.5 g, 0.97 mmol), as a yellow oil (0.025 g, 13%). 
1H 
NMR (400 NMR, CDCl3): 2.68-2.72 (4H, m, 2 x CH2S), 2.75 (4H, s, 2 x CH2S), 2.81 (4H, 
s, 2 x CH2N), 2.82-2.85 (4H, m, 2 x CH2N); m/z (CI): 207 (MH
+, 100%), 179 (2), 145 (2), 
113 (9), 103 (3), 85 (3), 69 (3).  
1,4-Dithia-7,11-diazacyclotridecane 136
159 
NH HN
S S
 
 
Using  general  procedure  E,  136  was  synthesised  from  7,11-bis(toluene-4-sulfonyl)-1,4-
thia-7,11-diazacyclotridecane 129 (0.5 g, 0.94 mmol), as a transparent oil (0.07 mg, 35%). 
1H NMR (400 NMR, CDCl3): 1.77 (2H, quin, J 5.4 Hz, CH2), 2.72-2.75 (4H, m, 2 x 
CH2S), 2.78-2.81 (8H, m, 2 x CH2S, 2 x CH2N), 2.83-2.86 (4H, m, 2 x CH2N), 3.77 (2H, 
bs, 2 x NH); m/z (CI): 221 (MH
+, 100%), 193 (2), 157 (2), 127 (9), 99 (4), 85 (6), 71 (5).  
4,7-Bis(2-hydroxyethyl)-1-thia-4,7-diazacyclononane 137
162 
N N
S
OH HO  
 
Using general procedure E, 137 was synthesised from 1-thia-4,7-diazacyclononane 133 
(40.0 mg, 0.27 mmol), as a transparent oil (24.2 mg, 39%). 
1H NMR (400 NMR, CDCl3): 
2.66-2.99 (8H, m, 2 x CH2S, 2 x CH2N), 2.71-2.74 (4H, m, 2 x CH2N), 2.78-2.81 (4H, m, 2 
x CH2N), 3.55 (4H, t, J 5.0 Hz, 2 x CH2O); m/z (CI): 235 (MH
+, 100%), 190 (1), 176 (2), 
135 (3), 90 (10), 76 (7).  Jennifer M. Wilson, 2007     Chapter 9, 135 
4,8-Bis(2-hydroxyethyl)-1-thia-4,8-diazacyclodecane 138 
N N
S
OH HO
 
Using general procedure E, 138 was synthesised from 1-thia-4,8-diazacyclodenane 132 
(83.1 mg, 0.52 mmo), as a transparent oil (17.5 mg, 14%). νmax (KBr)/cm
-1: 3381 (OH), 
2946, 1655, 1458, 1049; 
1H NMR (400 NMR, CDCl3): 1.56 (2H, quin, J 6.5 Hz, CH2), 
2.48-2.51 (8H, m, 2 x CH2S, 2 x CH2N), 2.63 (8H, m, 4x CH2N), 3.50 (4H, t, J 5.0 Hz, 2 x 
CH2O); 
13C NMR (100 MHz, CDCl3): 25.2 (CH2), 30.8 (CH2), 52.1 (CH2), 53.5 (CH2), 
55.8 (CH2), 59.2 (CH2); m/z (CI): 249 (MH
+, 7%), 243 (4), 216 (10), 90 (65).  
4,7,10-Tris(2-hydroxyethyl)-1-thia-4,7,10-triazacyclododecane 139 
N S
N N
OH
OH HO  
 
Using general procedure E, 139 was synthesised from 1-thia-4,7,10-triazacyclododecane 
134 (0.14 g, 0.74 mmol), as a transparent oil (0.14 g, 61%). νmax (KBr)/cm
-1: 3360 (OH), 
2812, 1654, 1452, 1070;  
1H NMR (400 NMR, CDCl3): 2.45 (4H, t, J 4.6 Hz, 2 x CH2S), 
2.54 (8H, bs, 4 x CH2N) 2.66 (10H, bs, 5 x CH2N), 3.56 (4H, t, J 5.0 Hz, 2 x CH2O); 
13C 
NMR (100 MHz, CDCl3): 28.5 (CH2), 50.9 (CH2), 51.8 (CH2), 54.2 (CH2), 56.8 (CH2), 
59.4 (CH2); m/z (CI): 322.2159 (MH
+, C14H32N3O3S requires 322.4922), 221 (5%), 154 
(10), 88 (15).  
7,10-Bis(2-hydroxyethyl)-1,4-dithia-7,10-diazacyclododecane 140 
S S
N N
OH HO  
 
Using general procedure E, 140 was synthesised from 1,4-dithia-7,10-diazacyclododecane 
135 (25.0 mg, 0.12 mmol), as a transparent oil (38.6 mg, 100%). νmax (KBr)/cm
-1: 3386 
(OH), 2809, 1451 (CH2), 1059; 
1H NMR (400 NMR, CDCl3): 2.49 (4H, t, J 4.8 Hz, 2 x 
CH2S), 2.60 (4H, s, 2 x CH2S) 2.67-2.73 (8H, m, 4 x CH2N), 2.86 (4H, s, 2 x CH2N), 3.56 
(4H, t, J 4.8 Hz, 2 x CH2O); 
13C NMR (100 MHz, CDCl3): 28.6 (CH2), 29.9 (CH2), 50.8 Jennifer M. Wilson, 2007     Chapter 9, 136 
(CH2), 54.2 (CH2), 56.4 (CH2), 59.5 (CH2); m/z (CI): 295 (MH
+, 100%), 201 (10), 172 
(35), 71 (10). 
7,11-Bis(2-hydroxyethyl)-1,4,-dithia-7,11-diazacyclotridecane 141 
N N
S S
HO OH 
Using general procedure E, 141 was synthesised from 1,4-dithia-7,11-diazacyclotridecane 
136 (70.0 mg, 0.32 mmol), as a transparent oil (27.5 mg, 28%). 
1H NMR (400 NMR, 
CDCl3): 1.65 (2H, quin, J 6.5 Hz, CH2), 2.50-2.56 (8H, m 4 x CH2S), 2.68 (8H, bs, 4 x 
CH2N), 2.76 (4H, bs, 2 x CH2N), 3.52 (4H, t, J 5.2 Hz, 2 x CH2O); 
13C NMR (100 MHz, 
CDCl3): 25.2 (CH2), 30.6 (CH2), 32.6 (CH2), 52.2 (CH2), 53.9 (CH2), 56.3 (CH2), 58.8 
(CH2); m/z (CI): 309.1668 (MH
+, C13H29N2O2S2 requires 309.1670), 215 (25%). 
9.4 Experimental to Chapter 7 
1,1-Ethylenedi-2-imidazoline 72
121 
N N
N N  
N,N’-Dimethylformamide  dimethyl  acetal  (10.9  mL,  82  mmol)  was  added  to 
triethylenetetraamine (6.1 mL, 41 mmol) and the mixture was heated under reflux for 1 h. 
Excess solvent was removed under vacuum and the white/yellow residue was recrystallised 
from tetrahydrofuran to give the desired product as white crystals (3.15 g, 46%). m.p. 107-
108 
oC (lit. 107-109 
oC); 
1H NMR (CDCl3, 400 MHz): 3.16 (4H, t, J 9.6 Hz, 2 x CH2N), 
3.20 (4H, s, 2 x CH2), 3.78 (4H, t, J 9.6 Hz, 2 x CH2N) 6.74 (2H, s, 2 x CH); m/z (EI): 166 
(M
+, 55%), 165 (16), 124 (7), 84 (34), 83 (100), 56 (100). 
N,N’-Bis(toluene-4-sulfonyl)-ethylenediamine-N,N’-diacetic acid-dimethyl ester 146
170 
TsN NTs
OMe
O
MeO
O  Jennifer M. Wilson, 2007     Chapter 9, 137 
Sodium (0.25 g, 10.9 mmol) was dissolved in absolute methanol (14 mL) in a 3-necked 
flask.  N,N’-Bis(toluene-4-sulfonyl)-ethylenediamine  (2.0  g,  5.4  mmol)  was  added.  The 
mixture  was  stirred  and  heated  under  reflux  for  2  h.  The  methanol  was  removed  by 
distillation and the residue was dried under vacuum. The powder was added portionwise 
over 30 min to a stirred ice-cooled flask of methyl bromoacetate (4.1 mL, 43.4 mmol). 
After  stirring  for  30  min  at  RT,  the  excess  methyl  bromoacetate  was  removed  under 
vacuum. A mixture of chloroform (10 mL) and water (10 mL) was added to the residue. 
The chloroform layer was washed with water (2 x 10 mL) before drying over calcium 
chloride. The solution was filtered and concentrated. The product was recrystallised from 
methanol (1.05 g, 40%). mp 123-125 
oC (lit. 124-126 
oC); 
1H NMR (400 MHz, CDCl3): 
2.36 (6H, s, 2 x CH3), 3.41 (4H, s, 2 x CH2), 3.55 (6H, s, 2 x OCH3), 4.00 (4H, s, 2 x CH2), 
7.24 (8H, d, J 8.0 Hz, 4 x ArH), 7.63 (8H, d, J 8.0 Hz, 4 x ArH); m/z (CI): 513 (MH
+, 
98%), 453 (35), 357 (21), 270 (13), 256 (35), 156 (23), 93 (30). 
N, N’-Bis(toluene-4-sulfonyl)-ethylenediamine-N,N’-diacetic acid 147
170 
TsN NTs
OH
O
HO
O  
A  mixture  of  N,N’-bis(toluene-4-sulfonyl)-ethylenediamine-N,N’-diacetic  acid-dimethyl 
ester (0.64 g, 1.24 mmol), acetic acid (5.2 mL) and conc. hydrochloric acid (1.3 mL) was 
stirred and heated under reflux for 12 h. The resulting white crystals were filtered and 
rinsed with acetic acid (2 x 3 mL) before drying under vacuum (0.80 g, 70%). mp 240-242 
oC (lit.
 228-229 
oC); 
1H NMR (400 MHz, DMSO): 2.41 (6H, s, 2 x CH3), 3.27 (4H, s, 2 x 
CH2), 3.98 (4H, s, 2 x CH2), 7.41 (8H, d, J 8.0 Hz, 4 x ArH), 7.66 (8H, d, J 8.0 Hz, 4 x 
ArH), 12.77 (2H, s, 2 x OH); m/z (FAB): 485 (MH
+, 17%), 439 (5), 285 (6), 238 (24), 170 
(21), 87 (100). 
N,N’-Bis(toluene-4-sulfonyl)-N,N’-ethanediyl-bis-glycyl chloride 143
170 
TsN NTs
Cl
O
Cl
O  
N,N’-Bis(toluene-4-sulfonyl)-ethylenediamine-N,N’-diacetic acid (0.51 g, 1.06 mmol) and 
thionyl chloride (5.4 mL, 74.2 mmol) were stirred and heated using a water bath at 80 
oC 
for 5 h. The reaction mixture was concentrated and the crude product was recrystallised 
from benzene (special permission was given to use benzene) yielding fluffy white crystals Jennifer M. Wilson, 2007     Chapter 9, 138 
(0.55 g, 86%). mp 127-129 
oC (lit. 223-224 
oC); 
1H NMR (D6-DMSO, 400 MHz): 2.40 
(6H, s, 2 x CH3), 3.25 (4H, s, 2 x CH2), 3.98 (4H, s, 2 x CH2), 7.39 (4H, d, J 8.1 Hz, 4 x 
ArH), 7.65 (4H, d, J 8.1 Hz, 4 x ArH). 
4,7-Bis(toluene-4-sulfonyl)-2-methyl-1,4,7,10-tetraazacylcododecane -2,9-dione 148 
NH TsN
NH TsN
O
O  
A stirred solution of triethylamine (0.86 mL, 6.17 mmol) and dichloromethane (140 mL) 
was  prepared.  Over  a  period  of  6  h,  N,N’-bis(toluene-4-sulfonyl)-N,N’-ethanediyl-bis-
glycyl chloride (1.61 g, 3.1 mmol) in dichloromethane (37.5 mL) and 1,2-diaminopropane 
(0.26 mL, 3.09 mmol) in dichloromethane (37.5 mL) were added using 2 syringe pumps. 
The reaction mixture was then stirred for an additional 2 h. The white precipitate was 
filtered off (0.78 g, 48%). mp ≥360 
oC; νmax (KBr)/cm
-1: 3212 (NH), 3090 (CH), 1644 
(CO), 1350, 1162, 822, 550. 
1H NMR (D6-DMSO, 400 MHz): 0.98 (3H, d, J 6.8 Hz, CH3), 
2.42 (6H, s, 2 x CH3), 2.66-2.77 (4H, m, 2 x CH2N), 3.21-3.47 (4H, m, 2 x CH2), 3.97-4.02 
(3H, m, CH, CH2), 7.47 (4H, d, J 7.6 Hz, 4 x ArH), 7.65 (4H, d, J 7.6 Hz, 4 x ArH); 
13C 
NMR (D6-DMSO, 100 MHz): 16.5 (CH3), 19.7 (CH3), 42.9 (CH2), 43.4 (CH), 45.9 (CH2), 
51.9 (CH2), 52.1 (CH2), 125.8 (CH), 128.6 (CH), 133.3 (C), 142.3 (C), 164.7 (C), 165.3 
(C). m/z (FAB): 523.1679 (MH
+, C23H29N4O6S2 requires 523.1685), 367 (14%), 239 (22) 
170 (45), 87 (100). 
4,7-Bis(toluene-4-sulfonyl)-2-methyl-1,4,7,10-tetraazacyclododecane 149 
NH TsN
NH TsN
 
A stirred solution of 4,7-bis(toluene-4-sulfonyl)-2-methyl-1,4,7,10-tetraazacyclododecane -
2,9-dione (0.2 g, 0.38 mmol) and tetrahydrofuran (10 mL) was prepared and cooled using 
an ice bath. Borane in tetrahydrofuran (3.64 mL, 38.0 mmol) was added dropwise. The 
reaction mixture was heated under reflux for 3 d. Methanol was added dropwise to quench 
the reaction. The reaction mixture was concentrated. The minimum volume of ethanol was 
added to dissolve the brown residue. 6M Hydrochloric acid (2 mL) was added and the 
reaction mixture was heated under reflux overnight. The mixture was cooled using an ice Jennifer M. Wilson, 2007     Chapter 9, 139 
bath and the resulting white precipitate was filtered off and dried (0.11 g, 59%). mp 216-
218 
oC; νmax (KBr)/cm
-1: 3612 (NH), 2974 (CH), 2369, 1596 (CO), 1332, 1155; 
1H NMR 
(D6-DMSO, 400 MHz): 1.57 (3H, bs, CH3), 2.44 (6H, s, 2 x CH3), 2.88-2.91 (2H, m, CH2), 
2.97-3.01 (2H, m, CH2), 3.19-3.38 (3H, m, CH, CH2), 3.90 (1H, bs, CH), 4.02 (2H, bs, 
CH2), 4.24 (1H, bs, CH2), 7.53 (4H, d, J 7.6 Hz, 4 x ArH), 7.72 (4H, d, J 7.6 Hz, 4 x ArH), 
9.46 (1H, bs, NH), 10.02 (1H, bs, NH); 
13C NMR (D6-DMSO, 100 MHz): 15.1 (CH), 19.0 
(CH3),  38.7  (CH2),  39.3  (CH2),  41.8  (CH2),  43.9  (CH3),  46.7  (CH2),  47.0  (CH2),  49.9 
(CH2),  125.7  (CH),  128.1  (CH),  129.2  (C),  142.6  (C);  m/z  (EI):  494.2018  (M
+, 
C23H34N4O4S2 requires 494.2021), 424 (30%), 339 (28), 296 (44), 91 (100). 
9.5 Experimental to Chapter 8 
9.5.1 General Procedures (A & B) 
General procedure A – Synthesis of aminouracils: 6-Chlorouracil (1 eq) and aniline (3 
eq) were heated at 170 °C under nitrogen for 20 min. The mixture was cooled and diethyl 
ether (15 mL) was added. The mixture was sonicated for 15 min. The white suspension 
was filtered and washed with distilled water (15 mL), methanol (15 mL) and diethyl ether 
(15 mL). The white solid was placed in a desiccator and dried overnight using silica and 
P2O5. 
General procedure B – Synthesis of deazaflavins: A suspension of aminouracil (0.30 g, 
1.40 mmol) and DMF (15 mL) was prepared. A 2-chloro-5-nitrobenzaldehyde (0.33 g, 1.7 
mmol) was added and the reaction mixture was heated at 110 °C for 90 min under nitrogen. 
The yellow transparent solution was cooled and distilled water (25 mL) was added. The 
resulting precipitate was filtered and washed with water (15 mL). The yellow solid was 
placed in a desiccator and dried overnight using silica and P2O5 
9.5.2 Experimental Details 
6-Chlorouracil 171
196 
N
N Cl
O
H
O
H  Jennifer M. Wilson, 2007     Chapter 9, 140 
2,4,6-Trichloropyrimidine (15 g, 8.2 mmol) was added to a stirring solution of sodium 
hydroxide (13.2 g, 0.328 mol) and distilled water (135 mL). The reaction mixture was 
heated under reflux for one hour. The solution was cooled and the pH was adjusted to ~2-3 
using conc. hydrochloric acid (18 mL). The mixture was stored at 0 °C overnight. The 
white precipitate was filtered and recrystallised from water (9.1g, 71%). mp 287-289 °C 
(lit. 300 °C); 
1H NMR (400 MHz, D6-DMSO): 5.76 (1H, s, 5-H), 11.33 (1H, s, NH), 12.09 
(1H, s, NH); m/z (FAB): 147 (MH
+, 
35Cl, 86%), 119 (2), 113 (12), 79 (100). 
6-Phenylamino-1H-pyrimidine-2,4-dione 169 
N
N N
H
O
H
O
H
 
Using  general  procedure  A,  169  was  synthesised  from  6-chlorouracil  171  (1.0  g,  6.82 
mmol) and aniline (1.8 mL, 20 mmol), as a white solid (1.2 g, 84%). mp 332-333 °C; 
Found:  C,  59.1;  H,  4.4;  N,  20.4.  C10H9N3O2  requires  C,  59.1;  H,  4.5;  N,  20.7.;  νmax 
(neat)/cm
-1:  3414 (NH), 1818 (CO), 1807 (CO);  
1H NMR (400 MHz, D6-DMSO): 4.70 
(1H, s, 5-H), 7.15-7.23 (3H, m, 3 x ArH), 7.40 (2H, t, J 7.8 Hz, 2 x ArH), 8.28 (1H, s, NH), 
10.20 (1H, s, NH), 10.50 (1H, s, NH); 
13C NMR (100 MHz, D6-DMSO): 75.8 (CH), 122.7 
(CH), 124.7 (CH), 129.4 (CH), 137.9 (C), 150.8 (C), 152.2 (C), 164.4 (C). m/z (FAB): 204  
(MH
+, 20%), 158 (40), 81 (100). 
6-(2-Chlorophenylamino)-1H-pyrimidine-2,4-dione 
N
N N
H
O
H
O
H Cl
3'
4'
5'
6'
 
Using  general  procedure  A,  6-(2-chlorophenylamino)-1H-pyrimidine-2,4-dione  was 
synthesised from 6-chlorouracil 171 (1.0 g, 6.82 mmol) and 2-chloroaniline (2.15 mL, 20.5 
mmol),  as  a  white  solid.  mp  321-323 
oC  (decomp);  Found:  C,  50.4;  H,  3.3;  N,  17.5, 
C10H8ClN3O2 requires C, 50.5; H, 3.4; N, 17.7; νmax (neat)/cm
-1: 3202 (NH), 1731 (CO), 
1632 (C=C), 1540, 1480, 1224, 1078, 796, 736 ;
  1H NMR (400 MHz, D6-DMSO): 4.37 
(1H, s, 5-H), 7.29 (1H, ddd, J 8.0, 8.0, 1.6 Hz, 4’-H), 7.41 (1H, ddd, J 8.0, 8.0, 1.3 Hz, 5’-Jennifer M. Wilson, 2007     Chapter 9, 141 
H), 7.46 (1H, dd, J 8.0, 1.6 Hz, 6’-H), 7.59 (1H, dd, J 8.0, 1.3 Hz, 3’-H), 8.10 (1H, s, NH) 
10.38 (1H, s, NH), 10.55 (1H, s, NH); 
13C NMR (100 MHz, D6-DMSO): 76.1 (CH), 126.8 
(CH), 127.4 (CH), 128.2 (CH), 128.4 (C), 130.1 (CH), 134.4 (C), 150.7 (C), 152.1 (C), 
164.2 (C); m/z (CI): 238 (MH
+, 
35Cl, 91%) 204 (8), 147 (10), 79 (100).  
6-(4-Chlorophenylamino)-1H-pyrimidine-2,4-dione 
N
N N
H
O
H
O
H
Cl  
Using  general  procedure  A,  6-(4-chloro-phenylamino)-1H-pyrimidine-2,4,dione  was 
synthesised from 6-chlorouracil 171 (1.0 g, 6.82 mmol) and 4-chloroaniline (2.61 g, 20.5 
mmol), as a white solid (0.97 g, 60%). mp 344-346 
oC (decomp); Found: C, 50.3; H, 3.2; 
N, 17.4, C10H8ClN3O2 requires C, 50.5; H, 3.4; N, 17.7; νmax (KBr)/cm
-1:  3195 (NH), 1754 
(CO), 1616 (C=C), 1488, 1298, 788, 752 ; 
1H NMR (400 MHz, D6-DMSO): 4.73 (1H, s, 5-
H), 7.23 (2H, d, J 8.6 Hz, 2 x ArH), 7.43 (2H, d, J 8.6 Hz, 2 x ArH), 8.42 (1H, s, NH), 
10.32 (1H, s, NH), 10.55 (1H, s, NH); 
13C NMR (100 MHz, D6-DMSO): 76.6 (CH), 124.1 
(CH), 128.2 (C), 129.3 (CH), 137.1 (C), 150.9 (C), 151.9 (C), 164.4 (C); m/z (CI): 238 
(MH
+, 
35Cl, 4%), 157 (60), 79 (100).  
6-(4-Methylphenyl)-1H-pyrimidine-2,4-dione 
N
N N
H
O
O
H
H
CH3 
Using general procedure A, 6-(4-methylphenyl)-1H-pyrimidine-2,4-dione was synthesised 
from 6-chlorouracil 171 (1.0 g, 6.82 mmol) and 4-tolylaniline (2.19 g, 20.0 mmol), as a 
white solid (1.35 g, 91%) mp 321-323 
oC; Found: C, 60.7; H, 5.1; N, 19.1, C11H11N3O2 
requires C, 60.8; H, 5.1; N, 19.3; νmax (KBr)/cm
-1: 3273 (NH), 2764, 1772 (CO), 1634 
(C=C) 1446, 822, 786; 
1H NMR (400 MHz, D6-DMSO): 2.29 (3H, s, CH3), 4.61 (1H, s, 5-
H), 7.10 (2H, d, J 8.4 Hz, 2 x ArH), 7.20 (2H, d, J 8.4 Hz, 2 x ArH), 8.23 (1H, s, NH), 
10.18 (1H, s, NH), 10.45 (1H, s, NH); 
13C NMR (100 MHz, D6-DMSO): 20.4 (CH3), 75.2 Jennifer M. Wilson, 2007     Chapter 9, 142 
(CH), 123.1 (CH), 129.8 (CH), 134.1 (C), 135.1 (C), 150.8 (C), 152.5 (C), 164.3 (C); m/z 
(EI): 217 (M
+, 10%), 154 (8), 78 (90), 63 (100), 45 (26). 
10-Phenyl-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione 165 
N
N
O
H
O N
NO2
10 9
8
7
6 5 4
3
2
1
 
 Using general procedure B, 165 was synthesised from 6-phenylamino-1H-pyrimidine-2,4-
dione (0.3 g, 1.47 mmol), and 2-chloro-5-nitrobenzaldehyde (0.33 g, 1.78 mmol), as a 
yellow solid (413 mg, 84%). mp >380 °C; Found: C, 60.7; H, 2.8; N, 16.4, C17H10N4O4 
requires C, 61.1; H, 3.0; N, 16.7; νmax (neat)/cm
-1: 3220 (NH), 1722 (CO), 1610; 
1H NMR 
(400 MHz, D6-DMSO): 6.87 (1H, d, J 9.6 Hz, 9-H), 7.47-7.75 (2H, m, 2 x ArH), 7.65-7.75 
(3H, m, 3 x ArH), 8.45 (1H, dd, J 9.2, 2.4 Hz, 8-H), 9.23 (1H, d, J 2.4 Hz, 6-H), 9.31 (1H, 
s, 5-H), 11.32 (1H, s, NH); 
13C NMR (100 MHz, D6-DMSO): 117.5 (C), 118.5 (CH), 120.4 
(C), 127.2 (CH), 128.3 (2 CH), 128.4 (2 CH), 129.7 (CH), 130.4 (CH), 137.2 (C), 142.1 
(C), 145.1 (C), 156.3 (C), 159.5 (C), 161.4 (C); m/z (FAB): 335 (MH
+, 13%), 232 (15), 157 
(80), 80 (100). 
10-(2-Chlorophenyl)-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione 174 
N
N
N
NO2
O
H
O
Cl
 
Using  general  procedure  B,  174  was  synthesised  from  6-(2-chlorophenylamino)-1H-
pyrimidine-2,4-dione (0.1 g, 0.42 mmol) and 2-chloro-5-nitrobenzaldehyde (94 mg, 0.5 
mmol), as a yellow solid (101 mg, 66%). mp 326-328 
oC; νmax (KBr)/cm
-1: 3144 (NH), 
2826, 1683 (CO), 1617, 1340, 1218, 825, 796; 
1H NMR (400 MHz, D6-DMSO): 6.88 (1H, 
d, J 9.6 Hz, 9-H), 7.56-7.70 (3H, m, 3 x ArH), 7.81-7.89 (1H, m, ArH), 8.48 (1H, dd, J 9.6, 
2.8 Hz, 8-H), 9.27 (1H, s, 5-H), 9.32 (1H, d, J 2.8 Hz, 6-H), 11.43 (1H, s, NH); 
13C NMR 
(100 MHz, D6-DMSO): 117.2 (C), 117.7 (CH), 120.4 (C), 127.5 (CH), 129.0 (CH), 129.5 
(CH), 130.4 (CH), 130.9 (CH), 131.6 (C), 131.9 (CH), 134.2 (C), 142.7 (CH), 143.3 (C). Jennifer M. Wilson, 2007     Chapter 9, 143 
143.8 (C), 156.2 (C), 158.8 (C), 161.1 (C); m/z (FAB): 369.0391 (MH
+, C17H10
35ClN4O4 
requires 369.0388), 232 (20%), 158 (40), 81 (100). 
6-Chloro-10-phenyl-10H-pyrimido[[4,5-b]quinoline-2,4-dione 175 
N
N
O
H
O N
Cl
 
Using general procedure B, 175 was synthesised from 6-phenylamino-1H-pyrimidine-2,4-
dione (0.15 g, 0.74 mmol) and 2,6-dichlorobenzaldehyde (0.26 g, 1.50 mmol), as a yellow 
solid (0.22 g, 92%). mp (decomp) 338-340 °C; νmax (neat)/cm
-1: 3381 (NH), 3234 (NH), 
1702 (CO), 1669 (CO);  
1H NMR (400 MHz, D6-DMSO): 6.70 (1H, dd, J 8.0, 1.2 Hz, 8-
H), 7.43-7.45 (2H, m, 7-H, 9-H), 7.63-7.71 (5H, m, 5 x ArH), 9.04 (1H, s, 5-H), 11.27 (1H, 
s, NH); 
13C NMR (100 MHz, D6-DMSO): 116.7 (C), 116.8 (CH), 118.4 (C), 124.9 (2 CH), 
128.3 (CH), 129.5 (2 CH), 130.3 (CH), 133.7 (C), 135.2 (CH), 136.5 (CH), 137.6 (C), 
143.1 (C), 156.3 (C), 158.5 (C), 161.6 (C); m/z (FAB): 324.0536 (MH
+, C17H11
35ClN3O2 
requires 324.0540), 292 (20%), 80 (100). 
6-Chloro-10-(2-chlorophenyl)-10H-pyrimido[4,5-b]quinoline-2,4-dione 176 
N
N
N
O
H
O
Cl
Cl
 
Using  general  procedure  B,  176  was  synthesised  from  6-(2-chlorophenylamino)-1H-
pyrimidine-2,4-dione (0.3 g, 1.26 mmol) and 2-chloro-6-fluorobenzaldehyde (0.24 g, 1.51 
mmol), as a yellow solid (55 mg, 36%). mp 305-307 
oC; νmax (KBr)/cm
-1: 3142 (NH), 
2801, 1709 (CO), 1685 (C=C), 1607, 1219, 794, 769; 
1H NMR (400 MHz, D6-DMSO): 
6.72 (1H, d, J 10.8 Hz, 9-H), 7.62-7.66 (1H, m, 8-H), 7.67-7.79 (4H, m, 4 x ArH), 7.85-
7.96 (1H, m, 7-H), 9.89 (1H, s, 5-H), 10.33 (1H, s, NH); 
13C NMR (100 MHz, D6-DMSO): 
115.9 (CH), 116.5 (C), 118.4 (C), 125.4 (CH), 129.5 (CH), 130.4 (CH), 130.8 (CH), 131.0 
(C), 131.7 (C), 134.1 (C), 134.5 (C), 135.9 (CH), 137.2 (C), 141.9 (C), 156.2 (C), 157.9 
(C), 161.3 (C); m/z (CI): 358.0151 (MH
+, C17H10
35Cl2N3O2 requires 358.0150), 128 (10%), 
79 (100).  Jennifer M. Wilson, 2007     Chapter 9, 144 
6-Chloro-10-(4-chlorophenyl)-10H-pyrimido[4,5-b]quinoline-2,4-dione 177 
N
N
N
O
H
O
Cl
Cl  
Using  general  procedure  B,  177  was  synthesised  from  6-(4-chlorophenylamino)-1H-
pyrimidine-2,4,dione (0.3 g, 1.26 mmol) and 2-chloro-6-fluorobenzaldehyde (0.24 g, 1.51 
mmol), as a yellow solid (0.28 g, 63%). mp 220-222 
oC (decomp); νmax (KBr)/cm
-1: 3254 
(NH), 1667 (C=C), 1602 (C=C), 1363, 1245, 797, 747; 
1H NMR (400 MHz, D6-DMSO): 
6.55 (1H, d, J 8.8 Hz, 9-H), 7.50 (2H, d, J 8.4 Hz, 2 x ArH), 7.59-7.65 (2H, m, 7-H, 8-H), 
7.79 (2H, d, J 8.4 Hz, 2 x ArH), 9.07 (1H, s, 5-H), 11.29 (1H, s, NH); 
13C NMR (100 MHz, 
D6-DMSO): 116.7 (C), 116.8 (CH), 118.5 (C), 124.9 (CH), 130.3 (CH), 130.4 (CH), 133.8 
(C), 134.2 (C), 135.3 (CH), 136.3 (C), 136.7 (CH), 142.9 (C). 156.2 (C), 158.6 (C), 161.5 
(C);  m/z  (FAB):  358.0152  (MH
+,  C17H10
35Cl2N3O2  requires  358.0150),  232  (8%),  158 
(100), 81 (100). 
5-Chloro-10-(4-methylphenyl)-10H-pyrimido[4,5-b]quinoline-2,4-dione 178 
N
N N
O
H
O
CH3
Cl
 
Using general procedure B, 178 was synthesised from 6-p-tolylamino-1H-pyrimidine-2,4-
dione (0.1 g, 0.46 mmol) and 2-chloro-6-fluorobenzaldehyde (87 mg, 0.55 mmol), as a 
yellow solid (69 mg, 44%). mp >360 
oC; νmax (KBr)/cm
-1: 3131 (NH), 3000, 2803, 1707 
(CO), 1656 (C=C), 1221, 796, 740; 
1H NMR (400 MHz, D6-DMSO): 2.49 (3H, s, CH3), 
6.75 (1H, d, J 9.2 Hz, 9-H), 7.30 (2H, d, J 8.2 Hz, 2 x ArH), 7.50 (2H, d, J 8.2 Hz, 2 x 
ArH), 7.66-7.73 (2H, m, 7-H, 8-H), 9.02 (1H, s, 5-H), 11.24 (1H, s, NH); 
13C NMR (100 
MHz, D6-DMSO): 20.8 (CH3), 116.9 (CH), 118.4 (C), 124.8 (CH), 125.3 (C), 127.9 (CH), 
130.7 (CH), 133.7 (C), 134.9 (C), 135.1 (CH), 136.4 (CH), 139.1 (C) 143.3 (C), 156.3 (C), 
158.6 (C), 161.6 (C); m/z (FAB): 338.0700 (MH
+, C18H13
35ClN3O2 requires 338.0696), 232 
(20%), 158 (65), 81 (100). Jennifer M. Wilson, 2007     Chapter 9, 145 
8-Chloro-10-phenyl-10H-pyrimido[4,5-b]quinoline-2,4-dione 179 
N
N
O
H
O N Cl
 
Using general procedure B, 179 was synthesised from 6-phenylamino-1H-pyrimidine-2,4-
dione (0.15 g, 0.74 mmol) and 2,4-dichlorobenzaldehyde (0.26 g, 1.50 mmol), as a yellow 
solid  (0.17  g,  71%).  mp  (decomp)  370-372  °C;  Found:  C,  62.8;  H,  3.1;  N,  12.8, 
C17H11ClN3O2 requires C, 63.1; H, 3.1; N, 13.0; νmax (neat)/cm
-1: 3335 (NH), 3145 (NH), 
1700 (CO), 1659 (CO);  
1H NMR (400 MHz, D6-DMSO): 6.50 (1H, d, J 1.6 Hz, 9-H), 
7.38-7.40 (2H, m, 2 x ArH), 7.52 (1H, dd, J 8.8, 2 Hz, 7-H), 7.57-7.65 (3H, m, 3 x ArH), 
8.22 (1H, d, J 8.8 Hz, 6-H) 9.08 (1H, s, 5-H), 11.10 (1H, s, NH); 
13C NMR (100 MHz, D6-
DMSO): 115.9 (C), 116.1 (CH), 119.8 (C), 124.7 (CH), 128.3 (CH), 129.6 (C), 130.4 
(CH), 133.2 (CH), 137.1 (C), 139.3 (C), 141.7 (CH), 142.5 (C), 156.3 (C), 158.5 (C), 158.8 
(C), 161.7 (C); m/z (FAB): 324 (MH
+, 
35Cl, 100%) 281 (7), 232 (12), 157 (25), 80 (50). 
10-(4-Chlorophenyl)-7-trifluoromethyl-10H-pyrimido[4,5-b]quinoline-2,4-dione 180 
N
N N
O
H
O
CF3
Cl  
Using  general  procedure  B,  180  was  synthesised  from  6-(4-chlorophenylamino)-1H-
pyrimidine-2,4,dione  (0.3  g,  1.26  mmol)  and  2-chloro-5-(trifluoromethyl)benzaldehyde 
(0.22 mL, 1.51 mmol), as a yellow solid (0.40 g, 83%). mp 342-343 
oC; νmax (KBr)/cm
-1: 
3155 (NH), 2825, 1690 (C=C), 1618, 1337, 1276, 831, 797; 
1H NMR (400 MHz, D6-
DMSO): 6.97 (1H, d, J 9.2 Hz, 9-H), 7.54 (2H, d, J 8.6 Hz, 2 x ArH), 7.79 (2H, d, J 8.6 
Hz, 2 x ArH), 8.01 (1H, dd, J 9.2, 2.0 Hz, 8-H), 8.54 (1H, d, J 1.2 Hz, 6-H), 9.22 (1H, s, 5-
H), 11.27 (1H, s, NH); 
13C NMR (400 MHz, D6-DMSO): 117.0 (C), 118.4 (CH), 120.6 
(C), 123.3 (C), 124.9 (CF3, J 33 Hz), 128.9 (CH), 130.5 (CH), 131.2 (CH), 132.8 (CH), 
134.3 (C), 136.1 (C), 142.1 (CH), 143.6 (C). 156.3 (C), 159.8 (C), 161.5 (C); 
19F NMR 
(376  MHz,  D6-DMSO):  -60.7  (CF3);  m/z  (FAB):  392.0413  (MH
+,  C18H10
35ClF3N3O2 
requires 392.0414), 349 (15%), 81 (30). Jennifer M. Wilson, 2007     Chapter 9, 146 
10-p-tolyl-6-trifluoromethyl-10H-pyrimido-[4,5-b]quinoline-2,4-dione 181 
N
N N
O
H
O
CH3
CF3
 
Using general procedure B, 181 was synthesised from 6-p-tolylamino-1H-pyrimidine-2,4-
dione (0.1 g, 0.46 mmol) and 2-chloro-5-(trifluoromethyl)benzaldehyde (80 µmol, 5.52 
mmol), as a yellow solid (67 mg, 40%). mp >360 
oC; νmax (KBr)/cm
-1: 3145 (NH), 3006, 
1714 (CO), 1670 (C=C), 1333, 1212, 796; 
1H NMR (400 MHz, D6-DMSO): 2.47 (3H, s, 
CH3), 6.90-6.93 (1H, d, J 9.2 Hz, 9-H), 7.32 (2H, d, J 8.2 Hz, 2 x ArH), 7.50 (2H, d, J 8.2 
Hz, 2 x ArH), 7.99-8.02 (1H, dd, J 9.2, 2.0 Hz, 8-H), 9.22 (1H, bs, 6-H), 10.33 (1H, s, 5-
H), 11.23 (1H, s, NH); 
13C NMR (100 MHz, D6-DMSO): 20.8 (CH), 117.0 (CH), 118.5 
(CH), 120.5 (C), 124.4 (CF3, J 33 Hz), 128.0 (CH), 128.8 (CH), 130.3 (CH), 130.8 (CH), 
134.7 (C), 139.1 (C), 141.9 (CH), 143.9 (C). 156.4 (C), 159.3 (C), 161.6 (C); 
19F NMR 
(367 MHz, D6-DMSO): -60.7 (CF3); m/z (FAB): 372.0966 (MH
+, C19H13F3N3O2 requires 
372.0960), 232 (20%), 158 (40), 81 (100). 
12-Phenyl-12H-1,3,11,12-tetraaza-naphthacene-2,4-dione 182 
N
N
O
H
O N N
 
Using general procedure B, 182 was synthesised from 6-phenylamino-1H-pyrimidine-2,4-
dione (0.2 g, 0.98 mmol) and 2-chloro-3-quinolinecarboxaldehyde (0.23 g, 1.18 mmol), as 
a yellow solid (0.24 g, 74%). mp (decomp) 353–355 °C; Found: C, 70.5; H, 3.5; N, 16.3, 
C20H12N4O2 requires C, 70.6; H, 3.5; N, 16.5; νmax (neat)/cm
-1: 3368 (NH), 3230 (H), 1713 
(CO), 1628 (C=C aromatic); 
1H NMR (400 MHz, D6-DMSO): 7.40-7.42 (2H, m, 7-H, 10-
H), 7.56-7.58 (1H, m, ArH), 7.62-7.68 (4H, m, 4 x ArH), 7.85-7.87 (1H, m, 8-H), 8.31 
(1H, d, J 7.6 Hz, 9-H), 9.21 (1H, s, 6-H), 9.34 (1H, s, 5-H), 11.3 (1H, s, NH). m/z (FAB): 
341 (MH
+, 1%) 232 (30), 157 (100), 80 (100). 
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5-tert-Butoxycarbonylamino-2-chlorobenzoic acid methyl ester 184 
N
H
O
O
Cl
O
O
 
2-Chloro-5-amino-benzoic acid (1.97 g, 11.5 mmol) was dissolved in methanol (22 mL) 
under a nitrogen atmosphere and cooled to 0 
oC using an ice bath. Trimethylsilyl chloride 
(2.93 mL, 22.9 mmol) was added dropwise to the lilac coloured solution. After 1 h, the 
reaction mixture was returned to RT and stirred overnight. Triethylamine (3.19 mL, 22.9 
mmol) and di-tert-butyl dicarbonate (2.75 mL, 12.6 mmol) were added dropwise to the 
grey  reaction  mixture  and  this  was  stirred  for  2  h.  The  brown  reaction  mixture  was 
concentrated. The greenish residue was dissolved in diethyl ether (30 mL) and filtered to 
remove the precipitate (triethylamine salt). The filtrate was concentrated and purified using 
column chromatography (eluant: pet ether/ethyl acetate 60/40) yielding a white solid (3.30 
g, 51%). mp 99-100 
oC; νmax (KBr)/cm
-1: 3356, 2969 (NH), 1725, 1699 (CO), 1528, 1310, 
1231, 1060, 972; 
1H NMR (400 MHz, CDCl3): 1.45 (9H, s, 3 x CH3), 3.90 (3H, s, OCH3), 
6.51 (1H, s, NH), 7.28 (1H, d, J 8.8 Hz, ArH), 7.41 (1H, dd, J 8.8, 2.8 Hz, ArH), 7.76 (1H, 
d, J 2.8 Hz, ArH). 
13C NMR (100 MHz, CDCl3): 27.4 (CH3), 28.3 (CH3), 52.5 (CH), 120.9 
(CH), 122.4 (CH), 127.3 (C), 130.2 (C), 131.5 (CH), 137.1 (C), 152.4 (C), 165.8 (C); m/z 
(EI): 285.0767 (M
+, C13H16
35ClNO4 requires 285.0768), 229 (35%), 185 (30), 83 (20), 57 
(100). 
 (1-Chloro-2-hydroxymethyl-4-tert-butoxycarbonylamino)benzene 185 
NHBoc
HO
Cl  
A suspension of lithium aluminium hydride (0.177 g, 4.62 mmol) in tetrahydrofuran (10 
mL) was prepared and cooled to 0 
oC using an ice bath. 5-tert-Butoxycarbonylamino-2-
chlorobenzoic acid methyl ester was added in small portions. The reaction mixture was 
heated at 40 
oC for 2 d. The reaction mixture was quenched by the careful addition of 
water.  Diethyl ether  was added  and  the  layers  were separated.  The  aqueous  layer  was 
washed with diethyl ether (3 x 20 mL). The combined organic layers were washed with 
water  (3  x  20  mL),  dried  (MgSO4),  concentrated  and  purified  using  column 
chromatography eluant: petroleum ether/ethyl acetate 70/30 yielding a pale yellow solid 
(1.18 g, 42%). mp 66-68 
oC; νmax (KBr)/cm
-1: 3287, 2812 (NH), 1608 (CO), 1238, 1056, Jennifer M. Wilson, 2007     Chapter 9, 148 
873; 
1H NMR (400 MHz, CDCl3): 2.86 (9H, s, 3 x CH3), 4.68 (2H, s, CH2), 6.49 (1H, dd, J 
8.4, 2.8 Hz, 6-ArH), 6.72 (1H, d, J 2.8 Hz, 2-ArH), 7.05 (1H, d, J 8.4 Hz, 5-ArH), 7.25 
(1H, s, NH); 
13C NMR (100 MHz, CDCl3) 30.8 (CH3), 63.2 (CH2), 77.3 (C), 112.5 (CH), 
112.6  (CH),  120.2  (C),  129.8  (CH),  138.6  (C),  148.3  (C);  m/z  (EI):  257.0816  (M
+, 
C12H16
35ClNO3 requires 257.0819), 201 (100%), 157 (92), 57 (100). Jennifer M. Wilson, 2007     Chapter 9, 149 
9.6 Biological Testing 
9.6.1 Biological Testing Chapter 5 
9.6.1.1  DNA Cross-linking Activity of Macrocyclic Mustards 
The  method  used  was  the agarose  gel cross-link  assay.
151a  pBR322  plasmid  DNA  was 
linearised  by  digestion  with HinDIII  and  dephosphorylated  by  treatment  with  bacterial 
alkaline phosphatase. The DNA was 5’-end labeled using T4 polynucleotide kinase and [γ-
32P]  ATP  (5000  Ci/mmol,  Amersham,  UK).  Following  precipitation  and  removal  of 
unincorporated  ATP,  the  DNA  was  resuspended  in  sterile  double-distilled  water  at  1 
mg/mL. Approximately 10 ng of labeled DNA were used for each experimental point. 
Reactions with drug were performed in 25 mM triethanolamine, 1 mM EDTA (pH 7.2) at 
37 
oC for 2 h. Reactions were terminated by the addition of a greater than equal volume of 
stop solution (0.6 M sodium acetate, 20 mM EDTA, 100 µg/mL tRNA) and the DNA was 
precipitated by the addition of 3 vols 95% ethanol. Following centrifugation and removal 
of supernatant, the DNA pellet was dried by lyophilisation. Samples were dissolved in 10 
µL strand separation buffer (30% DMSO, 1mM EDTA, 0.04% bromophenol blue, 0.04% 
xylene cyanol), heated at 90 
oC for 2 min and chilled immediately in an ice-water bath 
prior to loading. Control undenatured samples were dissolved in 10 µL 6% sucrose, 0.04% 
bromophenol blue and loaded directly. Electrophoresis was performed on 20 cm long 0.8% 
submerged horizontal agarose gels at 40 V for 16 h. The gel and running buffer were 40 
mM Tris, 20 mM acetic acid and 2 mM EDTA (pH 8.1). Gels were dried at 80 
oC onto one 
layer of Whatman 3 MM and one layer of DE81 filter papers on a BioRad Model 583 gel 
drier  connected  to  a  vacuum.  Autoradiography  was  performed  with  Hyperfilm  MP 
(Amersham, UK) at -70 
oC using a DuPont-Cronex Lightening-plus intensifying screen. 
Sharper images were obtained by overnight exposure without the intensifying screen. The 
percentage double stranded (cross-linked) DNA was obtained in each lane using a BioRad 
Imaging Densitometer. 
9.6.1.2  Cytotoxicity of Macrocyclic Mustards 
The cytotoxic effects of the free ligands studied were measured against the human chronic 
myeloid leukaemia cell line K562. Cells were maintained as a suspension in RPMI 1640 
medium supplemented with 10% foetal calf serum and 2 mM glutamine at 37 
oC in a 
humidified atmosphere containing 5% CO2. Following a 1 h exposure to the sample, the Jennifer M. Wilson, 2007     Chapter 9, 150 
corresponding IC50 value was determined using the MTT assay.
151b,151c This is based on the 
ability of viable tumour cells to convert a yellow tetrazolium salt [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolyium bromide, MTT] into mauve formazan crystals. 
9.6.1.3  Trypanosome Cell Line 
9.6.1.3.1 Trypanosoma brucei brucei 427 
T. b. brucei EATRO (East African Trypanosomiasis Research Organisation) 427 was used 
routinely for uptake assays. These stocks were supplied by Dr M. P. Barrett, University of 
Glasgow. 
9.6.1.3.2 T. b. brucei 427 ∆Tbat1 Mutant Clone 
The ∆Tbat1(P2) null mutant clone was constructed by sequential replacement of  TbAT1 
with the neomycin and puromycin resistance markers in T. b. brucei 427. This knockout 
cell line was four-fold less sensitive to melasoprol and melarsen oxide. These stocks are 
held at the University of Glasgow. 
9.6.1.4  Growth and Maintenance of Bloodstream-Form Trypanosome Stocks 
9.6.1.4.1  In vitro culture 
Cultures were incubated in sterile culture flasks at 37 
oC and 5% CO2 in HMI-9 medium 
containing 20% heat-inactivated foetal calf serum. 5 mL cultures were seeded with 200 µL 
of culture at 2 x 10
6 cells/mL. Cells were allowed to grow for 3 d after which they had 
reached maximum density (approximately 2 x 10
6 cells/mL) and were passaged again in 
the same way. 
9.6.1.5  Trypanotoxicity 
9.6.1.5.1 In vitro Toxicity Assay (Alamar Blue Assay) 
The Alamar Blue assay was used to assess toxicity in vitro.
153 Doubling serial dilutions of 
test compound were set out in a 96 well plate in duplicate, in a volume of 100 µL HMI-9 
medium.
154 100 µL of trypanosomes at 2 x 10
5 cells/mL were added to each well. After 48 
h incubation at 37 
oC and 5% CO2, 10% Alamar Blue (20 µL) was added to each well and 
the plates incubated for a further 24 h. Unspecified enzymes in the live cells reduce the 
Alamar Blue to the colourless form. The concomitant change in absorption at 600 nm can 
be measured spectrophotometrically, or fluorometric measurements can be taken at 530 nm 
excitation  and  590  nm  emission  as  the  amount  of  fluorescence  detectable  at  these 
wavelengths increases in the reduced dye. All measurements were taken fluorometrically. Jennifer M. Wilson, 2007     Chapter 9, 151 
The EC50 value was calculated by analysing the data with the EC50 algorithm of the Grafit 
4.0 (Erithracus Software) or using Prism 3.0 (GraphPad, San Diego, CA, USA). Values 
were  checked  for  accuracy  by  visually  examining  cell  viability  and  motility.  Each 
experiment was performed in duplicate and replicated at least once. 
9.6.1.6  Human Embryonic Kidney Cells 
Human Embryonic Kidney Cells (HEK), strain 293T, were used as the mammalian cell 
line for comparative analyses. HEK cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (Sigma)  with penicillin/streptomycin (10 mg/mL), L-Glutamax (200 nM), and 
10% newborn calf serum in vented culture flasks at 37 
oC in 5-10% CO2 atmosphere, 
passaging when cells on the monolayer are 80-85% confluent. The Alamar Blue assay 
protocol was modified from the one used for live trypanosomes; 100 µL of a 3 x 10
5 
cells/mL suspension was added to each well of a 96 well plate and incubated at 37 
oC for 3 
h to allow cells to adhere to the bottom of the wells. Preparation of drug stocks in doubling 
dilution was added after the incubation period, incubated for a further 12-16 h before the 
addition of 10% Alamar Blue (20 µL). After 24 h the plates were read fluorometrically and 
visually as above. 
9.6.1.7  Fluorescence Assays 
9.6.1.7.1 Wet Slides 
A culture of the cells in HMI-9 medium was centrifuged and the excess medium poured 
off. 5.0 mL of CBSS solution was used to re-suspend the cells before centrifuging and 
pouring off excess CBSS. This process was repeated twice to wash the cells and remove 
soluble blood components. 2.0 µL of 10.0 mM fluorescent drug compounds was added to 
0.5 mL cells in CBSS solution in a 0.5 mL vial. After five min the vial was centrifuged, the 
excess solution removed, and 0.2 µL solution removed to a glass slide and a cover slip 
added. The was viewed directly through the Zeiss Axioscope FL fluorescence microscope 
using a Zeiss 02 filter at an excitation wavelength of 330 nm and an emission wavelength 
of  400  nm.  Images  were  obtained  by  the  same  method  but  using  an  Axiovert  200M 
Fluorescence microscope. This technique was repeated to cover a 5-90 min time period. 
9.6.2 Biological Testing Chapter 8 
Protein expression levels were assessed by Western Blotting, after incubation of primary 
human pigment epithelial (RPE) cells with 1-20 µM of each compound for 24 h. Proteins Jennifer M. Wilson, 2007     Chapter 9, 152 
from whole cell extracts were separated by SDS 12% polyacrylamide gel electrophoresis 
and  analysed  by  Western  blotting  with  anti-p53  DO-1  (Pharmingen),  anti-HDM2 
AB1/AB2  (Oncogene  Science),  anti-phospho-p53  (serine-15)  (Cell  Signaling)  and  anti-
21
WAF1/CIP1 (Santa Cruz Biotechnology) antibodies. Blots were also probed with an anti-
Cdk4 antibody (Santa Cruz Biotechnology) to monitor protein loading. The effects of some 
of the compounds were assessed by flow cytometry. Jennifer M. Wilson, 2007     Chapter 9, 153 
9.7 Experimental Crystallography Details 
Details of data collection procedures and structure refinement are given in the following 
table. CIF data can be accessed online at http://www.chem.gla.ac.uk/~louis/data/. Single 
crystals of suitable size were attached to glass fibres using acrylic resin, and mounted on a 
goniometer head in a general position. Data was collected on an Enraf-Nonius KappaCCD 
diffractometer, running under Nonius Collect software, and using graphite monochromated 
X-radiation (λ=0.71073 Å). All data sets were collected at a temperature of 150 K using an 
Oxford Instruments Cryostream. Typically scan angles of 1-2 
o were used, with integration 
times  of  50-100  s  per  image.  Precise  unit  cell  dimensions  were  determined  by  post-
refinement of the setting angles of a large proportion of the data set. The frame images 
were integrated using Denzo(SMN)
216 and the resultant raw intensity files processed using 
a  locally  modified  version  of  DENZOX.
217  Absorption  corrections,  either  by  Gaussian 
quadrature,
218 based on the measured crystal faces, or by a semi-empirical correction
219 
were  applied  to  all  data  sets.  Data  were  then  sorted  and  merged  using  SORTAV.
220 
Structures  were  solved  either  by  Patterson  interpretation  (DIRDIF-99)
221  or  by  direct 
methods (SIR92).
222 Refinement with SHELXL97-2 using full-matrix least squares on F
2 
and  all  the  unique  data.  Neutral  atom  scattering  forces,  coefficients  of  anomalous 
dispersion and absorption coefficients were obtained from reference. All calculations were 
carried out using the WinGX package of crystallographic programs.
223 Jennifer M. Wilson, 2007     Chapter 9, 154 
 
Compound number  84  85  181 
Compound formula  C44H56N8O8  C32H64N8O8  C19H12F3N3O2 
Compound colour  colourless  colourless  yellow 
Mr  824.97  688.91  371.32 
Space group  P21/a  P21/a  P-1 
Crystal system  monoclinic  monoclinic  triclinic 
a/Å  11.0274 (5)  12.8699 (5)  10.0933 (4) 
b/Å  8.9869 (5)  9.5994 (4)  12.4331 (5) 
c/Å  21.2550 (8)  17.0767 (8)  14.8188 (6) 
β/deg  91.304 (3)  111.043 (2)  93.650 (2) 
V/Å
-3  2105.87 (17)  1969.01 (15)  1736.60 (12) 
Z  2  2   4 
Dcalc/ g cm
-3  1.301  1.162  1.42 
F(000)  880  752  760 
µ(Mo-Ka)/mm
-1  0.091  0.084  0.116 
Crystal size/mm  0.48 x 0.41 x 0.13  0.39 x 0.35 x 0.25  0.6 x 0.4 x 0.2 
Transmission coefficients (range)  1.000-0.798  n/a  n/a 
θ range/deg  2.46-26.45  1.28-26.14  1.46-26.51 
No. of data measured  21987  17875  33364 
No. of unique data  4331  3920  7137 
Rint  0.0758  n/a  0.0102 
No. of data in refinement  4331  3920  7137 
No. of refined parameters  280  218  501 
Final R[I>2σ(l)] (all data)  0.0589  0.0631  0.047 
Rw
2[I>2σ(l)] (all data)  0.1194  0.0998  0.0759 
Flack parameter  n/a  n/a  n/a 
Goodness of fit S  1.056  1.086  1.052 
Largest residuals/eÅ
-3  0.31, -0.323  0.444, -0.323  0.188, -0.19 
Max shift/esd in last cycle  0.001  0.004  0.008 
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